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The Journal of InterDisciplinary Research Applied to Medicine (J-DReAM) is one of the editorial aims of 
DREAM (Interdisciplinary Laboratory of Applied Research in Medicine - University of Salento and the local 
health authority - ASL Lecce). DREAM is an interdisciplinary laboratory that includes different scientific areas 
such as biology, biotechnology, biomedicine as well as physics and statistics, computer engineering and bio-
materials; it also involves juridical disciplines, political, social sciences and humanities. The purpose of DREAM 
is to translate the research activities of these scientific areas in clinical settings. 
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Abstract 
The omics sciences of systems biology including genomics, transcriptomics, lipidomics, metabolomics, and pro-
teomics, aim at understanding the biological mechanisms that give rise to the phenotype of an organism by using 
high-throughput technologies with the promise of great medical advances. The importance of all these sciences 
is that all, with the exception of genomics are context dependent. Genome is constant in time and place in each 
cell of an organism, but the entire complement of messenger RNA molecules, proteins and metabolites in a cell, 
tissue, organ or organism varies with physiological, pathological or developmental conditions (Keusch 2006). 
The term “omics” represents the study of biological processes as systems. It deciphers the dynamic interactions 
between the numerous components of a biological system to analyse networks, pathways, and interactive rela-
tions that exist among them, such as genes, transcripts, proteins, metabolites, and cells. This new scientific vision 
has opened the way to new research strategies and experimental technologies that have transformed the study of 
virtually all life processes. Expansion of the “–ome” concept was incessant and has created a host of new terms, 
including bacteriome, cardiome, epigenome, erythrome, immunome, microbiome, neurome, connectome, 
osteome, physiome, proteinome, transportome, degradome, psychome, transcriptome, and many others. 
In the present review, these concepts are briefly introduced with a major focus towards proteomics. 
 
Keywords: omics sciences, proteomics, bioinformatics, personalized medicine 
 
 
1. Genomics, metabolomics, lipidomics, epigenomics 
 
Genomics is the study of the genomes of or-
ganisms. For several years genomics was at the 
forefront of omics sciences, we were in the 
“Genomic Era”. Because many diseases are in-
timately associated with genetic mutations, the 
idea that the solutions for human pathologies 
lie on genes has catalysed the interest of scien-
tists for years, making genome-based analysis 
methods a central approach in omics science 
and setting the scene for the completion of the 
Human Genome Project  (HGP), undoubtedly 
a major landmark event in the field of genomics 
after the discovery of the double-helical struc-
ture of DNA. Since the completion of the hu-
man genome project, our ability to explore ge-
nome function is increased in specificity. In 
fact, substantial changes have occurred in the 
study of genome owing to the introduction of 
several approaches to DNA sequencing and 
expression. The massive quantification of mes-
senger RNA (mRNA), genome copy number, 
and single nucleotide polymorphisms (SNPs) by 
microarray technology has enabled to assess the 
expression of tens of thousands of genes shed-
ding light on the mechanisms underlying hu-
man pathologies, providing the basis for strati-
fying patients and predicting outcomes in a va-
riety of diseases. Together with microarrays, re-
cent advances in DNA sequencing with the in-
troduction of next-generation sequencing 
(NGS) technologies have made possible un-
precedented extensive analyses of genome of 
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individuals. Presently, there are three main 
NGS systems: the Roche/454 FLX, the Illu-
mina/Solexa Genome Analyzer, and the Ap-
plied Biosystems SOLiDTM System. Each one, 
by a different approach, seeks to amplify single 
strands of a fragment library and perform se-
quencing reactions on the amplified strands. 
Together with these technologies, a new gen-
eration of single-molecule sequencing tech-
nologies is now emerging offering advantages 
over current sequencing methods including 
small amounts of starting material (theoretically 
only a single molecule may be required for se-
quencing), and low cost.  
An important consequence of this new emerg-
ing scenario was the creation of multi-
disciplinary teams and the formation of large-
scale collaborative networks to handle and inte-
grate these large amounts of data. The HGP 
was the first example of a large collaborative 
project; others include the Cancer Genome At-
las (TCGA) and the 1000 genome project. 
TCGA has achieved comprehensive sequenc-
ing, characterization, and analysis of the ge-
nomic changes of major types of human can-
cers providing also a platform for researchers to 
search, download, and analyse data sets gener-
ated by TCGA (http://cancergenome.nih.gov). 
The 1000 genome project aims to establish an 
extensive catalogue of human variations from 
25 populations (www.1000genomes.org). The 
project provides an international open access 
resource that serves as a basis for subsequent 
phenotype related studies 
(www.1000genomes.org). 
Endogenous metabolites can be seen as part of 
the downstream output of the genome, com-
plementary as ‘‘upstream’’ changes in genes 
(Spratlin, Serkova, and Eckhardt 2009), and 
their study together with exogenous metabolite 
is important to understand what happens in an 
organism. The term “metabolome” was intro-
duced in 1998 as the total metabolite content of 
a biological sample, an enormous complex and 
dynamic number of components that belong to 
a wide variety of compound classes, including 
nucleic acids, amino acids, sugars, and lipids. 
The term metabolomics was used for the first 
time in 2000 by Fien, to describe the discipline 
devot 
ed to the study of global metabolite profiles 
produced in biosynthetic and catabolic path-
ways from biological systems or originating 
from host-specific microbes and the intake of 
nutrients and pharmaceuticals, present in cells, 
tissues, and biofluids.  
Different techniques have been developed to 
investigate the metabolome, distinguishing the 
different metabolites on the basis of their 
chemical and physical properties (Cacciatore 
and Loda 2015). 
Most commonly used techniques for me-
tabolomics are nuclear magnetic resonance 
(NMR), gas chromatography coupled to mass 
spectrometer (GC–MS) and mass spectroscopy 
(MS). Recently published papers describe the 
application of metabolomics in the study of 
heart disease, cancer, and other human pa-
thologies. Another potential application of me-
tabolomics involves the definition of biochemi-
cal pathways that contribute to drug response. 
Pharmaco-metabolomic signatures have also 
been identified for several drugs to predict in-
dividual responses to broader medical, dietary, 
microbiological or physiological challenges.  
Data generated experimentally by metabolomics 
are available in metabolite databases such as the 
Human Metabolome Database (HMDB). 
HMDB (www.hmdb.ca), the equivalent of the 
Human Genome Project for metabolomics, is a 
resource dedicated to providing scientists with 
the most current and comprehensive coverage 
of the human metabolome. Created in 2004, it 
contains information on biological properties, 
ontology, spectra and physical properties of 
human metabolites as well as data regarding 
metabolite concentrations, disease associations 
and tissue locations. Started as an inventory of 
2500 small molecules, its content has increased 
to 15000 entries (Liesenfeld et al. 2013). 
Lipidomics, term emerged for the first time in 
2003, is a sub-discipline of metabolomics that 
aims to define all of the lipid molecular species 
in a cell, including the metabolizing enzymes 
and lipid transporters and understand how lip-
ids function in a biological system. In detail, 
lipidomics involves the identification of indi-
vidual cellular lipid species, including the type 
and number of individual atoms in each lipid 
species, and their stereoelectronic interactions 
with other lipids and proteins. Cells use 5% of 
their genes to synthesize their lipids that fulfil 
three main functions. Lipids not only forms the 
bilayer matrix, not only are used as energy stor-
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An important consequence of this new emerg-
ing scenario was the creation of multi-
disciplinary teams and the formation of large-
scale collaborative networks to handle and inte-
grate these large amounts of data. The HGP 
was the first example of a large collaborative 
project; others include the Cancer Genome At-
las (TCGA) and the 1000 genome project. 
TCGA has achieved comprehensive sequenc-
ing, characterization, and analysis of the ge-
nomic changes of major types of human can-
cers providing also a platform for researchers to 
search, download, and analyse data sets gener-
ated by TCGA (http://cancergenome.nih.gov). 
The 1000 genome project aims to establish an 
extensive catalogue of human variations from 
25 populations (www.1000genomes.org). The 
project provides an international open access 
resource that serves as a basis for subsequent 
phenotype related studies 
(www.1000genomes.org). 
Endogenous metabolites can be seen as part of 
the downstream output of the genome, com-
plementary as ‘‘upstream’’ changes in genes 
(Spratlin, Serkova, and Eckhardt 2009), and 
their study together with exogenous metabolite 
is important to understand what happens in an 
organism. The term “metabolome” was intro-
duced in 1998 as the total metabolite content of 
a biological sample, an enormous complex and 
dynamic number of components that belong to 
a wide variety of compound classes, including 
nucleic acids, amino acids, sugars, and lipids. 
The term metabolomics was used for the first 
time in 2000 by Fien, to describe the discipline 
devot 
ed to the study of global metabolite profiles 
produced in biosynthetic and catabolic path-
ways from biological systems or originating 
from host-specific microbes and the intake of 
nutrients and pharmaceuticals, present in cells, 
tissues, and biofluids.  
Different techniques have been developed to 
investigate the metabolome, distinguishing the 
different metabolites on the basis of their 
chemical and physical properties (Cacciatore 
and Loda 2015). 
Most commonly used techniques for me-
tabolomics are nuclear magnetic resonance 
(NMR), gas chromatography coupled to mass 
spectrometer (GC–MS) and mass spectroscopy 
(MS). Recently published papers describe the 
application of metabolomics in the study of 
heart disease, cancer, and other human pa-
thologies. Another potential application of me-
tabolomics involves the definition of biochemi-
cal pathways that contribute to drug response. 
Pharmaco-metabolomic signatures have also 
been identified for several drugs to predict in-
dividual responses to broader medical, dietary, 
microbiological or physiological challenges.  
Data generated experimentally by metabolomics 
are available in metabolite databases such as the 
Human Metabolome Database (HMDB). 
HMDB (www.hmdb.ca), the equivalent of the 
Human Genome Project for metabolomics, is a 
resource dedicated to providing scientists with 
the most current and comprehensive coverage 
of the human metabolome. Created in 2004, it 
contains information on biological properties, 
ontology, spectra and physical properties of 
human metabolites as well as data regarding 
metabolite concentrations, disease associations 
and tissue locations. Started as an inventory of 
2500 small molecules, its content has increased 
to 15000 entries (Liesenfeld et al. 2013). 
Lipidomics, term emerged for the first time in 
2003, is a sub-discipline of metabolomics that 
aims to define all of the lipid molecular species 
in a cell, including the metabolizing enzymes 
and lipid transporters and understand how lip-
ids function in a biological system. In detail, 
lipidomics involves the identification of indi-
vidual cellular lipid species, including the type 
and number of individual atoms in each lipid 
species, and their stereoelectronic interactions 
with other lipids and proteins. Cells use 5% of 
their genes to synthesize their lipids that fulfil 
three main functions. Lipids not only forms the 
bilayer matrix, not only are used as energy stor-
JDREAM.indd   8 18/01/18   11:03
 Michele Maffia, Luana Conte, Marco Greco, Maria Chiara Maffia, Pasquale Simeone, Daniele Vergara  
9 
age, but can also act as second messengers and 
participate in signalling via specialized micro-
domains, lipid rafts, that have large amounts of 
lipids. The field of lipidomics is rapidly growing 
as demonstrated by the great utility of this ap-
proach to improve diagnostic–prognostic capa-
bilities for human disorders, and for the identi-
fication of new classes of lipids. Similarly to 
what happened for genome and metabolome, 
an attempt to characterize the mammalian lipi-
dome has started under the LIPID MAPS ini-
tiative (http://www.lipidmaps.org) in 2005. To 
accomplish this goal, a consortium of twelve 
independent laboratories from seven academic 
institutions and one company has been formed 
(Schmelzer et al. 2007; Fahy et al. 2009).  
Early separation and identification of lipids 
started with GC and HPLC, but other tech-
nologies coupled to chromatographic methods, 
such as MS, Matrix-assisted laser desorption-
ionization/time of flight (MALDI/TOF), 
NMR, and quadrupole–linear ion trap 
(QTRAP), provide now a powerful approach to 
the global analysis of complex lipid mixtures. 
Given the enormous complexity of cellular lipi-
domics, it has been estimated to encompass 
around 180 000 – 200 000 different lipid spe-
cies, high-throughput technologies are needed 
to approach the entire lipidome of cells. 
MALDI can also be used to reveal the distribu-
tion of lipids in tissues with the technique of 
imaging mass spectrometry (IMS) obtaining in-
formation relevant to the local distribution of 
lipids as they occur in tissues. 
The term ‘‘epigenetics’’ was originally coined by 
Conrad Waddington to describe heritable 
changes in a cellular phenotype that were inde-
pendent of alterations in the DNA sequence. 
DNA methylation, the transfer of a methyl 
moiety from S-adenosylmethionine (SAM) to 
the 5-position of cytosines in certain CpG di-
nucleotides, represents the most studied of epi-
genetic processes with a great impact on gene 
expression. Evidence is mounting for a direct 
link between DNA methylation and human dis-
eases. Chromatin changes are another central 
epigenetic process with a role in transcription, 
repair, replication, and condensation. Overall, 
there are now at least four different DNA 
modifications and 16 classes of histone modifi-
cations. Gene-specific techniques for determin-
ing DNA methylation include bisulfite sequenc-
ing, methylation-specific PCR (MSP) and quan-
titative MSP. The coupling of NGS platforms 
with established chromatin techniques such as 
chromatin immunoprecipitation (ChIP-Seq) 
represents the standard for identifying binding 
site locations for individual protein and histone 
modifications. 
 
 
2. The post-genome era: Proteomics 
 
The complete characterization of all proteins 
has been the goal of proteomics since its incep-
tion more than 20 years ago. Originally coined 
by Wilkins et al. in 1996, the term “proteome” 
refers to the entire PROTEin complement ex-
pressed by a genOME (Abdallah et al. 2012).  
Proteomics techniques offer several advantages 
over genome-based technologies, as they di-
rectly deal with the functional molecules rather 
than genetic code or mRNA abundance. Even 
though there is only one definitive genome in 
an organism, it codes for multiple proteomes 
since the accumulation of a protein changes in 
relation to the environment and is the result of 
a combination of transcription, translation, pro-
tein turnover, and posttranslational modifica-
tions. 
Proteins are the real-time executors of many 
biological functions and proteomics is the large-
scale study of proteins, including their struc-
tures, localizations, post-translational modifica-
tions (PTMs), and functions.  
Proteomics experiments also provide informa-
tion on protein interactions and complex for-
mation. For example, proteins interact with 
each other as part of large complexes that serve 
to execute most biological processes including 
signal transduction, transcription, and transla-
tion. A literature search at the start of 2013 
showed there were 38031 articles published on 
proteomics encompassing several research 
strategies; today, after four years, their number 
is more than doubled to a value of more than 
86000 articles. In both bacteria and eukaryotes, 
the cellular concentrations of proteins do not 
completely correlate with the abundances of 
their corresponding mRNAs. They often show 
a squared Pearson correlation coefficient of 
about 0.40, this means that about 40 % of the 
variation in protein concentration can be ex-
plained by knowing mRNA abundances. This 
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individuals. Presently, there are three main 
NGS systems: the Roche/454 FLX, the Illu-
mina/Solexa Genome Analyzer, and the Ap-
plied Biosystems SOLiDTM System. Each one, 
by a different approach, seeks to amplify single 
strands of a fragment library and perform se-
quencing reactions on the amplified strands. 
Together with these technologies, a new gen-
eration of single-molecule sequencing tech-
nologies is now emerging offering advantages 
over current sequencing methods including 
small amounts of starting material (theoretically 
only a single molecule may be required for se-
quencing), and low cost.  
An important consequence of this new emerg-
ing scenario was the creation of multi-
disciplinary teams and the formation of large-
scale collaborative networks to handle and inte-
grate these large amounts of data. The HGP 
was the first example of a large collaborative 
project; others include the Cancer Genome At-
las (TCGA) and the 1000 genome project. 
TCGA has achieved comprehensive sequenc-
ing, characterization, and analysis of the ge-
nomic changes of major types of human can-
cers providing also a platform for researchers to 
search, download, and analyse data sets gener-
ated by TCGA (http://cancergenome.nih.gov). 
The 1000 genome project aims to establish an 
extensive catalogue of human variations from 
25 populations (www.1000genomes.org). The 
project provides an international open access 
resource that serves as a basis for subsequent 
phenotype related studies 
(www.1000genomes.org). 
Endogenous metabolites can be seen as part of 
the downstream output of the genome, com-
plementary as ‘‘upstream’’ changes in genes 
(Spratlin, Serkova, and Eckhardt 2009), and 
their study together with exogenous metabolite 
is important to understand what happens in an 
organism. The term “metabolome” was intro-
duced in 1998 as the total metabolite content of 
a biological sample, an enormous complex and 
dynamic number of components that belong to 
a wide variety of compound classes, including 
nucleic acids, amino acids, sugars, and lipids. 
The term metabolomics was used for the first 
time in 2000 by Fien, to describe the discipline 
devot 
ed to the study of global metabolite profiles 
produced in biosynthetic and catabolic path-
ways from biological systems or originating 
from host-specific microbes and the intake of 
nutrients and pharmaceuticals, present in cells, 
tissues, and biofluids.  
Different techniques have been developed to 
investigate the metabolome, distinguishing the 
different metabolites on the basis of their 
chemical and physical properties (Cacciatore 
and Loda 2015). 
Most commonly used techniques for me-
tabolomics are nuclear magnetic resonance 
(NMR), gas chromatography coupled to mass 
spectrometer (GC–MS) and mass spectroscopy 
(MS). Recently published papers describe the 
application of metabolomics in the study of 
heart disease, cancer, and other human pa-
thologies. Another potential application of me-
tabolomics involves the definition of biochemi-
cal pathways that contribute to drug response. 
Pharmaco-metabolomic signatures have also 
been identified for several drugs to predict in-
dividual responses to broader medical, dietary, 
microbiological or physiological challenges.  
Data generated experimentally by metabolomics 
are available in metabolite databases such as the 
Human Metabolome Database (HMDB). 
HMDB (www.hmdb.ca), the equivalent of the 
Human Genome Project for metabolomics, is a 
resource dedicated to providing scientists with 
the most current and comprehensive coverage 
of the human metabolome. Created in 2004, it 
contains information on biological properties, 
ontology, spectra and physical properties of 
human metabolites as well as data regarding 
metabolite concentrations, disease associations 
and tissue locations. Started as an inventory of 
2500 small molecules, its content has increased 
to 15000 entries (Liesenfeld et al. 2013). 
Lipidomics, term emerged for the first time in 
2003, is a sub-discipline of metabolomics that 
aims to define all of the lipid molecular species 
in a cell, including the metabolizing enzymes 
and lipid transporters and understand how lip-
ids function in a biological system. In detail, 
lipidomics involves the identification of indi-
vidual cellular lipid species, including the type 
and number of individual atoms in each lipid 
species, and their stereoelectronic interactions 
with other lipids and proteins. Cells use 5% of 
their genes to synthesize their lipids that fulfil 
three main functions. Lipids not only forms the 
bilayer matrix, not only are used as energy stor-
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age, but can also act as second messengers and 
participate in signalling via specialized micro-
domains, lipid rafts, that have large amounts of 
lipids. The field of lipidomics is rapidly growing 
as demonstrated by the great utility of this ap-
proach to improve diagnostic–prognostic capa-
bilities for human disorders, and for the identi-
fication of new classes of lipids. Similarly to 
what happened for genome and metabolome, 
an attempt to characterize the mammalian lipi-
dome has started under the LIPID MAPS ini-
tiative (http://www.lipidmaps.org) in 2005. To 
accomplish this goal, a consortium of twelve 
independent laboratories from seven academic 
institutions and one company has been formed 
(Schmelzer et al. 2007; Fahy et al. 2009).  
Early separation and identification of lipids 
started with GC and HPLC, but other tech-
nologies coupled to chromatographic methods, 
such as MS, Matrix-assisted laser desorption-
ionization/time of flight (MALDI/TOF), 
NMR, and quadrupole–linear ion trap 
(QTRAP), provide now a powerful approach to 
the global analysis of complex lipid mixtures. 
Given the enormous complexity of cellular lipi-
domics, it has been estimated to encompass 
around 180 000 – 200 000 different lipid spe-
cies, high-throughput technologies are needed 
to approach the entire lipidome of cells. 
MALDI can also be used to reveal the distribu-
tion of lipids in tissues with the technique of 
imaging mass spectrometry (IMS) obtaining in-
formation relevant to the local distribution of 
lipids as they occur in tissues. 
The term ‘‘epigenetics’’ was originally coined by 
Conrad Waddington to describe heritable 
changes in a cellular phenotype that were inde-
pendent of alterations in the DNA sequence. 
DNA methylation, the transfer of a methyl 
moiety from S-adenosylmethionine (SAM) to 
the 5-position of cytosines in certain CpG di-
nucleotides, represents the most studied of epi-
genetic processes with a great impact on gene 
expression. Evidence is mounting for a direct 
link between DNA methylation and human dis-
eases. Chromatin changes are another central 
epigenetic process with a role in transcription, 
repair, replication, and condensation. Overall, 
there are now at least four different DNA 
modifications and 16 classes of histone modifi-
cations. Gene-specific techniques for determin-
ing DNA methylation include bisulfite sequenc-
ing, methylation-specific PCR (MSP) and quan-
titative MSP. The coupling of NGS platforms 
with established chromatin techniques such as 
chromatin immunoprecipitation (ChIP-Seq) 
represents the standard for identifying binding 
site locations for individual protein and histone 
modifications. 
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The complete characterization of all proteins 
has been the goal of proteomics since its incep-
tion more than 20 years ago. Originally coined 
by Wilkins et al. in 1996, the term “proteome” 
refers to the entire PROTEin complement ex-
pressed by a genOME (Abdallah et al. 2012).  
Proteomics techniques offer several advantages 
over genome-based technologies, as they di-
rectly deal with the functional molecules rather 
than genetic code or mRNA abundance. Even 
though there is only one definitive genome in 
an organism, it codes for multiple proteomes 
since the accumulation of a protein changes in 
relation to the environment and is the result of 
a combination of transcription, translation, pro-
tein turnover, and posttranslational modifica-
tions. 
Proteins are the real-time executors of many 
biological functions and proteomics is the large-
scale study of proteins, including their struc-
tures, localizations, post-translational modifica-
tions (PTMs), and functions.  
Proteomics experiments also provide informa-
tion on protein interactions and complex for-
mation. For example, proteins interact with 
each other as part of large complexes that serve 
to execute most biological processes including 
signal transduction, transcription, and transla-
tion. A literature search at the start of 2013 
showed there were 38031 articles published on 
proteomics encompassing several research 
strategies; today, after four years, their number 
is more than doubled to a value of more than 
86000 articles. In both bacteria and eukaryotes, 
the cellular concentrations of proteins do not 
completely correlate with the abundances of 
their corresponding mRNAs. They often show 
a squared Pearson correlation coefficient of 
about 0.40, this means that about 40 % of the 
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scale collaborative networks to handle and inte-
grate these large amounts of data. The HGP 
was the first example of a large collaborative 
project; others include the Cancer Genome At-
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nomic changes of major types of human can-
cers providing also a platform for researchers to 
search, download, and analyse data sets gener-
ated by TCGA (http://cancergenome.nih.gov). 
The 1000 genome project aims to establish an 
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project provides an international open access 
resource that serves as a basis for subsequent 
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produced in biosynthetic and catabolic path-
ways from biological systems or originating 
from host-specific microbes and the intake of 
nutrients and pharmaceuticals, present in cells, 
tissues, and biofluids.  
Different techniques have been developed to 
investigate the metabolome, distinguishing the 
different metabolites on the basis of their 
chemical and physical properties (Cacciatore 
and Loda 2015). 
Most commonly used techniques for me-
tabolomics are nuclear magnetic resonance 
(NMR), gas chromatography coupled to mass 
spectrometer (GC–MS) and mass spectroscopy 
(MS). Recently published papers describe the 
application of metabolomics in the study of 
heart disease, cancer, and other human pa-
thologies. Another potential application of me-
tabolomics involves the definition of biochemi-
cal pathways that contribute to drug response. 
Pharmaco-metabolomic signatures have also 
been identified for several drugs to predict in-
dividual responses to broader medical, dietary, 
microbiological or physiological challenges.  
Data generated experimentally by metabolomics 
are available in metabolite databases such as the 
Human Metabolome Database (HMDB). 
HMDB (www.hmdb.ca), the equivalent of the 
Human Genome Project for metabolomics, is a 
resource dedicated to providing scientists with 
the most current and comprehensive coverage 
of the human metabolome. Created in 2004, it 
contains information on biological properties, 
ontology, spectra and physical properties of 
human metabolites as well as data regarding 
metabolite concentrations, disease associations 
and tissue locations. Started as an inventory of 
2500 small molecules, its content has increased 
to 15000 entries (Liesenfeld et al. 2013). 
Lipidomics, term emerged for the first time in 
2003, is a sub-discipline of metabolomics that 
aims to define all of the lipid molecular species 
in a cell, including the metabolizing enzymes 
and lipid transporters and understand how lip-
ids function in a biological system. In detail, 
lipidomics involves the identification of indi-
vidual cellular lipid species, including the type 
and number of individual atoms in each lipid 
species, and their stereoelectronic interactions 
with other lipids and proteins. Cells use 5% of 
their genes to synthesize their lipids that fulfil 
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age, but can also act as second messengers and 
participate in signalling via specialized micro-
domains, lipid rafts, that have large amounts of 
lipids. The field of lipidomics is rapidly growing 
as demonstrated by the great utility of this ap-
proach to improve diagnostic–prognostic capa-
bilities for human disorders, and for the identi-
fication of new classes of lipids. Similarly to 
what happened for genome and metabolome, 
an attempt to characterize the mammalian lipi-
dome has started under the LIPID MAPS ini-
tiative (http://www.lipidmaps.org) in 2005. To 
accomplish this goal, a consortium of twelve 
independent laboratories from seven academic 
institutions and one company has been formed 
(Schmelzer et al. 2007; Fahy et al. 2009).  
Early separation and identification of lipids 
started with GC and HPLC, but other tech-
nologies coupled to chromatographic methods, 
such as MS, Matrix-assisted laser desorption-
ionization/time of flight (MALDI/TOF), 
NMR, and quadrupole–linear ion trap 
(QTRAP), provide now a powerful approach to 
the global analysis of complex lipid mixtures. 
Given the enormous complexity of cellular lipi-
domics, it has been estimated to encompass 
around 180 000 – 200 000 different lipid spe-
cies, high-throughput technologies are needed 
to approach the entire lipidome of cells. 
MALDI can also be used to reveal the distribu-
tion of lipids in tissues with the technique of 
imaging mass spectrometry (IMS) obtaining in-
formation relevant to the local distribution of 
lipids as they occur in tissues. 
The term ‘‘epigenetics’’ was originally coined by 
Conrad Waddington to describe heritable 
changes in a cellular phenotype that were inde-
pendent of alterations in the DNA sequence. 
DNA methylation, the transfer of a methyl 
moiety from S-adenosylmethionine (SAM) to 
the 5-position of cytosines in certain CpG di-
nucleotides, represents the most studied of epi-
genetic processes with a great impact on gene 
expression. Evidence is mounting for a direct 
link between DNA methylation and human dis-
eases. Chromatin changes are another central 
epigenetic process with a role in transcription, 
repair, replication, and condensation. Overall, 
there are now at least four different DNA 
modifications and 16 classes of histone modifi-
cations. Gene-specific techniques for determin-
ing DNA methylation include bisulfite sequenc-
ing, methylation-specific PCR (MSP) and quan-
titative MSP. The coupling of NGS platforms 
with established chromatin techniques such as 
chromatin immunoprecipitation (ChIP-Seq) 
represents the standard for identifying binding 
site locations for individual protein and histone 
modifications. 
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tion more than 20 years ago. Originally coined 
by Wilkins et al. in 1996, the term “proteome” 
refers to the entire PROTEin complement ex-
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over genome-based technologies, as they di-
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than genetic code or mRNA abundance. Even 
though there is only one definitive genome in 
an organism, it codes for multiple proteomes 
since the accumulation of a protein changes in 
relation to the environment and is the result of 
a combination of transcription, translation, pro-
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Proteins are the real-time executors of many 
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tures, localizations, post-translational modifica-
tions (PTMs), and functions.  
Proteomics experiments also provide informa-
tion on protein interactions and complex for-
mation. For example, proteins interact with 
each other as part of large complexes that serve 
to execute most biological processes including 
signal transduction, transcription, and transla-
tion. A literature search at the start of 2013 
showed there were 38031 articles published on 
proteomics encompassing several research 
strategies; today, after four years, their number 
is more than doubled to a value of more than 
86000 articles. In both bacteria and eukaryotes, 
the cellular concentrations of proteins do not 
completely correlate with the abundances of 
their corresponding mRNAs. They often show 
a squared Pearson correlation coefficient of 
about 0.40, this means that about 40 % of the 
variation in protein concentration can be ex-
plained by knowing mRNA abundances. This 
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demonstrates that proteomics represents a 
complementary to genomics approaches. 
The classic proteomics screening methodology 
combine two different approaches. The first 
one, called expression-based proteomics, has 
the aim to define the expression of all proteins 
present in biological samples. Traditionally, it is 
performed through the combination of several 
sequential steps including protein extraction, 
separation and identification. The general start-
ing point is the protein separation by an elec-
trophoresis system, one- or two-dimensional 
electrophoresis (1-DE or 2-DE), and the sub-
sequent identification of digested proteins by 
MS. Alternatively, proteins can also be digested 
using a specific protease and the resulting pep-
tides separated and analysed immediately by 
MS. Such approach, namely as shotgun, is con-
sidered the method of choice for the large-scale 
analysis of proteins. The strength of this ap-
proach is that it is unbiased; a drawback is that 
the outcome relies on analysis and interpreta-
tion of experimental data. By contrast, targeted 
proteomic using multiple-reaction monitoring 
mass spectrometry (MRM-MS) allows the selec-
tive detection and quantification of selected 
peptide ions. Such approach uses the capability 
of triple quadrupole mass spectrometers to act 
as ion filters. In a MRM-MS experiment, the 
precursor ion is isolated in the first quadrupole 
(Q1), fragmented within Q2 producing frag-
ment ions that are monitored using Q3. 
The second approach, functional proteomics, 
aims to define the biological role of proteins 
and to identify protein–protein interactions, or 
interactomes. Protein complexes can be puri-
fied in several ways, one very common ap-
proach is to use an affinity tag to the protein of 
interest and purify the interacting partners. 
Proteomics has emerged more than two dec-
ades ago as a post-genomic technology with the 
promise to unravel the cellular mechanisms of 
diseases and to develop reliable markers of di-
agnosis or treatment. However, such studies 
remain challenging owing to the high degree of 
complexity of cellular proteomes, in particular 
the serum/plasma proteome, and the low 
abundance of regulatory proteins hidden by 
abundant proteins. Due to the enormous varia-
tion in protein diversity, there is currently no 
single methodological platform that can be used 
for a full characterization of the proteome. 
2.1. Methods for protein separation 
 
The separation of all the proteins contained 
within cells, tissues, and biofluids remains a 
challenging analytical problem. Existing meth-
odologies are not adequate to completely isolate 
and resolve the large number of proteins pre-
sent at such different levels of concentration. 
Proteomic approaches can be classified as ei-
ther gel-based or gel-free methods that can be 
further subdivided in “label-free” or “label-
based”. 
 
2.1.1. Gel-based Proteomics: 2-DE 
The attempts to develop a 2-DE started in the 
late 60’, but it was O'Farrell in 1975 who opti-
mized a method on the basis that each electro-
phoresis separation must be done in independ-
ent parameter, to avoid protein being distrib-
uted across a diagonal rather than across the en-
tire surface of the gel (Magdeldin 2012). In the 
first dimension, protein molecules are resolved 
depending on their isoelectric point (pI); in the 
second dimension, protein separation is per-
formed based on molecular weight (Magdeldin 
et al. 2014). 
This technique has broadly affected life science 
research and successfully used applied to the 
study of biological or clinical samples for the 
purposes of identifying novel disease-specific 
protein biomarkers or gaining better under-
standings novel protein targets for therapeutic 
interventions and drug developments. During 
these years, several advances that have en-
hanced resolution, detection, quantitation, and 
reproducibility of the technique, increasing the 
robustness of the entire 2-DE workflow. One 
of the most notable improvements was the in-
troduction of immobilized pH gradient (IPG) 
gels that led to standardized procedures for 2-
DE permitting higher resolution and improved 
reproducibility for inter laboratory compari-
sons. More recently, the development of 2-D 
differential in-gel electrophoresis (DIGE) in 
1997 overcame problems of reproducibility and 
quantitation because allowed running test and 
control sample in the same gel. This method 
was designed in an attempt to increase sensitiv-
ity and reproducibility of 2-DE using multi-
plexed fluorescent dyes- labelled protein sam-
ples. 2D-DIGE is based mainly on running 
more than one sample (maximum 3) on a single 
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quantitation because allowed running test and 
control sample in the same gel. This method 
was designed in an attempt to increase sensitiv-
ity and reproducibility of 2-DE using multi-
plexed fluorescent dyes- labelled protein sam-
ples. 2D-DIGE is based mainly on running 
more than one sample (maximum 3) on a single 
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gel at once. Different fluorescent cyanine (Cy) 
dyes are used for labelling proteins from differ-
ent samples 
This technique enables protein detection at sub 
picomolar levels and relies on pre electropho-
retic labelling of samples with one of three 
spectrally resolvable fluorescent CyDyes (Cy2, 
Cy3, and Cy5) (Abdallah et al. 2012). Images are 
subsequently imported into dedicated 2-DE 
image analysis softwares. 
Although there has been a significant progress 
towards liquid chromatography and MS meth-
ods to separate and analyse proteins, 2-DE still 
remain a popular technique for conducting pro-
teomic studies. Proteins of interest are excised 
from the gel, proteolytically digested, and iden-
tified using MS (Figure 1). In a single run, up to 
1,000 – 2,000 protein species from one com-
plex sample can be separated. In specialised 
laboratories, using large-gel 2-DE method, the 
number of protein spots detected were drasti-
cally increased up to 10, 000. Subsequently, 2-
DE gel easily and efficiently couples with many 
other analysis and biochemical techniques; 
spots can be excised, proteins can be extracted 
and after a tryptic digestion analysed by mass 
spectrometry. 
Figure 1. A schematic workflow of two-dimensional gel elec-
trophoresis (2-DE). 2-D gel electrophoresis is an experimental 
technique that combines two separation methods. Biological 
samples are grown under different conditions and total proteins 
are extracted and subjected to isoelectric focusing (IEF) (first-
dimension electrophoresis), where proteins are separated ac-
cording to their isoelectric point (pI). After first dimension, 
IPG-strips are re-equilibrated to the second dimension buffer 
conditions, and transferred to the SDS-PAGE gels. Proteins on 
gels are visualized by MS-compatible stains, including 
Coomassie or silver staining. Software-based image analysis is 
then crucial for the biological interpretation of experiments. 
After statistical validation, differentially expressed spots from 2-
DE gels are excised, and a tryptic digestion is performed to 
generate tryptic peptide mixtures of the proteins that are ap-
plied to MALDI- or LC-MS/MS for identification of the ex-
cised proteins. The peptide data then are compared with the 
entire protein database (Swiss-Prot, NCBI). 
 
2.1.2 Gel free-based approaches 
Because of problems in quantitative reproduci-
bility and limitations on the ability to study cer-
tain classes of proteins, researchers have devel-
oped alternatives to 2-DE, for MS-based pro-
teomics techniques. 
High-resolution liquid chromatography (LC) 
separation coupled on line with a mass spec-
trometer is the central component of a gel free-
approach. Complex protein mixtures are di-
gested by trypsin into polypeptides, which are 
then separated by LC and analyzed by MS via 
an electro spray ionization (ESI) interface.  
In this approach is not the protein itself, which 
is separated and identified. Instead, proteins are 
cleaved into peptides using proteolytic enzymes 
and, subsequently, these peptides are separated 
and subjected to mass spectrometric analysis. 
This allows the determination of the protein 
content of the initial sample (Baggerman et al. 
2005). 
For this purpose, chromatographic separations 
are performed using flow rates in the range of 
low nanoliter per minute (nano-flow liquid 
chromatography or nanoLC). The relative 
quantification of peptides usually involves ei-
ther label-free or stable isotope labelling tech-
niques to identify differences in protein abun-
dances. The labelling methods can be classified 
into two main groups: chemical isotope tags 
and metabolic labelling. A variety of labelling 
approaches including, Proteolytic Labelling, 
Isotope-Coded Protein Labelling (ICPL), Iso-
tope-Coded Affinity Tags (ICATs), Isobaric 
Tags for Relative and Absolute Quantification 
(iTRAQ), TandemMass Tag (TMT), 14N/15N 
Labelling and Stable Isotope Labelling by 
Amino Acids in Cell Culture (SILAC) are valu-
able techniques in quantitative proteomic analy-
sis. The rationale behind each labelling strategy 
is to create a mass shift that distinguishes iden-
tical peptides that exhibit the same chroma-
tographic and ionisation properties, from dif-
ferent samples within a single MS analysis.  
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Figure 2. A schematic workflow of gel free electrophoresis 
(Yang and Han 2016)  
 
3. Limitations of current proteomics approach 
 
In recent decades gel based proteomics tech-
niques became robust and reproducible, how-
ever two distinctive issues remains a challenge: 
the problems to detect low abundance and hy-
drophobic proteins. 
The question of under-representation of hy-
drophobic protein and in particular membrane 
proteins is well known and to explain this prob-
lem very different possible mechanisms have 
been proposed: (i) aggregation caused by the 
low solubility of these protein species in the 
aqueous media; (ii) protein loss over the se-
quential steps of the 2-DE processes; (iii) pre-
cipitation at the protein corresponding pI dur-
ing isoelectrofocusing phase; (iv) expression in 
low copy numbers; (v) difficulties to identify  
them by MS than hydrophilic proteins. Several 
fruitful strategies were considered to solve the 
problem. Usually, the best strategy in 2-DE ex-
periments is to solubilize proteins from the 
lipid layers by detergent and chaotropic salt. 
This can be performed by applying a solution 
of 2M thiourea, 8M urea, and 4% chaps. In the 
most recent years, other solutions were pro-
posed: use of different zwitterionic detergents, 
nonionic n-dodecyl β-D-maltoside and zwit-
terionic amidosulfobetaine ASB-14, and 1,2-
diheptanoyl-sn-glycero-3-phosphatdiyl choline 
(DHPC). Two organic solvents have been rec-
ommended for miscible extraction of red blood 
cells membrane proteins using methanol 
(MeOH), 2,2,2-tri- fluoroethanol (TFE) and 
urea. 
Despite the many solutions proposed in the re-
cent years the problems with hydrophobic pro-
teins, on 2D gels are widely unsolved. In fact, 
membrane protein solubility is low at their pI, 
and therefore membrane proteins tend to pre-
cipitate at their pI range. It is evident that the 
issue represents a built-in problem for all 2D 
electrophoresis systems IEF-based, for this rea-
son IEF-free separation systems represent a 
natural alternative in the analysis of membrane 
proteins. 
 
 
3.1 Protein abundance 
The large number of gene and gene splice-
variants that encode proteins, as well as the ex-
tensive post-translational modifications of eu-
karyotic proteins renders proteomic studies ex-
tremely difficult. The detection of specific, dis-
ease-related protein markers, notoriously diffi-
cult to identify, because expressed at low con-
centration, can be extremely challenging on a 
classical proteomic experiments where highly 
abundant proteins could obscure the rare ones. 
Consequently, there has been an extensive in-
vestment into developing techniques and 
methods capable of revealing the so named 
“hidden proteome”. This cannot be achieved 
by one single approach. In fact, several meth-
ods are used for the enrichment and visualiza-
tion of the low-abundance proteins and also for 
the depletion of the high-abundance proteins.  
It was demonstrated that the 10% most-
expressed gene products represented the 75% 
of the total protein content, and the 2/3 of less-
expressed only 10% of the protein content. In 
this situation is simple to argue that the signal 
of high-abundance proteins tends to hide the 
signal of rare species. 
Some of these technical difficulties can be by-
passed loading more sample, exploiting the 
great capacity of 2D gels, allowing many of low 
abundant proteins to be detected because above 
the detection limit. But high-loading approach 
is restricted by gel crowding and is related to 
the strong presence of normal and modified 
forms of high abundance protein species. This 
strategy gives gel with completely saturated 
zones with no increased performance in the 
visualization of low abundant species. Possible 
solutions proposed the use of giant gels with 
greater resolution and capacity. However, this 
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technology is inadequate and difficult to use 
due to the extreme fragility of the gels em-
ployed in the analysis. 
To address these issues, analytical chemists 
have attempted to develop pre-fractionation 
methods to separate large numbers of proteins. 
Fractionation based-methods that take advan-
tage of proteins function or structure are exten-
sively used, allowing the isolation of specific 
proteomes: glyco-proteome by lectin columns, 
phospho-proteome by anti-phospho-aminoacid 
antibodies or metal-chelating resins. However, 
these protocols do not resolve the challenge of 
signal suppression due to high-abundance spe-
cies present. Immunodepletion columns, con-
taining immobilized antibodies addressing the 
highest abundance proteins, were proposed as a 
possible solution. Though, these approaches 
cause the dilution of the initial sample, render-
ing it even more difficult to detect low-
abundance proteins. 
In this scenario, combinatorial hexapeptide 
ligand libraries have arisen as a powerful 
method for sample handling and are recently 
used to better elucidate and obtain extensive in-
formation on the protein composition of com-
plex samples like serum, bile fluid, human 
urine, platelet extracts, and red blood cell lysate. 
The ligand libraries, designed as batch of chro-
matographic beads, are synthesized by modified 
Merrifield approach described by Lam and col-
laborators. The library consists of millions of 
affinity baits (hexapeptides) so that each bead 
comprises multiple copies of the same bait. The 
beads represent the affinity solid phase of 
chromatographic column. This hexapeptide 
ligand library is assembled in order to be able to 
bind each single protein species present in a 
given biological extract. On the basis of the 
saturation-overloading chromatographic princi-
ple the loaded proteins are captured by their re-
spective specific ligand until saturation whereas 
the excess, unbound proteins are washed away. 
The proteins are captured from the peptide li-
brary by several and different combination of 
interacting forced: Van der Walls interactions, 
hydrogen bonding, structural docking, hydro-
phobic associations etc. Thus, high represented 
proteins species rapidly saturate their specific 
bead ligands while the excess of the same pro-
tein remains unbound. On the contrary, low-
abundance proteins were concentrated by their 
ligand up to saturation. Washing steps eliminate 
the protein excess not bound to the library and 
are removed from the chromatographic col-
umn. The protein species bound are eluted by a 
single appropriate elution buffer able of destroy 
proteins–hexapeptides interaction or by a se-
quence of desorbing agents, each of them ad-
dressing a selected type of binding. These frac-
tions can then be analyzed using well-known 
methods, such as SDS-PAGE, 2D electropho-
resis and MS. An application of hexapeptide li-
braries to cellular lysates is reported in Figure 2. 
Proteins obtained from the human T cell lym-
phoblast-like cell line Jurkat were used as start-
ing material to show the feasibility of this ap-
proach. 
 
Figure 3. Figure shows the 2-DE maps (pH 3-10) obtained 
from initial Jurkat cell line extract (top) as compared with those 
obtained from: (A) 2.5 mg/ml of proteins treated with library 
and eluted with RS solution (2 M thiourea, 7 M urea, 4% 
CHAPS); (B) 5 mg/ml of proteins treated with library and 
eluted with RS solution (2 M thiourea, 7 M urea, 4% CHAPS); 
(C) and (D) 14 mg/ml of proteins treated with library and 
eluted with RS solution (2 M thiourea, 7 M urea, 4% CHAPS) 
and RSA solution (2 M thiourea, 7 M urea, 4% CHAPS, acetic 
acid to pH 3.3), respectively. 
Jurkat cell line was maintained in RPMI-1640 medium contain-
ing 10% fetal bovine serum (FBS) and antibiotics. Cells were 
harvested by centrifugation followed by lysis via sonification in 
Tris buffer containing protease inhibitors. Varying amounts of 
cell lysate (2.5 mg/ml, 5 mg/ml, 14 mg/ml) were subjected to 
column chromatography over a solid-phase combinatorial 
ligand library (ProteoMiner, Biorad). Following washing, each 
individual column was subjected to two distinct elutions using a 
RS solution (2 M thiourea, 7 M urea, 4% CHAPS) and a RSA 
solution (2 M thiourea, 7 M urea, 4% CHAPS, acetic acid to pH 
3.3) respectively. RSA eluted sample was precipitated with 2D 
Clean-Up (GE Healthcare) and resuspended in RS. 
For 2-DE studies, 80 μg of proteins were dissolved in sample 
buffer and isoelectric focusing of protein samples was carried 
out by using commercial 13 cm IPG polyacrylamide strips (pH 
3 to 10 NL). Separation in the second dimension was carried 
out in 12% SDS-PAGE gels. Silver stained gels were scanned 
and analyzed by the software Image-Master 2-D Platinum. 
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4. Bioinformatics for high-throughput platforms 
 
Over the last decades, large-scale genome se-
quencing of model organisms and humans 
(Lander et al. 2001) has been a landmark 
achievement in biomedical sciences that was 
fueled by extraordinary advances in molecular 
biology and computer science. The broad appli-
cation of genomics and proteomics fields as 
well as the diffusion of high-throughput plat-
forms, have led to increasing the volume of 
available data requiring efficient algorithms 
along with new data management, new analysis 
and novel visualization techniques. This is in 
turn helped in redefining the synergy between 
biology, information sciences, mathematics, and 
computational techniques. This synergy is large-
ly used by researchers to analyze the infor-
mation on a large-scale, through the integration 
of computational algorithms, software tools and 
databases in an effort to address biological and 
medical questions. 
Luscombe et al. proposed a definition on bioin-
formatics as a union of biology and informatics: 
it involves the technology that uses computers 
for storage, retrieval, manipulation and distribu-
tion of information related to biological mac-
romolecules such as DNA, RNA, and proteins 
(Luscombe, Greenbaum, and Gerstein 2001).  
Initial research applications of bioinformatics 
were primarily focused on analysis of biological 
sequence data, genome content and rearrange-
ment, as well as for prediction of function and 
structure of macromolecules (Luscombe, 
Greenbaum, and Gerstein 2001). Over the last 
few decades, with the advent of high through-
put “omics”, it is now feasible to systematically 
profile a biological system at different levels of 
molecular and cellular organization, including 
its epigenome, transcriptome, metabolome, 
proteome, and interactome (Joyce and Palsson 
2006). Overtime, then, the broad nature and 
scale of these data types have spawned from 
conventional bioinformatics to specialized 
branch of bioinformatics such as comparative 
genomics (Miller et al. 2004), functional ge-
nomics (Vukmirovic and Tilghman 2000), net-
work biology (Barabási and Oltvai 2004) and 
computational proteomics (Colinge and Ben-
nett 2007). Moreover, with the subsequent real-
ization that the complete understanding of bi-
ology is obtained from multi level data integra-
tion, computational system biology has come 
into prominence.  
Mass spectrometry based proteomics has un-
dergone important advances in the scientific 
community, due to technological instrumenta-
tion and innovation in computational prote-
omics (Cox and Mann 2007) that is am inten-
sive discipline that requires extensive analytical 
and data-mining support and bioinformatics 
approaches.  
We can distinguish between qualitative prote-
omics and quantitative proteomics. In qualita-
tive proteomics, most of the bioinformatics ac-
tivities are focused on functional data mining of 
the dataset to extract the global biological 
theme underlying the proteome. The first step 
for functional interpretation of a protein list is 
to connect the protein identifier with its associ-
ated Gene Ontology Terms (GO_terms). 
Genes are then associated to hierarchically clus-
tered, functional terms that describe the “bio-
logical process”, “molecular function” or “cel-
lular component” (Schmidt 2014). Similarly to 
GO term enrichment analysis, proteins can also 
be analyzed for pathway abundance which 
might be more meaningful since allow the iden-
tification of functional biological processes as-
sociated to that protein (Schmidt 2014). Com-
prehensive pathway databases such as KEGG, 
include many interaction data coming from in-
tracellular reactions such as metabolism or sig-
naling pathways, genetic alterations or drug 
studies (Kanehisa et al. 2012). 
Genome-wide annotational datasets like GO, 
protein domain organization (PFAM, InterPro) 
(Mulder et al. 2007), pathways (KEGG) 
(Kanehisa et al. 2004) and disease mutations 
(OMIM) have been successfully used for func-
tional proteomics (Pasini et al. 2006). These an-
notations can be further used in conjuction 
with statistical tests to find over/under-
represented functional categories  (Adachi et al. 
2007). Additionally, integration with other high 
throughput “omics” datasets, such as microar-
ray, may provide valuable insights into proteo-
me expression and disease mechanisms 
(Graumann et al. 2008). 
In quantitative proteomics, we know that mass 
spectrometry provide quantitative data of pro-
teome changes in the cellular states. This in-
formation can be used on a binary level of pro-
tein changes, for instance normal vs cancer, 
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stimulated vs non-stimulated cells with growth 
factors as well as a step of cell cycle or differen-
tiation. There are a lot of methods and ap-
proaches for proteomics datasets across multi-
ple conditions or samples. However, in clinical 
applications of proteomics, biomarker discov-
ery can be done by comparison of proteome 
profiles of healthy and disease profiles, using 
genetic algorithms (Petricoin et al. 2002) and on 
building classification models for disease pre-
dictions. 
Microarrays have now permeated literally every 
field of biology and have found many applica-
tions in translational research. Large-scale mi-
croarray data are also becoming crucial for ex-
perimental biology along with computational 
algorithms, which find wider application in 
basic research, target discovery, drug discovery, 
biomarker identification and disease determina-
tion. Microarray Bioinformatics include, indeed, 
a range of inferential (Rhodes et al. 2002) and 
descriptive statistical methods. Reverse engi-
neering of gene networks using gene expression 
data based in Bayesian statistics (probabilistic 
models) (Friedman et al. 2000), Boolean and 
Relevance networks (Butte and Kohane 2000) 
and graph theoretic algorithms (Tringe, Wag-
ner, and Ruby 2004) are successfully applied to 
microarray data to uncover patterns in disease, 
especially in cancer (Lapointe et al. 2004).  
Bioinformatics approach for identification of 
cis-regulatory sequences has gained impetus in 
computational prediction of the gene regula-
tion, especially from recent discoveries in tran-
scriptional regulation by regulatory RNA 
(miRNA, siRNA, piRNA) and their targets 
(Bentwich 2008) as well as the current apprecia-
tion of the role of epigenetics. Bioinformatics 
applied to gene regulation is one of the most 
exciting areas of computational research. One 
of the principle means of coordinating tran-
scription spatially and temporally is through the 
presence of cis-regulatory elements. These 
short DNA sequence motifs, proximal to the 
transcriptional start site (TSS), are bound by 
transcription factors responsible for the re-
cruitment of the transcriptional initiation ma-
chinery and represent principle components 
that act in response to a particular cellular con-
text and extra-cellular inputs. Global elucidation 
of gene-specific cis-regulatory control will per-
mit the understanding of global transcriptional 
networks and facilitate our understanding of 
the properly functioning of biological system. 
In addition, de novo prediction of these bind-
ing sites has become an active area of research 
in the field of functional genomics. A complete 
understanding of this molecular algorithm give 
great impact on biological research, essential for 
gaining insights into development, cellular re-
sponses to environmental and genetic altera-
tions and the molecular basis of many diseases.  
The dynamic interplay between genes, proteins 
and metabolites leads to a complex biological 
network that include protein-protein interac-
tions, regulatory circuits linking transcription 
factors, cis-regulatory elements, signal transduc-
tion pathways and metabolic pathways. Net-
work bioinformatics is a fascinating areas of bi-
oinformatics and aims to study this complex 
biological circuit using mathematical modeling 
and simulation of pathways, graph-theory anal-
ysis of global network structure, application of 
engineering concept of network analysis as well 
as de novo design of networks. Protein-Protein 
interaction network, are typically visualized as 
“graph networks” where the nodes represent 
the protein, while an edge connecting two 
nodes. Protein-Protein interactions are often 
displayed as a networks illustrating the high de-
gree of connectivity and the presence of partic-
ular hub proteins. 
Genomics and bioinformatics are now poised 
to revolutionize our healthcare system by de-
veloping personalized and customized medi-
cine. The high speed genomic sequencing cou-
pled with sophisticated informatics technology 
will allow clinician to quickly sequence a pa-
tient’s genome and easily detect potential harm-
ful mutations and to engage in early diagnosis 
and effective treatment of diseases (Xiong 
2006).  
 
 
5. Clinical applications of proteomics 
 
With the advent of proteomics several large-
scale studies were launched to investigate the 
protein profile in different biological systems 
with the aim of discovering potential diagnostic 
and prognostic biomarkers. For example, in 
2000, the National Cancer Institute (NCI) es-
tablished an initiative titled the Early Detection 
Research Network (EDRN) which the objec-
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stimulated vs non-stimulated cells with growth 
factors as well as a step of cell cycle or differen-
tiation. There are a lot of methods and ap-
proaches for proteomics datasets across multi-
ple conditions or samples. However, in clinical 
applications of proteomics, biomarker discov-
ery can be done by comparison of proteome 
profiles of healthy and disease profiles, using 
genetic algorithms (Petricoin et al. 2002) and on 
building classification models for disease pre-
dictions. 
Microarrays have now permeated literally every 
field of biology and have found many applica-
tions in translational research. Large-scale mi-
croarray data are also becoming crucial for ex-
perimental biology along with computational 
algorithms, which find wider application in 
basic research, target discovery, drug discovery, 
biomarker identification and disease determina-
tion. Microarray Bioinformatics include, indeed, 
a range of inferential (Rhodes et al. 2002) and 
descriptive statistical methods. Reverse engi-
neering of gene networks using gene expression 
data based in Bayesian statistics (probabilistic 
models) (Friedman et al. 2000), Boolean and 
Relevance networks (Butte and Kohane 2000) 
and graph theoretic algorithms (Tringe, Wag-
ner, and Ruby 2004) are successfully applied to 
microarray data to uncover patterns in disease, 
especially in cancer (Lapointe et al. 2004).  
Bioinformatics approach for identification of 
cis-regulatory sequences has gained impetus in 
computational prediction of the gene regula-
tion, especially from recent discoveries in tran-
scriptional regulation by regulatory RNA 
(miRNA, siRNA, piRNA) and their targets 
(Bentwich 2008) as well as the current apprecia-
tion of the role of epigenetics. Bioinformatics 
applied to gene regulation is one of the most 
exciting areas of computational research. One 
of the principle means of coordinating tran-
scription spatially and temporally is through the 
presence of cis-regulatory elements. These 
short DNA sequence motifs, proximal to the 
transcriptional start site (TSS), are bound by 
transcription factors responsible for the re-
cruitment of the transcriptional initiation ma-
chinery and represent principle components 
that act in response to a particular cellular con-
text and extra-cellular inputs. Global elucidation 
of gene-specific cis-regulatory control will per-
mit the understanding of global transcriptional 
networks and facilitate our understanding of 
the properly functioning of biological system. 
In addition, de novo prediction of these bind-
ing sites has become an active area of research 
in the field of functional genomics. A complete 
understanding of this molecular algorithm give 
great impact on biological research, essential for 
gaining insights into development, cellular re-
sponses to environmental and genetic altera-
tions and the molecular basis of many diseases.  
The dynamic interplay between genes, proteins 
and metabolites leads to a complex biological 
network that include protein-protein interac-
tions, regulatory circuits linking transcription 
factors, cis-regulatory elements, signal transduc-
tion pathways and metabolic pathways. Net-
work bioinformatics is a fascinating areas of bi-
oinformatics and aims to study this complex 
biological circuit using mathematical modeling 
and simulation of pathways, graph-theory anal-
ysis of global network structure, application of 
engineering concept of network analysis as well 
as de novo design of networks. Protein-Protein 
interaction network, are typically visualized as 
“graph networks” where the nodes represent 
the protein, while an edge connecting two 
nodes. Protein-Protein interactions are often 
displayed as a networks illustrating the high de-
gree of connectivity and the presence of partic-
ular hub proteins. 
Genomics and bioinformatics are now poised 
to revolutionize our healthcare system by de-
veloping personalized and customized medi-
cine. The high speed genomic sequencing cou-
pled with sophisticated informatics technology 
will allow clinician to quickly sequence a pa-
tient’s genome and easily detect potential harm-
ful mutations and to engage in early diagnosis 
and effective treatment of diseases (Xiong 
2006).  
 
 
5. Clinical applications of proteomics 
 
With the advent of proteomics several large-
scale studies were launched to investigate the 
protein profile in different biological systems 
with the aim of discovering potential diagnostic 
and prognostic biomarkers. For example, in 
2000, the National Cancer Institute (NCI) es-
tablished an initiative titled the Early Detection 
Research Network (EDRN) which the objec-
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4. Bioinformatics for high-throughput platforms 
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tive to facilitate the development of biomarkers 
or technology that enable early detection of 
cancer. 
Specifically, this technology offers the possibil-
ity of identifying and quantifying proteins asso-
ciated with a particular disease by means of 
their altered levels of expression and/or PTMs 
between the control and disease states. This 
type of comparative analysis enables correla-
tions to be drawn between the range of pro-
teins, their variations and modifications pro-
duced by a cell, tissue and bio-fluids and the ini-
tiation, progression, therapeutic monitoring or 
remission of a disease state. Then, clinical pro-
teomics should be defined as the application of 
proteomic analysis with the aim of solving a 
specific clinical problem within the context of a 
clinical study. The potential applications of pro-
teomics goes from metabolic syndromes like 
inflammatory diseases or diabetes, to neurologi-
cal disorder, cancer, dietary interventions, to 
drug discovery or screening (Yang and Han 
2016). 
As clinical proteomics consists of a variety of 
experimental procedures, pre-analytical variabil-
ity, as well as analytical and post-analytical pro-
cedures can markedly affect a proteomic exper-
iment. Collection of appropriate clinical speci-
mens (e.g. urine, blood, tissue), duration of 
storage, number of freeze-thaw cycles, analysis 
of proteins and peptides of interest, data inter-
pretation, data validation of protein dataset in a 
specific clinical context should effectively be 
standardized to reduce bias. As a result, rec-
ommendations concerning minimal infor-
mation about a proteomic experiment (MIAPE) 
were released from the Human Proteome Or-
ganisation (HUPO). Reference materials are al-
so expected to support both qualitative and 
quantitative proteomic measurements. 
Despite substantial progress in the field, clinical 
proteomic approaches have not matured into 
routine diagnostic applications. As described 
above, proteomic analysis of blood and other 
body fluids and tissues is extremely difficult due 
to the complexity of samples and the dynamic 
range of concentrations of proteins in biologi-
cal fluids. Major challenges exist for plasma bi-
omarkers discovery, where the large dynamic 
concentration range of up to ten orders of 
magnitude for plasma proteins and the presence 
of very high abundance proteins such as serum 
albumin and immunoglobulins mask the lower 
abundance plasma biomarkers. Moreover, to 
validate biomarkers in a clinical setting it is re-
quired the analysis of hundreds (and perhaps 
more) of high-quality clinical samples. In fact, a 
huge amount of data and samples is necessary 
to ensure a bio-statistical significance. This large 
set of samples is in contrast with the time con-
suming and intensive proteomic approach that 
are distant from the routine of a clinical labora-
tory. 
Improvements in this field could lead the way 
to the use of “omic sciences” as a diagnostic 
tool for screening and early detection of many 
pathologies. But they also could represent 
prognostic and predictive tools, providing in-
formation about the outcome of diseases like 
breast cancers; triple negative tumours have a 
very worst prognosis than hormone responsive 
ones (Crutchfield et al. 2016).  
One of the major factors for successful prote-
omic analysis of clinical samples is the selection 
of an appropriate workflow. For instance, in 
studies that use biological fluids, samples 
should be pre-treated to remove high-
abundance proteins (running the risk also to 
eliminate proteins of interest because of pro-
tein-protein interactions) or concentrated to en-
rich the protein fraction (in the case of urine). 
In biomarkers discovery, caution must be exer-
cised in preserving samples for protein degrada-
tion, a problem that can lead to misinterpreta-
tion of data. 
Working with proximal fluids (synovial fluid, 
pleural fluid, peritoneal fluid, ascites) it should 
be necessary to eliminate the contamination of 
mucosa and salts before sample separation by 
2DE-MS, LC-MS), or capillary electrophoresis 
coupled to mass spectrometry (CE-MS). 
With regard to clinical proteomics, among the 
strategies that have the highest potential to re-
duce the gap between proteomics and its clini-
cal application there is the possibility to con-
duct a differential proteome analysis on tissue 
samples with the advantage to investigate the 
disease directly at the origin. Moreover, bi-
omarkers present in tissue are more concentrat-
ed than those released in the blood making this 
biological sample suitable for specific isolation 
or fractionation schemas. However, researchers 
who work with this type of sample are well-
aware that the great heterogeneity of human tis-
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sues represents a well-known limit in the inves-
tigation of biomarkers. Several approaches were 
developed to overcome this problem with the 
potential to be clinically useful. 2D electropho-
resis or SELDI (surface-enhanced laser desorp-
tion/ionization) have been coupled to laser 
capture microdissection (LCM), allowing the 
precise procurement of enriched cell popula-
tions from a heterogeneous tissue, or live cell 
culture, under direct microscopic visualization, 
or laser microdissection and pressure catapult-
ing techniques (LMPC). In this last procedure, 
after microdissection, the sample is directly cat-
apulted into an appropriate collection device. 
As the entire process works without any me-
chanical contact, it enables pure sample retriev-
al from morphologically defined origin without 
cross contamination. 
Among the strategies that have the highest po-
tential to reduce the gap between proteomics 
and its clinical application there is the possibil-
ity to conduct a differential proteome analysis 
directly on tissue samples with the advantage to 
investigate the disease directly at the origin. In 
these years, MALDI Imaging has emerged has 
another promising technique for the combined 
morphologic and molecular tissue analyses. In 
detail, MALDI Imaging allows to image/profile 
intact tissue sections placed onto a conductive 
glass side obtaining information about protein 
expression and localization. Because of its prac-
tical simplicity and ability to obtain reliable in-
formation from tissue section, MALDI imaging 
might have the potential to complement 
histopathologic evaluation for assisting in diag-
nostics, patient stratification, or predicting drug 
response. 
Together with technological challenges, other 
issues that could affect proteomic results 
should not be underestimated including har-
vesting, handling and storage of samples. Con-
sidering that the proteome is dynamic over time 
and expression of a myriad of factors, research-
ers should also consider the clinical history of 
the patient such as age, sex, and race. To mini-
mize these systemic problems is desirable to es-
tablish a specimen bank (biorepository). A 
sample, to become eligible for a biorepository, 
must be collected and analysed immediately be-
cause cells and proteins degradation and /or 
modification may affect the analysis. Moreover, 
sample should be subject to an accurate quality 
control and catalogued according to trusted, 
safe and standardized clinical data. 
Based on these observations we conclude that 
proteomics can be considered as a main strate-
gy for biomarker discovery. However, special 
attention has to be paid to reduce pre-analytical 
variables, analytical variability, and biological 
variation. This will require a close interdiscipli-
nary collaboration involving clinicians, statisti-
cians / bioinformatics, epidemiologists, chem-
ists, biochemists and biologists. 
 
 
6. Omics science: toward omic personalized medicine 
 
The availability of human genome sequence has 
transformed biomedical research over the past 
decade. The end of the 20th century was 
marked by the genomics revolution. However, 
over the past decades it has become clear that 
common diseases develop as a result of multi-
ple defects at different levels including proteins, 
lipids and metabolites, defects can that cannot 
be completely predicted by the simple analysis 
of genes. A systems-level approach, that inte-
grate the results of genomics with those ob-
tained by the analysis of metabolomes and pro-
teomes, has enabled researchers to utilize novel 
strategies to tackle unexplored research ques-
tions in human diseases. The ultimate goal is to 
evolve an integrated omics picture of the genes, 
transcripts, proteins, and metabolites to fully 
describe cellular functioning. At this regard in 
2014, a draft map of the human proteome was 
realised, using the high-resolution Fourier-
transform mass spectrometry (Kim MS et al. 
Nature 2014). In that review was reported a 
proteomic profiling of 30 histologically normal 
human samples, including 17 adult tissues, 7 fe-
tal tissues and 6 purified primary haematopoiet-
ic cells, that resulted in the identification of 
proteins encoded by 17,294 genes accounting 
for approximately 84% of the total annotated 
protein-coding genes in humans. The 
proteogenomic analysis revealed a number of 
novel protein-coding regions, which includes 
translated pseudogenes, non-coding RNAs and 
upstream open reading frames. This large hu-
man proteome catalogue (available as an inter-
active web-based resource at 
http://www.humanproteomemap.org) will 
complement available human genome and 
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transcriptome data to accelerate biomedical re-
search and in particular in the diagnosing and 
treating of human diseases 
The greatest benefits for patients are likely to 
be realized from the monitoring and manage-
ment of early stage disease rather than from 
treatment of late stage disease. In this field, a 
comprehensive integrative omic profiles was 
applied with success to perform an integrated 
Personal Omics Profiling (iPOP) on a single 
healthy individual. Authors of this study com-
bined genomic, transcriptomic, proteomic, 
metabolomic, and autoantibody profiles, in 
conjunction with routine laboratory testing, 
from a single individual over a 14 months peri-
od, generating an individual iPOP over the 
course of healthy states and two viral infections 
that occurred during the study interval. Periph-
eral blood mononuclear cells, plasma and serum 
were collected and results from whole-genome 
sequencing predicted an increased disease risks 
for various diseases, including hypertriglycer-
idemia, and type 2 diabetes (T2D). Markers as-
sociated with T2D became elevated during the 
course of study, in particular, following a res-
piratory infection. Moreover, data from omics 
experiments before and after viral infections al-
lowed for the creation of a dynamic picture of 
this process.  
Omics-based approaches will identify at risk 
groups supporting the implementation of risk-
stratified health screening. This may lead to sig-
nificant cost-savings at the societal level. 
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Abstract 
Mitochondria of spermatozoa significantly differ, structurally and functionally, from the corresponding orga-
nelles of somatic cells. Nevertheless, sperm mitochondria, as well as the somatic ones, are the location of the ox-
idative phosphorylation (OXPHOS) process, which is necessary for the production of metabolic energy in the 
form of adenosine triphosphate (ATP). In addition to their basic role in oxidative energy generation, mitochon-
dria are also a source of reactive oxygen species (ROS), which, at low concentrations, play a physiological role in 
many sperm processes. 
It is commonly accepted that a proper functionality of mitochondria is necessary for a high quality of sperm 
cells; this last parameter, in its turn, is a prerequisite for a high sperm fertilizing ability.  
Evaluation of mitochondrial respiratory efficiency represents therefore a valuable test that could integrate routine 
semen analysis. 
 
Keywords: mitochondria, spermatozoa, oxidative phosphorylation, ROS, sperm motility 
 
 
 
1. Introduction  
 
Mitochondria are cellular cytoplasmic organ-
elles which take part in a variety of cellular 
metabolic functions. They are involved in sev-
eral pathways, such as the Krebs cycle, the oxi-
dative decarboxylation of α-ketoacids, the β-
oxidation of fatty acids, many reactions of the 
amino-acid metabolism and of the pyrimidine 
synthesis. Furthermore, mitochondria are ac-
tively implicated in other processes, such as cell 
differentiation, ROS generation, apoptosis, cal-
cium signalling, iron metabolism, etc. However, 
these organelles are generally known as the en-
ergy-generating powerhouses of the cell, be-
cause they play a fundamental role in the pro-
duction of adenosine triphosphate (ATP) 
through the sophisticated mechanism of the 
oxidative phosphorylation (OXPHOS).  
This last process, which is the topic of this 
manuscript, requires the coordinated operation 
of two main components: the respiratory chain 
and the ATP-synthase, both located in the inner 
mitochondrial membrane.  
The mitochondrial respiratory chain is involved 
in the transport of reducing equivalents from 
some electron-donors to the molecule of oxy-
gen with the final formation of water. The en-
ergy released from these oxidation/reduction 
reactions is used to drive the synthesis of ATP 
from ADP. A strict coupling is therefore re-
quired between respiration, which is the elec-
tron transfer through respiratory chain com-
plexes, and phosphorylation, which is necessary 
to synthesize ATP. 
In addition to their basic role in ATP synthesis, 
mitochondria are a major source of reactive 
oxygen species (ROS), which are key mediators 
of cellular physiology and pathology. 
Mitochondria of spermatozoa are different 
from the corresponding organelles of somatic 
cells, in both their morphology and biochemis-
try (Piomboni et al., 2012; Ferramosca and 
Zara, 2015).  
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They are helically arranged around the mid-
piece of sperm and show a peculiar morphol-
ogy and arrangement. The biochemical differ-
ence is essentially related to the existence of 
specific enzyme isoforms, which are character-
ized by peculiar kinetic and regulatory proper-
ties.  
It has been demonstrated that a proper func-
tionality of mitochondria is necessary for a high 
quality of sperm cells and, in particular, for 
sperm motility. According to this hypothesis, 
structural and functional alterations are usually 
found in mitochondria from asthenozoo-
spermic subjects.  
However, not only motility but also several es-
sential sperm functions require ATP as an en-
ergy source. Therefore, a careful and detailed 
investigation of mitochondrial bioenergetics of 
spermatozoa could provide more insight on the 
role of these organelles in the overall quality of 
the gametes. We are confident that evaluation 
of mitochondrial respiratory efficiency could 
integrate routine semen analysis in clinical in-
vestigation of male infertility. 
 
 
2. A reliable tool for the evaluation of sperm respiratory 
efficiency 
 
In 2008 we reported a relatively simple and fast 
method for analysing oxygen consumption, and 
therefore mitochondrial functionality, in indi-
vidual human ejaculates (Ferramosca et al. 
2008).  
Human spermatozoa were incubated in hypo-
tonic buffer to selectively disrupt the plasma 
membrane and were subsequently used for 
studies of mitochondrial respiration. The rup-
ture of the plasma membrane, followed by the 
washing steps, caused the loss of the various 
metabolites contained inside the cells, thus ex-
posing sperm mitochondria to an environment 
with a well- defined composition. At the same 
time, mitochondria maintained their intactness 
and functionality. 
Oxygen uptake by hypotonically-treated sper-
matozoa was therefore measured at 36°C by us-
ing a Clark-type oxygen probe, in the presence 
of respiratory substrates (10 mM pyruvate and 
10 mM malate) and 0.76 µM adenosine diphos-
phate (ADP) (Fig. 1). The ratio between the 
rate of oxygen uptake in presence of respiratory 
substrates plus ADP (V3) and the rate of oxy-
gen uptake in presence of the substrates alone 
(V4), allowed for the calculation of a respiratory 
control ratio (or RCR).  
In normozoospermic samples RCR was about 
2.5, hence indicating a good coupling between 
respiration and phosphorylation. Interestingly, 
whereas the rates of oxygen uptake, as ex-
pected, changed with different sperm concen-
trations, the RCR values remained constant, 
thus demonstrating a linear response of the as-
say. The limit of sensitivity of this experimental 
system was found to be 1.5 x 107 sperm cells.  
 
 
Figure 1: Assay of oxygen consumption in sperm cells 
 
 
In order to test the possibility of a difference in 
mitochondrial function between progressively 
motile and less active sperm, we measured the 
respiration capacity of human sperm mito-
chondria from some asthenozoospermic sub-
jects with a mean percentage of sperm motility 
of 36%. In these samples we found a significant 
reduction in the active state of respiration (V3) 
when measured in the same experimental con-
ditions used for normozoospermic samples. On 
the contrary, the V4 value was almost unaf-
fected, thus leading to a significantly lower 
value of RCR in asthenozoospermic subjects in 
comparison with the normozoospermic ones 
(Ferramosca et al. 2008). 
The importance of mitochondrial functionality 
was also extended to hyperactivated motility 
observed during sperm capacitation. We meas-
Mitochondria and fertility: the mitochondria critical role on spermatozoa function 
22 
They are helically arranged around the mid-
piece of sperm and show a peculiar morphol-
ogy and arrangement. The biochemical differ-
ence is essentially related to the existence of 
specific enzyme isoforms, which are character-
ized by peculiar kinetic and regulatory proper-
ties.  
It has been demonstrated that a proper func-
tionality of mitochondria is necessary for a high 
quality of sperm cells and, in particular, for 
sperm motility. According to this hypothesis, 
structural and functional alterations are usually 
found in mitochondria from asthenozoo-
spermic subjects.  
However, not only motility but also several es-
sential sperm functions require ATP as an en-
ergy source. Therefore, a careful and detailed 
investigation of mitochondrial bioenergetics of 
spermatozoa could provide more insight on the 
role of these organelles in the overall quality of 
the gametes. We are confident that evaluation 
of mitochondrial respiratory efficiency could 
integrate routine semen analysis in clinical in-
vestigation of male infertility. 
 
 
2. A reliable tool for the evaluation of sperm respiratory 
efficiency 
 
In 2008 we reported a relatively simple and fast 
method for analysing oxygen consumption, and 
therefore mitochondrial functionality, in indi-
vidual human ejaculates (Ferramosca et al. 
2008).  
Human spermatozoa were incubated in hypo-
tonic buffer to selectively disrupt the plasma 
membrane and were subsequently used for 
studies of mitochondrial respiration. The rup-
ture of the plasma membrane, followed by the 
washing steps, caused the loss of the various 
metabolites contained inside the cells, thus ex-
posing sperm mitochondria to an environment 
with a well- defined composition. At the same 
time, mitochondria maintained their intactness 
and functionality. 
Oxygen uptake by hypotonically-treated sper-
matozoa was therefore measured at 36°C by us-
ing a Clark-type oxygen probe, in the presence 
of respiratory substrates (10 mM pyruvate and 
10 mM malate) and 0.76 µM adenosine diphos-
phate (ADP) (Fig. 1). The ratio between the 
rate of oxygen uptake in presence of respiratory 
substrates plus ADP (V3) and the rate of oxy-
gen uptake in presence of the substrates alone 
(V4), allowed for the calculation of a respiratory 
control ratio (or RCR).  
In normozoospermic samples RCR was about 
2.5, hence indicating a good coupling between 
respiration and phosphorylation. Interestingly, 
whereas the rates of oxygen uptake, as ex-
pected, changed with different sperm concen-
trations, the RCR values remained constant, 
thus demonstrating a linear response of the as-
say. The limit of sensitivity of this experimental 
system was found to be 1.5 x 107 sperm cells.  
 
 
Figure 1: Assay of oxygen consumption in sperm cells 
 
 
In order to test the possibility of a difference in 
mitochondrial function between progressively 
motile and less active sperm, we measured the 
respiration capacity of human sperm mito-
chondria from some asthenozoospermic sub-
jects with a mean percentage of sperm motility 
of 36%. In these samples we found a significant 
reduction in the active state of respiration (V3) 
when measured in the same experimental con-
ditions used for normozoospermic samples. On 
the contrary, the V4 value was almost unaf-
fected, thus leading to a significantly lower 
value of RCR in asthenozoospermic subjects in 
comparison with the normozoospermic ones 
(Ferramosca et al. 2008). 
The importance of mitochondrial functionality 
was also extended to hyperactivated motility 
observed during sperm capacitation. We meas-
JDREAM.indd   22 18/01/18   11:0325 2 57
Alessandra Ferramosca, Vincenzo Zara 
23 
ured the respiration capacity of human sperm 
mitochondria before and after swim up treat-
ment (Stendardi et al., 2011). In sperm samples 
selected by swim up, we found a significant in-
crease of about 10 fold in the V3 and V4 values. 
These results suggest that sperm motility 
strongly depends on mitochondrial respiratory 
function. Furthermore, high values of V3 and 
V4 obtained with sperm samples selected by 
swim up suggest that our experimental system 
responds also with a limited amount (less than 
5 million) of sperm cells.  
 
 
3. Sperm motility and mitochondrial respiratory effi-
ciency 
 
In a following study, we correlated sperm mito-
chondrial respiration, evaluated by the polaro-
graphic assay of oxygen consumption and RCR 
values, with variations in sperm motility (Fer-
ramosca et al., 2012). Interestingly, we found a 
profile for RCR values with respect to a gradual 
increase or decrease in sperm motility (Fig. 2) 
 
 
 
 
Figure 2: Sperm motility vs RCR values 
 
In particular, V3 (active state of mitochondrial 
respiration) positively correlated with progres-
sive sperm motility, whereas V4 (resting state of 
mitochondrial respiration) showed a lower posi-
tive correlation with sperm motility.  
In the same study we also investigated a possi-
ble relationship between RCR values and the 
percentage of morphologic anomalies affecting 
the head, midpiece, or tail of spermatozoa. In-
terestingly, a strong negative correlation be-
tween mitochondrial respiration and defects in 
sperm midpiece, where mitochondria are exclu-
sively localized, was found, suggesting that 
structural anomalies were accompanied by a 
parallel decrease in mitochondrial respiration. 
In agreement with these results, the anomalies 
in the sperm midpiece were also associated with 
decreased sperm motility.  
 
 
4. Oxidative stress and sperm mitochondrial respiratory 
efficiency 
 
For proper functionality of spermatozoa, an 
adequate level of ROS is required. Free radicals 
are involved in sperm hyperactivation and ca-
pacitation, acrosome reaction, spermatozoa-
oocyte fusion, and other molecular events im-
plicated in human fertility. However, high levels 
of ROS have negative influence on sperm qual-
ity and function.  
What is the relationship between ROS and 
sperm mitochondria? 
In this context we analyzed the dependence of 
mitochondrial respiration efficiency on seminal 
lipoperoxides (LPO) levels. LPO are a specific 
indicator of oxidative stress in seminal fluid. 
We found a strong negative correlation of RCR 
values with seminal LPO, suggesting that an in-
crease of oxidative stress in seminal fluid 
(which is associated to an increase in the levels 
of LPO) was able to impair mitochondrial func-
tionality. 
Sperm DNA damage could be a marker of 
sperm quality and is often associated to oxida-
tive stress. The analysis of dependence of 
sperm mitochondrial respiratory efficiency on 
sperm DNA fragmentation showed a strong 
negative correlation between RCR values and 
the percentage of DNA fragmentation.  
When we analyzed V3 and V4 values, we found 
a moderate dependence of V3 (which is the rate 
of oxygen consumption after the addition of 
ADP) on the levels of LPO and a strong corre-
lation between V4 and LPO. V4 shows also a 
significant dependence on sperm DNA frag-
mentation, while V3 seems to be independent. 
We can therefore hypothesize that a condition 
of oxidative stress in the seminal fluid (which is 
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associated to an increase in the levels of LPO 
and in the percentage of DNA fragmentation) 
produces an increase in V4, suggesting a stimu-
lus of mitochondrial respiration, which is inde-
pendent of ADP phosphorylation. These re-
sults suggest that oxidative stress, along with 
the concomitant phenomenon of sperm DNA 
fragmentation, negatively affects sperm mito-
chondrial respiration by an uncoupling between 
electron transport and ATP synthesis. 
At least in principle, a double link exists be-
tween mitochondria and oxidative stress. In 
fact, on the one hand, mitochondria represent 
one of the ROS generators whereas, on the 
other hand, they might represent one of the 
ROS targets.  
We eventually investigated the dependence of 
sperm mitochondrial respiratory efficiency on 
serum reactive oxygen species, a systemic indi-
cator of oxidative stress (Fig. 3). Blood oxida-
tive stress might also be a consequence of un-
healthy lifestyles such as smoking, alcohol 
abuse, or exposition to chemical or electromag-
netic pollution. Interestingly, we found a strong 
negative correlation between RCR values and a 
condition of oxidative stress. In fact, RCR val-
ues decreased at the increasing of serum reac-
tive oxygen species. Also in this case, only V4 
showed a significantly correlation with radical 
species.  
The analysis of blood oxidative status showed a 
parallel negative correlation between the levels 
of serum reactive oxygen species and the per-
centage of sperm progressive motility. There-
fore, the analysis of blood oxidative status 
could be useful, together with the seminal pro-
file, for the evaluation of sperm quality.  
 
 
 
Figure 3: Serum ROMs vs RCR values 
 
 
 
5. Varicocele and sperm mitochondrial respiratory effi-
ciency 
 
Varicocele is an enlargement of the veins that 
drain the testicle. This pathology is one of the 
main causes of male infertility and can impair 
sperm quality. Current evidence suggests that 
oxidative stress is a key element contributing to 
infertility in men with varicocele. Accordingly 
to these observations, we found a strong in-
crease in the level of seminal LPO in varicocele 
samples and a higher incidence of spermatozoa 
with DNA damage in varicocele patients. Inter-
estingly, in the same patients, we found for the 
first time an increase in the level of serum ROS, 
a systemic indicator of oxidative stress (Fer-
ramosca et al., 2015).  
The increased levels of ROS in serum and 
seminal fluid of varicocele patients negatively 
affected sperm mitochondrial respiration. In 
fact, when we analyzed the mitochondrial respi-
ratory efficiency by polarography, we found 
that sperm mitochondria of varicocele patients 
showed a lower RCR values. In particular, we 
found a significant decrease in the V3 values, 
indicating an impairment of active state of mi-
tochondrial respiration (Ferramosca et al., 
2015). We also observed a parallel increase in 
the percentage of structural defects in the 
sperm midpiece, corresponding to the sperm 
mitochondrial sheath.  
The defective energy metabolism may play an 
important role in the impairment of sperm 
quality in varicocele patients, whose spermato-
zoa showed a decrease in motility and concen-
tration when compared with control subjects. 
Mitochondria and fertility: the mitochondria critical role on spermatozoa function 
24 
associated to an increase in the levels of LPO 
and in the percentage of DNA fragmentation) 
produces an increase in V4, suggesting a stimu-
lus of mitochondrial respiration, which is inde-
pendent of ADP phosphorylation. These re-
sults suggest that oxidative stress, along with 
the concomitant phenomenon of sperm DNA 
fragmentation, negatively affects sperm mito-
chondrial respiration by an uncoupling between 
electron transport and ATP synthesis. 
At least in principle, a double link exists be-
tween mitochondria and oxidative stress. In 
fact, on the one hand, mitochondria represent 
one of the ROS generators whereas, on the 
other hand, they might represent one of the 
ROS targets.  
We eventually investigated the dependence of 
sperm mitochondrial respiratory efficiency on 
serum reactive oxygen species, a systemic indi-
cator of oxidative stress (Fig. 3). Blood oxida-
tive stress might also be a consequence of un-
healthy lifestyles such as smoking, alcohol 
abuse, or exposition to chemical or electromag-
netic pollution. Interestingly, we found a strong 
negative correlation between RCR values and a 
condition of oxidative stress. In fact, RCR val-
ues decreased at the increasing of serum reac-
tive oxygen species. Also in this case, only V4 
showed a significantly correlation with radical 
species.  
The analysis of blood oxidative status showed a 
parallel negative correlation between the levels 
of serum reactive oxygen species and the per-
centage of sperm progressive motility. There-
fore, the analysis of blood oxidative status 
could be useful, together with the seminal pro-
file, for the evaluation of sperm quality.  
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Varicocele is an enlargement of the veins that 
drain the testicle. This pathology is one of the 
main causes of male infertility and can impair 
sperm quality. Current evidence suggests that 
oxidative stress is a key element contributing to 
infertility in men with varicocele. Accordingly 
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crease in the level of seminal LPO in varicocele 
samples and a higher incidence of spermatozoa 
with DNA damage in varicocele patients. Inter-
estingly, in the same patients, we found for the 
first time an increase in the level of serum ROS, 
a systemic indicator of oxidative stress (Fer-
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tration when compared with control subjects. 
JDREAM.indd   24 18/01/18   11:03
Alessandra Ferramosca, Vincenzo Zara 
25 
       References 
 
 Ferramosca, A., Focarelli, R., Piomboni, P., 
Coppola, L., Zara, V. (2008) Oxygen uptake by 
mitochondria in demembranated human sper-
matozoa: a reliable tool for the evaluation of 
sperm respiratory efficiency. Int J Androl. 
31:337-45. 
 Ferramosca, A., Pinto Provenzano, S., Coppola, 
L., Zara, V. (2012) Mitochondrial respiratory ef-
ficiency is positively correlated with human 
sperm motility. Urology 79:809-14. 
 Ferramosca, A., Pinto Provenzano, S., Mon-
tagna, D.D., Coppola, L., Zara, V. (2013) Oxi-
dative stress negatively affects human sperm mi-
tochondrial respiration. Urology 82:78-83. 
 Ferramosca, A., Albani, D., Coppola, L., Zara, 
V. (2015) Varicocele negatively affects sperm 
mitochondrial respiration. Urology 86: 735-739. 
 Ferramosca, A., Zara, V. (2015) Bioenergetics of 
mammalian sperm capacitation. Biomed Res 
Int. 2014;2014:902953. 
 Piomboni, P., Focarelli, R., Stendardi, A., Fer-
ramosca, A., Zara V. (2012) The role of mito-
chondria in energy production for human 
sperm motility. Int J Androl. 35:109-24. 
 Stendardi, A., Focarelli, R., Piomboni, P., 
Palumberi, D., Serafini, F., Ferramosca, A., Za-
ra, V. (2011) Evaluation of mitochondrial res-
piratory efficiency during in vitro capacitation 
of human spermatozoa. Int J Androl. 34:247-55. 
Alessandra Ferramosca, Vincenzo Zara 
25 
       References 
 
 Ferramosca, A., Focarelli, R., Piomboni, P., 
Coppola, L., Zara, V. (2008) Oxygen uptake by 
mitochondria in demembranated human sper-
matozoa: a reliable tool for the evaluation of 
sperm respiratory efficiency. Int J Androl. 
31:337-45. 
 Ferramosca, A., Pinto Provenzano, S., Coppola, 
L., Zara, V. (2012) Mitochondrial respiratory ef-
ficiency is positively correlated with human 
sperm motility. Urology 79:809-14. 
 Ferramosca, A., Pinto Provenzano, S., Mon-
tagna, D.D., Coppola, L., Zara, V. (2013) Oxi-
dative stress negatively affects human sperm mi-
tochondrial respiration. Urology 82:78-83. 
 Ferramosca, A., Albani, D., Coppola, L., Zara, 
V. (2015) Varicocele negatively affects sperm 
mitochondrial respiration. Urology 86: 735-739. 
 Ferramosca, A., Zara, V. (2015) Bioenergetics of 
mammalian sperm capacitation. Biomed Res 
Int. 2014;2014:902953. 
 Piomboni, P., Focarelli, R., Stendardi, A., Fer-
ramosca, A., Zara V. (2012) The role of mito-
chondria in energy production for human 
sperm motility. Int J Androl. 35:109-24. 
 Stendardi, A., Focarelli, R., Piomboni, P., 
Palumberi, D., Serafini, F., Ferramosca, A., Za-
ra, V. (2011) Evaluation of mitochondrial res-
piratory efficiency during in vitro capacitation 
of human spermatozoa. Int J Androl. 34:247-55. 
JDREAM.indd   25 18/01/18   11:0325 2 57
Alessandra Ferramosca, Vincenzo Zara 
25 
       References 
 
 Ferramosca, A., Focarelli, R., Piomboni, P., 
Coppola, L., Zara, V. (2008) Oxygen uptake by 
mitochondria in demembranated human sper-
matozoa: a reliable tool for the evaluation of 
sperm respiratory efficiency. Int J Androl. 
31:337-45. 
 Ferramosca, A., Pinto Provenzano, S., Coppola, 
L., Zara, V. (2012) Mitochondrial respiratory ef-
ficiency is positively correlated with human 
sperm motility. Urology 79:809-14. 
 Ferramosca, A., Pinto Provenzano, S., Mon-
tagna, D.D., Coppola, L., Zara, V. (2013) Oxi-
dative stress negatively affects human sperm mi-
tochondrial respiration. Urology 82:78-83. 
 Ferramosca, A., Albani, D., Coppola, L., Zara, 
V. (2015) Varicocele negatively affects sperm 
mitochondrial respiration. Urology 86: 735-739. 
 Ferramosca, A., Zara, V. (2015) Bioenergetics of 
mammalian sperm capacitation. Biomed Res 
Int. 2014;2014:902953. 
 Piomboni, P., Focarelli, R., Stendardi, A., Fer-
ramosca, A., Zara V. (2012) The role of mito-
chondria in energy production for human 
sperm motility. Int J Androl. 35:109-24. 
 Stendardi, A., Focarelli, R., Piomboni, P., 
Palumberi, D., Serafini, F., Ferramosca, A., Za-
ra, V. (2011) Evaluation of mitochondrial res-
piratory efficiency during in vitro capacitation 
of human spermatozoa. Int J Androl. 34:247-55. 
Alessandra Ferramosca, Vincenzo Zara 
25 
       References 
 
 Ferramosca, A., Focarelli, R., Piomboni, P., 
Coppola, L., Zara, V. (2008) Oxygen uptake by 
mitochondria in demembranated human sper-
matozoa: a reliable tool for the evaluation of 
sperm respiratory efficiency. Int J Androl. 
31:337-45. 
 Ferramosca, A., Pinto Provenzano, S., Coppola, 
L., Zara, V. (2012) Mitochondrial respiratory ef-
ficiency is positively correlated with human 
sperm motility. Urology 79:809-14. 
 Ferramosca, A., Pinto Provenzano, S., Mon-
tagna, D.D., Coppola, L., Zara, V. (2013) Oxi-
dative stress negatively affects human sperm mi-
tochondrial respiration. Urology 82:78-83. 
 Ferramosca, A., Albani, D., Coppola, L., Zara, 
V. (2015) Varicocele negatively affects sperm 
mitochondrial respiration. Urology 86: 735-739. 
 Ferramosca, A., Zara, V. (2015) Bioenergetics of 
mammalian sperm capacitation. Biomed Res 
Int. 2014;2014:902953. 
 Piomboni, P., Focarelli, R., Stendardi, A., Fer-
ramosca, A., Zara V. (2012) The role of mito-
chondria in energy production for human 
sperm motility. Int J Androl. 35:109-24. 
 Stendardi, A., Focarelli, R., Piomboni, P., 
Palumberi, D., Serafini, F., Ferramosca, A., Za-
ra, V. (2011) Evaluation of mitochondrial res-
piratory efficiency during in vitro capacitation 
of human spermatozoa. Int J Androl. 34:247-55. 
JDREAM.indd   25 18/01/18   11:0325 2 57
JDREAM.indd   26 25/01/18   12:57
 
JDREAM. Journal of interDisciplinary REsearch Applied to Medicine  
JDREAM (2017), v. 1 i. 1, 27-32 
ISSN 2532-7518 
DOI 10.1285/i25327518v1i1p27 
                                                                                       http://siba-ese.unisalento.it, © 2017 Università del Salento 
 
27 
Neuroscience Lab: Section of Cognitive Neuroscience and Psychophysiology 
 
Sara Invitto1, Giuseppe Nicolardi1 
 
1 Human Anatomy and Neuroscience Laboratory; Department of Biological and Environmental Sciences and Technologies,  
University of Salento, Lecce, Italy 
 
sara.invitto@unisalento.it; giuseppe.nicolardi@unisalento.it 
 
 
Abstract 
Experimental research in this area focuses, in a section of the laboratory of Neurosciences, on new technologies 
applied to Cognitive Neuroscience and Psychophysiology. The aim of this paper will be highlighting the link be-
tween basic research and innovative multidisciplinary experimentation. According with this perspective the pro-
jects developed in the Neuroscience Lab will be briefly  described: two devices deposited as European patents, a 
protocol of olfactory stimulation on EEG and neurodegenerative processing, the research on women with IPV 
(Intimate Partner Violence disorder), projects on neuroaesthetic (applied in museum learning), a study on the 
marine soundscape and related brain responses, and an experimental work on an haptic and virtual interfaces and 
on a comparison of motor imagery training with haptic training of augmented reality, as well as training of han-
dling real objects with grasping affordances. These topics would set out a new view of research, extending be-
yond the technological interfaces in neurocognitive protocols. Will be described the leitmotif of the research ac-
tivities carried out over the last five years. 
 
Keywords: Cognitive Neuroscience, Psychophysiology, Olfactory Perception, New Technologies 
 
 
 
Neurosciences apply to many fields: most re-
search protocols developed and applied in the 
Human Anatomy and Neuroscience Lab are 
focused neurodegenerative diseases (through a 
murine model); here we will describe the activi-
ties which are developed specifically for the 
DREAM facilities, that, instead, are focused on 
human Cognitive Neuroscience and Psycho-
physiology(Boone and Piccinini, 2016; 
Caramazza, 1992; Stramandinoli et al., 2012). 
Neurosciences are also applied to robotics, to 
Artificial Intelligence systems (Anderson, 2003; 
Artemiadis, 2014; Vernon, 2014), models of 
pattern recognition, aesthetics, and ergonomics. 
Also, new paradigms are being defined, which 
on one hand are interfaced with experimental 
and “hard” technologies, and on the other 
hand, they have re-modulated philosophical 
concepts on meta models, meta-cognition, 
thought the process and conscience state. They 
are also contaminated by epigenetics(Eccleston 
et al., 2007) in a way that creates a sort of 
“neuro-psychoanalysis” of a nonconscious 
which becomes collective as an evolutionary 
product.  
The first EEG device present in Laboratory, 
was acquired by the laboratory with a PRIN on 
Women and Power. In fact, since 2009, a teach-
ing agreement (which later turned to a research 
agreement) has been activated with the Women 
Shelter of Lecce, the so called “Centro 
Antiviolenza Renata Fonte”. We started a re-
search agreement with the Center  and the De-
partment of Biological and Environmental Sci-
ences; together we studied, using an electroen-
cephalographic technique called Event Related 
Potential, or ERP (Luck, 2005), the psycho-
physiological aspect of women subjected to In-
timate Partner violence (IPV), a research that 
goes on to the present day (Invitto et al., 2014b, 
2017d). This was just the first of the many 
works in the field of neurocognitive sciences 
that took part at the Laboratory of Human 
anatomy and Neurosciences in the Department 
of Biological and Environmental Sciences at 
University of Salento. Thus, having started 
from a psychophysiological basis, Invitto 
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worked on brain Synchronization, by perfecting 
a non-invasive, brain-stimulating instrument 
which was linked to physiological rhythms 
(Synchronization’s coil). Such work subsequent-
ly got an international patent (Invitto, 2013). 
After about one year, thanks to the collabora-
tion with the CNR of Microelectronics and 
Microsystemics – Lecce Unit, and specifically 
with Simonetta Capone, Giovanni Montagna 
and Pietro Aleardo Siciliano (director of the 
CNR IMM in Lecce), we built a device, which 
was capable of interfacing an olfactometer with 
controlled olfactive stimulations to an electro-
encephalography system (Invitto et al., 2014a). 
 
 
 
Fig.1 Experiment on Olfactive perception with 
MI2014A001344 Requested Patent 
 
 
 
 
Fig.2 Odorous Vials for MI2014A001344  
Such device, named VOS EEG (Virtual Olfac-
tory Stimulation) allows the production of con-
trolled olfactive potentials. In this case, the 
olfactive response is used either for base re-
search and for clinical research, in order to 
evaluate possible predictive factors of neuro-
degenerative processes (which showed evidence 
of an early impairment of olfactive perception 
ability). This device allowed the development of 
psychophysiological studies in health subjects 
and in clinical ease subjects (Invitto et al., 
2016b, 2016e, 2017a, 2017c) 
In lab’s activity, we were involved in an interna-
tional COST (European Cooperation in Science 
and Technology), project on “Pain Assessment 
in Patient with Impairment Cognition, especial-
ly in Dementia and Dementia” (coordinator S. 
Lautenbacher – Bamberg University-German). 
In COST activity we are studying Pain in Hun-
tington Korea Patients and in other clinical sub-
jects (Defrin et al., 2015). 
 Also, about Huntington Korea Patients, 
Invitto developed an interaction with University 
of Bari (de Tommaso et al., 2017).  
For her innovative activities, Invitto was award-
ed, in December 2015, of the IWIIN (Italian 
Women Innovators and Inventors) prize, with 
an ad hoc mention for innovative research. She 
received, in 2017, an International Award on 
Innovation: the Gold Innovator Winner 2017. 
The Prize was awarded by Global Women In-
ventors and Innovators Network, and by Euro-
pean Women Inventors and Innovators Net-
works.   
The projects relative to innovation started with 
the mentioned patents and was later developed 
along with other projects which also received 
national and international funding. The first 
project started with the shared request by the 
Museums of the University of Salento of having 
innovative interfaces which would value learn-
ing objects in the museum (Invitto et al., 2014c) 
. So, the project was pushed forward with the 
Cetma and the company Agilex, in order to cre-
ate products in augmented reality and immer-
sive virtual reality, with interfaces which were 
analyzed with neuroaesthetics criteria. We 
choose elements from plancton, which were 
later developed in the ICT project. In the pro-
ject, of which Invitto was scientific referent, the 
Human Neuroscience and Anatomy Laboratory 
at DiSTeBA, together with Cetma and Agilex 
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Srl, have built a network- project for museum 
learning (Ep_Lab). 
Other research work, with  the use of Aug-
mented and Virtual Reality, are dedicated to the 
psychophysiological analysis of augmented real-
ity interfaces in entertaining and educational 
processes (Invitto et al., 2015, 2016c). With the 
help of EEG techniques and ERP, was ana-
lyzed how “real”, virtual and augmented inter-
action are deeply different for our perceptive 
system, and how this, based on some learning 
styles, can represent an advantage or a tool 
which is difficult to interact with, which can 
slow down behavioural responses and some 
components of psychophysiological response. 
In our latest works, we also introduced the 
comparison between the handling of 3D-
printed models(Invitto et al., 2016a). 
We are also working on a haptic effector, which 
we will be developed together with Nabidit 
Network (CNR Nano-University of Salento) 
thanks to project Person, with an EEG-
interfaced serious game, of Technological Clus-
ters Regione Puglia. 
In 2016 a research exchange was developed 
with The Centre of Robotics and Neural Sys-
tem (CRNS) of University of Plymouth (UK). 
These exchanges produced research paper 
(Cangelosi and Invitto, 2017) and a Workshop, 
in University of Salento, with Prof. Angelo 
Cangelosi, the Director of the CRNS. The 
Workshop was titles ‘Motion Control and Cog-
nitive Sciences. Two sides of the same coin: 
Robotics’ (fig.3). The meeting focused on theo-
retical and experimental research based on ac-
tion and language processing, and on number 
learning and gestures, that clearly demonstrates 
the role of embodiment in cognition and lan-
guage processing. In psychology and neurosci-
ence this evidence constitutes the basis of em-
bodied cognition, also known as grounded cog-
nition (Borghi and Cangelosi, 2014; Caligiore et 
al., 2013; Pezzulo et al., 2013). In robotics, the-
se studies have important implications for the 
design of linguistic capabilities in cognitive 
agents and robots for human-robot communi-
cation, and have led to the new interdisciplinary 
approach of Developmental Robotics 
(Cangelosi, A; Schlesinger, 2015). During the 
workshop, we presented examples of develop-
mental robotics models and experimental re-
sults from iCub experiments on the embodi-
ment biases in early word acquisition and 
grammar learning  (Morse et al., 2015), experi-
ment on the pointing and finger counting in 
number learning (De La Cruz et al., 2014) and 
on mental imagery and rotation (Seepanomwan 
et al., 2015). The presentation also discussed 
the implications for the symbol grounding 
problem and how embodied robots can help 
addressing the issue of embodied cognition and 
the grounding of symbol manipulation use on 
sensorimotor intelligence. 
    
 
 
 
 
Within a research project on music and brain, 
we developed another experimentation based 
on sounds, specifically sounds of the sea, which 
were recorded with hydrophones; the study 
were focused on the effects that such sounds 
have at a cortical level on humans, and thanks 
to the Zoological Station of Naples, also on an-
imals (Baldascino et al., 2016).  
Other studies on music were investigated in 
Humans (Invitto et al., 2016d, 2017b). 
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Recently a project was financed through the 
Cinque Per Mille for University of Salento, on 
olfactive evocated potentials (developed 
through VOS EEG patent). This work is based 
on the cortical analysis of different kinds of 
olfactive stimulations and the different re-
sponses given by healthy individuals and neu-
rodegenerative patients. 
 Some others clinical experiments were devel-
oped through a research agreement with the 
Department of Basic Medical Science, Neuro-
science and Sensory System Department–
SMBNOS, within University of Bari (de 
Tommaso et al., 2014a, 2014b; Vecchio et al., 
2016). 
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Abstract 
During the radiation therapy (RT) process, the treatment is planned and simulated with a treatment planning sys-
tem (TPS). Contouring identifies the Planning Treatment Volume (PTV), that is the physical RT treatment vol-
ume. PTV of Glioblastoma (GB) includes, after expansion, Gross Tumor Volume (GTV, the tumor) and Clinical 
Target Volume (CTV, tumor plus edema). GlioCAD, a Computer-Assisted Detection software for contouring 
gliomas in MRI/DTI, was used to delineate GTV. The dataset included the images of 21 patients undergoing RT 
for GB. For each patient, we co-registered CT-planning images and diagnostic MRI (16 T1-gad, 6 T2 Flair, 13 
Flair Fat Sat), which were used for GlioCAD training and validation. CAD outlined the tumor with good accura-
cy, after ruling out in post-processing some false positives. We identified reliable GTVs, suitable for RT require-
ments. An evolution of GlioCAD will take into account edema for outlining CTV. The method is promising. 
Together with a further automatic system for the delineation of organs at risk (OAR) in the brain, the procedure 
may be helpful for standardization of RT-treatment planning. 
Keywords: glioma, glioblastoma, radiotherapy, GTV, contouring, segmentation 
 
 
 
1. Introduction 
 
Malignant gliomas are aggressive tumors of the 
Central Nervous System. The gold standard 
treatment provides for an initial surgical time 
followed by radiotherapy and chemotherapy 
with temozolomide in concomitant and adju-
vant setting (Stupp et al. 2005). The prognosis 
of glioblastoma (GB) multiforme has not im-
proved much over the past ten years since a 
beneficial in survival with this integrated sched-
ule has been shown. Radiotherapy inevitably 
induces neurotoxicity and it is normal to con-
sider that limited treatment volumes may con-
sequently reduce it.  
However the definition of the optimal radio-
therapy treatment volumes in GB remains con-
troversial and may be important to obtain  
systems that can make the practice of contour-
ing this kind of tumors as homogeneous as 
possible. Contouring in radiotherapy mainly 
consists in the identification of two volumes to 
be treated, when possible, with different doses: 
the macroscopically visible tumor (GTV,  
Gross Tumor Volume) and a region (edema) of 
likely infiltration (CTV, Clinical Target  
Volume), Fig. 1.  
A further margin is added to CTV to create the 
PTV (Planning Target Volume), which takes 
into account the uncertainty that may result 
from positioning errors in the treatment phase. 
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Figure 1. Left: Diagram of the main irradiation volumes (from 
ICRU 50). Right: an example of manual assessment of GTV, 
CTV, and PTV (the GBM is in the left brain hemisphere, and 
the three irradiation volumes are roughly concentric, respective-
ly from the smallest to the largest one). 
 
To improve contouring reliability the radiation 
oncologist uses centering CT images and diag-
nostic MR scans. 
The treatment volumes in glioblastoma, over 
the years, have varied in the various cooperative 
group trials especially differing in margin from 
the GTV and inclusion of peritumoral edema. 
For example, the RTOG (The Radiation Ther-
apy Oncology Group) recommends that the ini-
tial clinical CTV covers the whole T2 high-
intensity areas defined in post-operative MR 
imaging plus a 2-cm margin, followed by a 
boost with a field defined by the areas of T1-
enhancement (macroscopical residual tumor) 
and/or the surgical cavity with 2.5-cm margin 
(Gilbert et al. 2013, 2014). The rationale for 
peritumoral edema inclusion is the histologically 
confirmed presence of tumor cells in this area. 
On the other hand, the EORTC (Organization 
for Research and Treatment of Cancer) rec-
ommends that CTV should include the T1 en-
hancement area and/or the surgical cavity plus 
2-3 cm without the intentional inclusion of T2 
areas of edema (Stupp et al. 2005). To support 
the EORTC protocols there are data that show 
that the majority of recurrences were within 2 
cm away from the primary tumor. Therefore 
today there is no consensus about the definition 
of treatment in GB volumes. 
It should also be considered that in addition to 
the heterogeneity in the contouring protocol 
that can be adopted by each center, there is 
heterogeneity in contouring due to manual skill, 
to image interpretation, and to the experience 
of each radiation oncologist. There are studies 
assessing the heterogeneity in contouring in 
which, after surgical resection, some radiation 
oncologists have surrounded GTV as the entire 
surgical cavity, which includes both the space of 
missing tissue filled by fluid and the resection 
margin, while others have strictly confined the 
GTV only in the resection margin (see e.g. 
(Wee et al. 2015)). 
In this context, the need for a reproducible and 
efficient method for delineating the tumor vol-
umes for RT is critical. In particular, it has been 
demonstrated that MRI is more sensitive than 
CT in both lesion detection and in the margin 
delineation of gliomas, see e.g. (TenHaken et al. 
1992), which makes MRI modalities the most 
appropriate for an automatic or semiautomatic 
GB contouring system and GTV/CTV delinea-
tion. 
In this preliminary work, GlioCAD (De Nunzio 
et al. 2011), a CAD (Computer-Assisted Detec-
tion) software system for the contouring of cer-
ebral gliomas in MRI/DTI, was used to deline-
ate the GTV treatment volumes in patients with 
glioblastomas, in order to get quick and opera-
tor-independent semi-automatic contouring. 
The application of GlioCAD was preceded and 
followed by data processing steps whose pur-
pose was to conform data to the software, and 
to make the resulting segmentation more ap-
propriate to RT requirements. In this paper, 
CAD principles and operations are described, 
the post-processing procedure designed to 
make the automatically-contoured volumes 
comply with radiotherapy needs is analyzed, 
and some segmentation results are shown. 
In Section II, the used dataset is described, to-
gether with the manual procedure for GTV 
contouring, which is needed by GlioCAD to 
initially learn gross tumor delineation, and the 
software pipeline is illustrated. Section III 
shows some preliminary results, while the dis-
cussion with a small review of the related litera-
ture is in Section IV. The conclusions end the 
paper. 
 
 
2. Materials and methods.  
 
The dataset consisted of the images of 21 pa-
tients treated for GB at the Radiotherapy Unit 
of Siena (Italy). For each patient we had center-
ing helical CT images and diagnostic MRI, 
which were coregistered. MR images (16 T1-
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pose was to conform data to the software, and 
to make the resulting segmentation more ap-
propriate to RT requirements. In this paper, 
CAD principles and operations are described, 
the post-processing procedure designed to 
make the automatically-contoured volumes 
comply with radiotherapy needs is analyzed, 
and some segmentation results are shown. 
In Section II, the used dataset is described, to-
gether with the manual procedure for GTV 
contouring, which is needed by GlioCAD to 
initially learn gross tumor delineation, and the 
software pipeline is illustrated. Section III 
shows some preliminary results, while the dis-
cussion with a small review of the related litera-
ture is in Section IV. The conclusions end the 
paper. 
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The dataset consisted of the images of 21 pa-
tients treated for GB at the Radiotherapy Unit 
of Siena (Italy). For each patient we had center-
ing helical CT images and diagnostic MRI, 
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Figure 1. Left: Diagram of the main irradiation volumes (from 
ICRU 50). Right: an example of manual assessment of GTV, 
CTV, and PTV (the GBM is in the left brain hemisphere, and 
the three irradiation volumes are roughly concentric, respective-
ly from the smallest to the largest one). 
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gad, 6 T2 Flair, 13 Flair Fat Sat scans) were 
used to better identify the macroscopic tumor 
regions (GTV) and the surrounding edema 
(CTV). The images, comprising manually de-
fined treatment volumes and organs at risk 
(OAR), were used for the training of GlioCAD, 
a CAD system for the contouring and volume 
calculation of cerebral gliomas in conventional 
MRI and DTI. 
The manual contouring procedure had the fol-
lowing steps: 
1. We started from the manual segmenta-
tions in T1-gad images and used these 
series to define the macroscopic tumor 
volume (GTV) corresponding to the ar-
ea of contrast enhancement; in the case 
of a post-operative series, the surgical 
cavity was contoured including any are-
as with contrast enhancement sur-
rounding the cavity.  
2. A margin of 2 cm was added to this 
volume to obtain the CTV; edema in-
clusion was verified by exploiting the 
FLAIR images; in case of imprecise in-
clusion, we had to apply manual chang-
es to include edema, by comparing the 
levels of hyperintensity in FLAIR series. 
If the expansion gave a volume beyond 
the limits of the cranial theca or beyond 
natural anatomical barriers (such as 
bone structures, falx, ventricular sys-
tem), manual correction was performed. 
3. We added a further margin of 0.5 cm to 
CTV to create the PTV (Planning Tar-
get Volume. 
When the patients were candidate to receive an 
additional dose (up to 60-70 Gy), an expansion 
of about 0.5 cm was given to the initial GTV to 
create the so-called CTVboost and another 0.5 
cm to create a PTVboost; if there are adjacent 
critical structures these two volumes may coin-
cide (CTVboost = PTVboost). 
In conclusion, in each series of images there 
was a single GTV but possibly more CTV and 
related PTV  (CTV1 with PTV1 and CTV2 
with PTV2) which corresponded to the first 
part of the treatment at lower doses and the 
subsequent boost – i.e. an additional dose to a 
limited volume.  
The following part describes the application of 
GlioCAD to automatic GTV contouring, which 
is depicted in Figs. 2 and 3. The procedure is 
based on the combined use of T1-gad images 
and FLAIR images, all of them coregistered 
with the CT scans. 
     
      
Figure 2. Semiautomatic GTV delineation: preprocessing  
and CAD training. 
 
 
 
 
Figure 3. Semiautomatic GTV delineation: Segmentation and 
post-processing. 
 
GlioCAD is a supervised system, in that it 
needs an initial set of images where the desired 
GTV has already been delineated by experts. 
GlioCAD working scheme (De Nunzio et al. 
2011), is based on the calculation of texture fea-
tures (derived from gray-level histograms, 
cooccurrence matrices, and run-length matri-
ces) with a sliding-window approach, and on 
the Fisher Linear Discriminant Analysis as the 
classification method. After training, the soft-
ware becomes able to locate and contour by it-
self the volumes of interest on a different set of 
images (“validation” set). Accordingly, a pre-
processing step followed by a training step is 
needed. In first place (Fig. 2), the CT images are 
coregistered (12-parameters affine 
coregistration) to the corresponding T1-gad, 
 Giorgio De Nunzio, Benedetta Tafuri, Marina Donativi, Marta Vannini, Lorenzo Mazzoni, Giovanni Rubino, Antonella Castellano, Luigi Pirtoli  
35 
gad, 6 T2 Flair, 13 Flair Fat Sat scans) were 
used to better identify the macroscopic tumor 
regions (GTV) and the surrounding edema 
(CTV). The images, comprising manually de-
fined treatment volumes and organs at risk 
(OAR), were used for the training of GlioCAD, 
a CAD system for the contouring and volume 
calculation of cerebral gliomas in conventional 
MRI and DTI. 
The manual contouring procedure had the fol-
lowing steps: 
1. We started from the manual segmenta-
tions in T1-gad images and used these 
series to define the macroscopic tumor 
volume (GTV) corresponding to the ar-
ea of contrast enhancement; in the case 
of a post-operative series, the surgical 
cavity was contoured including any are-
as with contrast enhancement sur-
rounding the cavity.  
2. A margin of 2 cm was added to this 
volume to obtain the CTV; edema in-
clusion was verified by exploiting the 
FLAIR images; in case of imprecise in-
clusion, we had to apply manual chang-
es to include edema, by comparing the 
levels of hyperintensity in FLAIR series. 
If the expansion gave a volume beyond 
the limits of the cranial theca or beyond 
natural anatomical barriers (such as 
bone structures, falx, ventricular sys-
tem), manual correction was performed. 
3. We added a further margin of 0.5 cm to 
CTV to create the PTV (Planning Tar-
get Volume. 
When the patients were candidate to receive an 
additional dose (up to 60-70 Gy), an expansion 
of about 0.5 cm was given to the initial GTV to 
create the so-called CTVboost and another 0.5 
cm to create a PTVboost; if there are adjacent 
critical structures these two volumes may coin-
cide (CTVboost = PTVboost). 
In conclusion, in each series of images there 
was a single GTV but possibly more CTV and 
related PTV  (CTV1 with PTV1 and CTV2 
with PTV2) which corresponded to the first 
part of the treatment at lower doses and the 
subsequent boost – i.e. an additional dose to a 
limited volume.  
The following part describes the application of 
GlioCAD to automatic GTV contouring, which 
is depicted in Figs. 2 and 3. The procedure is 
based on the combined use of T1-gad images 
and FLAIR images, all of them coregistered 
with the CT scans. 
     
      
Figure 2. Semiautomatic GTV deli eation: preprocessing  
and CAD training. 
 
 
 
 
Figure 3. Semiautomatic GTV delineation: Segmentation and 
post-processing. 
 
GlioCAD is a supervised system, in that it 
needs an initial set of images where the desired 
GTV has already been delineated by experts. 
GlioCAD working scheme (De Nunzio et al. 
2011), is based on the calculation of texture fea-
tures (derived from gray-level histograms, 
cooccurrence matrices, and run-length matri-
ces) with a sliding-window approach, and on 
the Fisher Linear Discriminant Analysis as the 
classification method. After training, the soft-
ware becomes able to locate and contour by it-
self the volumes of interest on a different set of 
images (“validation” set). Accordingly, a pre-
processing step followed by a training step is 
needed. In first place (Fig. 2), the CT images are 
coregistered (12-parameters affine 
coregistration) to the corresponding T1-gad, 
JDREAM.indd   35 18/01/18   11:0325 2 57
Semiautomatic segmentation of glioblastoma for radiotherapy treatment plannin 
36 
and the related transformation matrices are 
used to project the GTV drawn by the radiation 
oncologist onto the T1-gad images. 
Coregistrations were performed by elastix 
(http://elastix.isi.uu.nl) (Klein et al. 2010) 
(Shamonin et al. 2014), which is an open source 
software tool based on the Insight Segmenta-
tion and Registration Toolkit (ITK). Elastix 
consists of a collection of algorithms for (medi-
cal) image registration. The modular design of 
elastix allows to quickly configure and compare 
different registration methods. We used elastix 
command-line interface, which enables auto-
mated processing of a large number of images 
by means of scripting. After coregistration, the 
T1-gad series with the coregistered GTV was 
resliced to have homogeneous voxel size in the 
data set, and was then used to train GlioCAD 
to recognize and segment the tumor regions in 
T1-gad. 
During segmentation and post-processing (Fig. 
3), the trained CAD locates probably cancerous 
regions in the T1-gad images of the validation 
set, reducing false positives through a mask ob-
tained from the FLAIR image by thresholding 
and appropriate morphological operations. An 
active contour model merges the found regions 
into a single ROI, smoothing borders and solv-
ing inhomogeneity problems. The final identi-
fied ROI is used as the (computer calculated) 
GTV. The quantification of the system accura-
cy is obtained by the Jaccard coefficient, by 
comparing the results with the manually de-
fined GTV. 
The extension to the CTV will be performed by 
using again the mask obtained from the FLAIR 
image, and by considering a 2-cm border added 
to the GTV by morphological dilation. Finally, 
to avoid false positives, a descalping mask au-
tomatically obtained from the T1-gad images 
will be applied. 
 
 
3. Results 
 
Segmentation and accuracy assessment were 
carried out with Leave One Patient Out 
(LOPO) Cross Validation: the CAD system was 
applied in turn to each patient scan (Fig. 3), af-
ter training on the remaining images (Fig. 2). In 
all cases, the CAD outlined the tumor structure 
with good accuracy. A post-processing step was 
needed to eliminate some false positives and to 
make the identified volumes compliant with ra-
diotherapy treatment requirements, with an ac-
ceptable hypothesis for the final GTV estima-
tion (Fig. 4). Most of post-processing is auto-
matic, with some manual interventions for veri-
fication and refinement. The mean Jaccard co-
efficient with its standard deviation was 
J=0.73±0.08, while the Dice coefficient was 
0.83±0.09. 
 
 
Figure 4. CAD GTV segmentation examples. 
 
 
4. Discussion 
 
Automatic and semiautomatic segmentation of 
gliomas (in particular GBs) for volumetric as-
sessment and therapy follow-up have been the 
subject of an innumerable number of papers 
(see some recent reviews, such as (Bauer et al. 
2013) (Gordillo, Montseny, and Sobrevilla 
2013) (Liu et al. 2014) (Simi and Joseph 2015) 
(Srinivasa Rao and Sreenivasa Reddy 2016)). 
On the other hand, few works specifically de-
voted to radiotherapic applications, with a fo-
cus on the (semi)automatic contouring of GTV 
for brain glioma treatment planning, have been 
published. The subsequent steps, namely auto-
matic expansion to CTV and PTV, have been 
studied in many papers, some dating back to 
the nineties, such as (Stroom and Storchi 1997), 
up to recent works such as (Yan et al. 2014), in 
which the Authors introduce a method for gen-
erating the CTV from GTV using the geodesic 
distance calculation. These articles will be thor-
oughly reviewed in a future paper on the ex-
pansion to CTV/PTV. 
Among the papers concerning (semi)automatic 
GTV contouring, (Mazzara et al. 2004) com-
pared the effectiveness of knowledge-guided 
Semiautomatic segmentation of glioblastoma for radiotherapy treatment plannin 
36 
and the related transformation matrices are 
used to project the GTV drawn by the radiation 
oncologist onto the T1-gad images. 
Coregistrations were performed by elastix 
(http://elastix.isi.uu.nl) (Klein et al. 2010) 
(Shamonin et al. 2014), which is an open source 
software tool based on the Insight Segmenta-
tion and Registration Toolkit (ITK). Elastix 
consists of a collection of algorithms for (medi-
cal) image registration. The modular design of 
elastix allows to quickly configure and compare 
different registration methods. We used elastix 
command-line interface, which enables auto-
mated processing of a large number of images 
by means of scripting. After coregistration, the 
T1-gad series with the coregistered GTV was 
resliced to have homogeneous voxel size in the 
data set, and was then used to train GlioCAD 
to recognize and segment the tumor regions in 
T1-gad. 
During segmentation and post-processing (Fig. 
3), the trained CAD locates probably cancerous 
regions in the T1-gad images of the validation 
set, reducing false positives through a mask ob-
tained from the FLAIR image by thresholding 
and appropriate morphological operations. An 
active contour model merges the found regions 
into a single ROI, smoothing borders and solv-
ing inhomogeneity problems. The final identi-
fied ROI is used as the (computer calculated) 
GTV. The quantification of the system accura-
cy is obtained by the Jaccard coefficient, by 
comparing the results with the manually de-
fined GTV. 
The extension to the CTV will be performed by 
using again the mask obtained from the FLAIR 
image, and by considering a 2-cm border added 
to the GTV by morphological dilation. Finally, 
to avoid false positives, a descalping mask au-
tomatically obtained from the T1-gad images 
will be applied. 
 
 
3. Results 
 
Segmentation and accuracy assessment were 
carried out with Leave One Patient Out 
(LOPO) Cross Validation: the CAD system was 
applied in turn to each patient scan (Fig. 3), af-
ter training on the remaining images (Fig. 2). In 
all cases, the CAD outlined the tumor structure 
with good accuracy. A post-processing step was 
needed to eliminate some false positives and to 
make the identified volumes compliant with ra-
diotherapy treatment requirements, with an ac-
ceptable hypothesis for the final GTV estima-
tion (Fig. 4). Most of post-processing is auto-
matic, with some manual interventions for veri-
fication and refinement. The mean Jaccard co-
efficient with its standard deviation was 
J=0.73±0.08, while the Dice coefficient was 
0.83±0.09. 
 
 
Figure 4. CAD GTV segmentation examples. 
 
 
4. Discussion 
 
Automatic and semiautomatic segmentation of 
gliomas (in particular GBs) for volumetric as-
sessment and therapy follow-up have been the 
subject of an innumerable number of papers 
(see some recent reviews, such as (Bauer et al. 
2013) (Gordillo, Montseny, and Sobrevilla 
2013) (Liu et al. 2014) (Simi and Joseph 2015) 
(Srinivasa Rao and Sreenivasa Reddy 2016)). 
On the other hand, few works specifically de-
voted to radiotherapic applications, with a fo-
cus on the (semi)automatic contouring of GTV 
for brain glioma treatment planning, have been 
published. The subsequent steps, namely auto-
matic expansion to CTV and PTV, have been 
studied in many papers, some dating back to 
the nineties, such as (Stroom and Storchi 1997), 
up to recent works such as (Yan et al. 2014), in 
which the Authors introduce a method for gen-
erating the CTV from GTV using the geodesic 
distance calculation. These articles will be thor-
oughly reviewed in a future paper on the ex-
pansion to CTV/PTV. 
Among the papers concerning (semi)automatic 
GTV contouring, (Mazzara et al. 2004) com-
pared the effectiveness of knowledge-guided 
JDREAM.indd   36 18/01/18   11:0325 2 57
 Giorgio De Nunzio, Benedetta Tafuri, Marina Donativi, Marta Vannini, Lorenzo Mazzoni, Giovanni Rubino, Antonella Castellano, Luigi Pirtoli  
37 
(KG) and supervised k-Nearest Neighbors 
(kNN) segmentation for delineating the GTV 
from MR images of high and low-grade 
gliomas. The GTV corresponded to the area 
enclosing several contiguous clusters of enhanc-
ing pixels. The average accuracy of the kNN 
was 56%±6% for 11 cases, whereas that of the 
KG was 52%±7% for 7 of the 11 cases, com-
pared with the physician’s contours. It was ob-
served that kNN and KG are less accurate in 
contouring GTV in non-enhancing GBs. The 
study showed severe limitations of the KG-
system in handling particular cases such as non-
enhancing tumor margins or the presence of 
non-enhancing cystic necrotic tissues at the 
center of the tumor. On the other hand, the 
kNN segmentation method, trained with sam-
ple data from MRI slices to segment, lead to 
more robust segmentation results on all pa-
tients. 
(Beyer et al. 2006), from the same group, pre-
sented a similar and comparative study, extract-
ing GTV with the same two segmentation 
methods and evaluating the results in terms of 
predictive dose measurement for therapy plan-
ning. It was found that the expert physician ref-
erence volume was irradiated within the same 
level of conformity when using the plans gener-
ated from the contours of the segmentation 
methods. In addition, any uncertainty in the 
identification of the actual gross tumor volume 
by the segmentation methods, had small effects 
when used to generate 3D radiation therapy 
treatment planning due to the averaging process 
in the generation of margins used in defining a 
planning target volume. 
(Hori et al. 2010) proposed a method for semi-
automated GTV segmentation of GB on brain 
MR images for radiotherapy planning. Three-
dimensional (3D) MR images of 28 GB cases 
were used. First, a spherical volume of interest 
(VOI) including the GB was interactively de-
fined. Then, the VOI was transformed to a 
two-dimensional (2D) image by a spiral-
scanning technique. Active contour models 
were used to delineate an optimal outline of the 
GB in the transformed 2D image. After inverse 
transform to the 3D space, a morphological fil-
ter was applied to smooth the shape of the 3D 
segmented region. The computer output was 
compared with the manually segmented regions 
by the Jaccard similarity coefficient (JSC) and 
the True Segmentation Coefficient (TSC), giv-
ing on average 74.2±9.8% and 84.1±7.1%, re-
spectively. This paper is written in Japanese. 
The Expectation Maximization (EM) algorithm, 
applied on a Gaussian mixture model consisting 
of pure superpositions of Gaussian distribu-
tions, was employed in (Simon et al. 2012) to 
delineate the Apparent Diffusion Coefficient 
(ADC) areas of high and low proliferation in 
heterogeneous gliomas from predefined manual 
GTVs on 2D DWI slices. The EM was initial-
ized manually from the contoured ROIs. The 
result was a reproducible quantification in re-
gions of tissue inhomogeneity. Reproducibility 
of this approach was evaluated in 10 patients 
with glioma. Moreover, an automatic initializa-
tion approach that completely removes user-
induced variability was introduced. 
In (Unkelbach et al. 2014) brain segmentation 
(normal tissues vs tumor) was obtained by an 
algorithm based on EM, which uses a probabil-
istic normal tissue atlas as spatial prior. For eve-
ry voxel, it estimates the posterior probability 
for three normal tissue classes (white matter, 
gray matter, and CSF), as well as the lesion out-
lines on T1 post gadolinium and T2-FLAIR. It 
then uses the Fisher-Kolmogorov glioma 
growth model to assess lesion infiltrations in 
normal appearing regions of the brain. In the 
paper, the need for reliable segmentation of an-
atomical boundaries such as the falx cerebri and 
the tentorium cerebella is put in evidence. The tar-
get volume for radiotherapy planning is defined 
as an isoline of the simulated tumor cell density. 
Dice metrics are given between manual and 
model-derived CTV volumes (values range 
from 0.74 to 0.84). 
(Dittmann et al. 2013) considers that conven-
tional imaging modalities reveal only the central 
part of the tumor with a high cellular density, 
but fail to detect microscopic tumor cell infil-
trations. Mathematical models can be used to 
integrate known growth characteristics of 
gliomas into the target delineation process. In 
the paper, the Authors demonstrate the use of 
diffusion tensor imaging (DTI) for simulating 
anisotropic cell migration in a glioma growth 
model that is based on the Fisher-Kolmogorov 
(FK) equation. For a clinical application of the 
model, it is crucial to develop a detailed under-
standing of its behavior, capabilities, and limita-
tions. For that purpose, the Authors perform a 
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model, it is crucial to develop a detailed under-
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retrospective analysis of glioblastoma patients. 
It was found that, depending on the location of 
the tumor relative to major fiber tracts, DTI 
can have significant influence on the shape of 
the radiotherapy target volume. 
Finally, the work described in (Stretton et al. 
2013) is worth noting and is related to 
(Dittmann et al. 2013). Tumor growth models 
based on the FK equation are employed again, 
but replacing DTI (costly and not always avail-
able) with an isotropic diffusion map or an ani-
sotropic high-resolution DTI atlas formed by 
averaging DTIs of multiple patients. Three 
metrics are used to quantify the impact of re-
placing the patient DTI: the shape of the simu-
lated glioma, the estimation of the tumor 
growth parameters, and the prediction perfor-
mance on clinical cases. 
The preceding review shows that the literature 
does not offer a large quantity of papers devot-
ed to the specific subject of GTV automatic or 
semiautomatic contouring. Direct comparison 
of our results is possible only with (Mazzara et 
al. 2004) and (Hori et al. 2010).  
In (Mazzara et al. 2004) the ground truth for 
accuracy assessment is obtained by multiple 
contours drawn by three physicians, and the 
probability that a given pixel is properly classi-
fied as part of the tumor (its “weight”) is de-
termined by the number of times that this pixel 
was included in the outlines prepared by the ra-
diation oncologists. Accuracy for the computer 
segmentation is then defined as the ratio of the 
total sum of weights contained within the com-
puter segmentation volume to the total weights 
generated from the volumes produced by the 
physicians. This measure is a kind of probabilis-
tic true-positive rate (i.e. sensitivity). Observing 
that by definition the Jaccard coefficient is al-
ways lower than or equal to sensitivity, our 
method clearly outperforms their results. As to 
(Hori et al. 2010), the absence of an English 
version of the paper makes a detailed compari-
son difficult. As to segmentation quality, our 
results in terms of Jaccard coefficient look simi-
lar.  
 
 
5. Conclusions 
 
The proposed method is promising, although 
still under development and not fully automatic. 
In the next future, it will be tested on a larger 
set of images, and the procedure will be made 
as automatic as possible. The following step will 
be CTV/PTV automatic delineation, which is 
currently work in progress. Together with the 
use of automatic or semiautomatic systems for 
OAR delineation, for which the literature al-
ready presents various solutions often based on 
atlas-driven approaches, e.g. (Isambert et al. 
2008) (Daisne and Blumhofer 2013) (Consona 
et al. 2014), the procedure may be of help to 
optimize radiation-treatment planning in pa-
tients with GB, in particular to make the pro-
cess of contouring as homogeneous as possible 
without operator-dependent variability and to 
obtain limited treatment volumes in order to 
reduce RT-related neurotoxicity. 
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Abstract 
Follicular Lymphoma (FL) is the second most frequent non-Hodgkin lymphoma accounting for approximately 
10-20% of all lymphomas in Western Countries. Histologic transformation (HT) is a frequent event in the clini-
cal course of patients with indolent lymphoma that is often accompanied by a dramatic change in the clinical fea-
tures of the disease towards a more aggressive course. Although the transformation of Follicular Lymphoma 
(tFL) was described several decades ago, there is a strong need for a better understanding of both the dynamics 
of the tumor clonal evolution and the genetic events  leading to ()transformation. In addition, the management 
of patients with tFL is challenged by the heterogeneity of the previous treatments. The present review describes 
the state of art of tFL, outlining recent advances in the understanding of genetic basis and the evolutionary pro-
cess governing the initiation and persistence of tumor evolution. It will be also addressed the key questions pend-
ing on this incurable disease, such as a lack of a standard therapeutic strategy for tFL patients as well as its out-
come in the Rituximab (R) era. 
 
Keywords: Non Hodgkin Lymphoma, Follicular Lymphoma, Transformed Follicular Lymphoma, 
immunochemotherapy 
 
 
 
Introduction 
 
Follicular Lymphoma is defined by the World 
Health Organization (WHO) classification 
(Swerdllow SH, Campo E 2008) as a “neoplasm 
composed of follicle center (germinal center – 
GC) B cells, typically both centrocytes and 
centroblasts which usually has at least a partially 
follicular pattern”. FL arises then by a malig-
nant transformation of the normal germinal 
center B cells and therefore carries the charac-
teristics of centrocytic/centroblastic morpholo-
gy. 
The disease is usually characterized by an indo-
lent clinical course, excellent response to initial 
therapy with frequent relapses and shorter du-
ration responses to salvage therapy.  
At present, thanks to the advances in the treat-
ment of FL, the disease is moving from an in-
curable to curable one. Regarding the manage-
ment chemoimmunotherapy – usually followed 
by Rituximab maintenance – is the standard of 
care; whereas patients with nonbulky or asymp-
tomatic disease may be treated with Rituximab 
monotherapy or simply observed (Jonathan W 
Friedberg et al. 2009). Although many asymp-
tomatic patients with low-volume disease may 
not require early therapy and can be observed, 
the majority of patients will lastly experience 
disease progression and will need therapy dur-
ing the course of the disease. In particular, 
some patients have long-term remission lasting 
years, others have a rapidly progression of the 
disease and develop treatment resistance 
and/or transformation to aggressive lymphoma 
(Link et al. 2013; S. M. Smith 2013). Priorities 
in goals of care include avoiding relapses, trans-
formation to aggressive subtypes and death.  
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In the past, approximately 25% of cases trans-
form to aggressive disease, mostly  Diffuse 
Large B-cell Lymphoma (DLBCL),with a very 
poor prognosis (Montoto et al. 2007). The his-
tologic changes seen in patients with HT are, in 
the great majority of cases, accompanied by a 
change in the clinical features of the disease to-
wards a more aggressive course (Montoto 
2015). 
 More recently, contradictory data are emerging 
with respect to the impact of initial treatment  
on the risk of transformation (Montoto 2015), 
In particular, the adoption of Rituximab in first 
line therapy seems associated with a lower risk 
of transformation. Therefore, decisions on the 
management of tFL patients come from ex-
trapolation data of retrospective studies or from 
prospective trials in DLBCL, as this is the 
commonest transformed lymphoma. 
The present review will be focused on the state 
of art of tFL and will try to address pending 
questions about this condition. 
 
 
Definition of tFL 
 
Definition of tFL is still a great challenge as it 
varies among different series. Over the past 
years, definition of transformation have been 
largely varying from “an histological features of 
DLBCL as opposed to cytologic progression with an 
increase in the proportion of large cells (from grade 1/2 
to grade 3 FL)” (Montoto et al. 2007) to “refracto-
ry/recurrent disease with either clinical or pathologic di-
agnosis of transformed lymphoma” (Link et al. 2013); 
passing through other definitions. The main is-
sue in considering a unique definition is the fact 
that transformation is diagnosed in different se-
ries based on cytological samples, on histologic 
samples or in some cases on clinical grounds 
alone. Indeed  diagnosis should be based on bi-
opsy or adopting clinical criteria in the cases in 
which it is not  possible to obtain a biopsy, ei-
ther because of the poor performance status of 
the patient or because of progression of the 
disease in inaccessible areas (Montoto and Fitz-
gibbon 2011). In 2008, Al-Tourah et al. (Al-
Tourah et al. 2008) published clinical criteria to 
define transformation: a rapid discordant lym-
phadenopathy growth, unusual sites of extra-
nodal involvements, a sudden rise in the LDH 
level, hypercalcemia, or presence of new B-
symptoms. 
 
Incidence, Prognosis and Outcome of tFL 
 
Historically, transformation was largely consid-
ered a catastrophic event. Although the clinical 
course of FL patients may span more than ten 
years, transformation occurrence heralds a 
change from an indolent to an aggressive dis-
ease course, and is associated with major mor-
bidity and mortality (14). In particular, most of 
the studies have reported a poor prognosis after 
transformation, with a median duration of sur-
vival generally ranging from 2.5 months to 2 
years, with most deaths being due to lymphoma 
(5,7,12,13,15–21).  
The incidence of HT have wavered over the 
past several decades, due to the adoption of dif-
ferent diagnostic methods, definition of trans-
formation and duration of follow-up. Thus, the 
considerable variability in the incidence of tFL 
reported in literature may be explained by the 
heterogeneity in the definition of transfor-
mation, population included and diagnostic 
tools. 
The clinical significance of transformation was 
seen in 325 FL patients from the St Bartholo-
mew’s Hospital of London, in which the risk of 
transformation by 10 years was 28% and the 
median survival after transformation was 1.2 
years. Patients with tFL  had a significantly 
shorter OS and a shorter survival from progres-
sion compared to others (Montoto et al. 2007). 
Al-Tourah et al. analyzed the incidence of HT 
in a population based-study of 600 patients. 
The annual risk of transformation was estimat-
ed to be 3% per year, and the median survival 
after transformation was 1.7 years (7).  
In another recent study from the University of 
Iowa/Mayo Clinic (Link et al. 2013), the cumu-
lative risk of transformation and death without 
transformation (competing risk) increased 
steadily over time up through 5 years of follow-
up and then appeared to slow, with only four 
transformations observed beyond 5 years from 
diagnosis. Transformation rate at 5 years was 
highest in patients who were initially observed 
and lowest in patients who initially received 
Rituximab monotherapy (Link et al. 2013). 
However, in a group of 107 patients with ad-
vanced FL and low tumor burden registered in 
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the F2 database and managed with a W&W pol-
icy, the 5-year risk of transformation was quite 
low. After a median follow-up of 64 months, 
five patients experienced transformation to ag-
gressive non-Hodgkin lymphoma, two during 
the W&W no treatment period and three after 
progression, with an estimated rate of less than 
1% per year (Solal-Céligny et al. 2012). 
Wagner-Johnston et al. have investigated the 
incidence, prognostic features, and outcomes 
associated with tFL among 2652 patients with 
FL prospectively enrolled in the US National 
LymphoCare Study. At a median follow-up of 
6.8 years, 14.3% of patients underwent trans-
formation; patients who were treated at diagno-
sis had a reduced risk of transformation as well 
as maintenance Rituximab was associated with 
reduced transformation risk. The median  OS 
post transformation was 5 years (Wagner-
Johnston et al. 2015).  
The clinical and laboratory findings with better 
Overall Survival (OS) at the time of transfor-
mation include normal LDH levels, limited dis-
ease extent, good performance status, absence 
of B symptoms, fewer number of previous re-
lapses, transformation after expectant manage-
ment, having had no prior CR, or having had 
no response to salvage chemotherapy 
(5,7,12,13).  
Despite the overall poor outcome of tFL pa-
tients, Yuen et al., identified a subset of patients 
having a relatively good outcome (Yuen et al. 
1995). Limited extent of disease, attainment of 
Complete Remission (CR) to treatment given at 
the time of transformation and no prior therapy 
had a particularly favorable prognosis. In addi-
tion, patients who achieved CR after transfor-
mation had a better OS than those with ad-
vanced stage disease (108 vs 18 months) (Yuen 
et al. 1995). The impact of limited disease on 
tFL patients’ prognosis was also seen by Basti-
on et al., (Bastion et al. 1997) and Al-Tourah et 
al.,(Al-Tourah et al. 2008). This latter group 
shown that the 5-year OS was 66% for patients 
with a limited transformation compared to 19% 
for those with advanced-stage at transformation 
in a significant way (Al-Tourah et al. 2008). 
Only slight improvement were observed in re-
cent studies, mostly showing the shorter OS of 
tFL patients in comparison to non-transformed 
FL patients. This adverse effect of transfor-
mation on survival was clearly illustrated by Al-
Tourah et al., where the 10-year OS for non-
transformed FL patients was 75%, whereas was 
only 36% for tFL patients were alive 10 years 
from the time of their initial FL diagnosis (Al-
Tourah et al. 2008). Similar behaviors were also 
seen in other studies (Montoto et al. 2007).  
Importantly, most of the patients in the report-
ed studies received therapies not incorporating 
Rituximab. However, differences in patients’ 
series, treatment and outcome is not a good 
condition to take advantage of; a lot of work is 
still needed to find out standard clinical criteria. 
Table 1 summarizes transformation risk in re-
cent series. 
 
Table 1. Outcome of tFL patients in recent series  
 
Studies Transformation risk 
Montoto et al., 2007 17% at 5 years (100% biopsy proven) 
1.9 RR in W&W 
Al-Tourah et al., 2008 18% at 5 years (63% biopsy proven) 
30% at 10 years 
(18% Doxo vs 30% Alk P=0.001) 
Link et al., 2008 10.7% at 5 years (85% biopsy proven) 
14.4% in W&W 
3.2% in Rituximab 
Wagner et al., 2005 12.8% at 5 years (39% biopsy) 
13.4% Rituximab chemotherapy 
18.3% NonRituximab chemotherapy 
Sarkozi et al., 2016 4.1% at 6 years (100% biopsy proven) 
 
 
 Can we assess any improvement in the outcome of tFL 
in the Rituximab era? 
 
Whether the addition of Rituximab in intial 
treatment modifies the outcome of tFL pa-
tients, still needs to be addressed. However, 
over the last 5 years, several  studies have been 
suggesting that the outcome of tFL patients has 
improve in the Rituximab era (Conconi et al. 
2012; Ban-Hoefen et al. 2013; Lerch et al. 2015; 
Link et al. 2013; Guirguis et al. 2014). 
Very recently Sarkozy and all analyzed risk fac-
tors, incidence and outcome of HT at first re-
currence in the PRIMA patient cohort: after 6 
years after a chemoimmunotherapy induction, 
the cumulative incidence of HT was 4.1% (Sar-
kozy et al. 2016). 
Literature suggests that patients treated with 
Rituximab-containing chemotherapy achieve a 
longer OS compared with retrospective cohorts 
of patients treated with chemotherapy alone 
(Link et al. 2013; Bastion et al. 1997). In con-
trast, the most recent trial comparing a W&W 
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approach vs R did not show any differences in 
terms of risk of transformation (Ardeshna et al. 
2014). As commented by the same authors, in 
the most of the reported series, the majority of 
patients have received chemotherapy prior to 
the diagnosis of HT and have advanced stage at 
the time of transformation  so the better out-
come cannot be attributed to an earlier identifi-
cation of transformation leading to a better risk 
population (Montoto 2015).  
Controversial results were also found in wheth-
er prior treatment with Rituximab has a good 
effect on the outcome after transformation. In 
a recent study, Lerch et al. (Lerch et al. 2015), 
showed that the treatment with Rituximab be-
fore the diagnosis of tFL was not correlated 
with a worse outcome in those patients. In con-
trast, patients with relapsed DLBCL treated 
with Rituximab have a significantly worse 
prognosis at progression (Montoto 2015). Oth-
er two studies demonstrated that prior R treat-
ment did not result in a worse outcome in tFL 
patients who received high dose therapy with 
autologous stem cell rescue (HDT-ASCR) 
(Ban-Hoefen et al. 2013; Madsen et al. 2015). 
Patients who have previously received CHOP 
(Rituximab, Cyclophosphamide, 
Hydroxydaunorubicin, Vincistrine [Oncovin], 
Prednisone) chemotherapy, with or without R, 
are frequently treated with second line regimens 
for DLBCL (Montoto 2015). 
The role of Rituximab maintenance in DLBCL 
patients is also still unconcluded. In a recent 
study, R Maintenance was associated with re-
duced transformation risk. The median  OS 
post transformation was 5 years, suggesting an 
improved outcomes for transformation in the 
modern era (Wagner-Johnston et al. 2015). 
Habermann et al., (Habermann et al. 2006) 
showed that addition of maintenance with R 
did not improve the outcome of DLBCL pa-
tients treated with R-CHOP. Other two studies 
showed that R maintenance after HDT-ASCR 
in DLBCL patients was not associated with a 
better outcome (Haioun et al. 2009; 
Gisselbrecht et al. 2012). 
Based on heterogeneity of the treatment used 
before diagnosis of HT, it is a challenge to pull 
out any conclusions about specific regimen. 
 
 
 
Pathology and biology of tFL  
 
Although the FL transformation to DLBCL 
was described several decades ago, there is a 
strong need for a better understanding of both 
the dynamics of tumor clonal evolution and the 
genetic events that are responsible for trans-
formation.  
The pathogenesis of FL is best explained by a 
unifying hypothesis that takes into account ge-
netic alterations harbored by the neoplastic B 
cells and an immunological model that suggests 
prominent crosstalk between the tumor cells 
and non-neoplastic immune cells in the tumor 
microenvironment, which include T cells, mac-
rophages, follicular dendritic cells and stromal 
elements (de Jong and de Boer 2009; de Jong 
2005; I S Lossos 2005). 
 
It is well known that the translocation t(14;18) 
characteristic of most cases of FL leads to con-
stitutive B-cell Lymphoma 2 (BCL2) protein 
expression and is a critical early event in the de-
velopment of FL (Izidore S. Lossos and Gas-
coyne 2011). These cells then slowly proliferate, 
but do not die by apoptosis, and they can ac-
quire genetic alterations. This condition can in-
clude chromosomal alterations that result from 
the localization in the GC (Küppers 2005). 
Others are driver mutations and alterations that 
provide the malignant cells with a growth ad-
vantage including gains, losses of chromosomal 
material and even balanced translocations in-
volving the activation of dominant oncogenes, 
such as MYC (Izidore S. Lossos and Gascoyne 
2011). 
Recent studies have shown divergent pathways 
of disease progression and transformation in 
FL.  
Recent whole-exome studies have highlighted 
that low-grade FL at diagnosis frequently shows 
some “driver” mutations not found in the 
transformed clone (Okosun et al. 2014; 
Pasqualucci et al. 2014; Carlotti et al. 2009). 
Some of these data derived from genetic meth-
ods, and suggest that FL may evolve as a “non 
linear” transformation (Okosun et al. 2014; 
Pasqualucci et al. 2014; Bouska et al. 2014; 
Wartenberg et al. 2013; Green et al. 2013; Eide 
et al. 2010; Carlotti et al. 2009; Ruminy et al. 
2008; Halldórsdóttir et al. 2008) , in which the 
clone detected at transformation is more closely 
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related to a common progenitor than the clone 
predominating at the time (or site) of prior 
sampling (Casulo, Burack, and Friedberg 2015). 
The clonal evolution models to tFL were de-
fined by investigating genomic alterations that 
are present in the dominant clone of both pre- 
and post- specimens (“Shared lesions”), and 
contrasting them to those that are present ex-
clusively in the FL or tFL  biopsy (“phase-
specific lesions”). This analysis allowed to dis-
criminate between i. a linear model, in which 
the tFL dominant clone will maintain all lesions 
present in the original FL clone, in combination 
with additional tFL-acquired alterations; ii. a di-
vergent evolution model, where there are le-
sions that are unique to the dominant clone of 
the FL or the tFL, in addition to the set of 
shared alterations (Pasqualucci et al. 2014).  
 
Thus, data mostly supported a divergent evolu-
tion model in a significant proportion of pa-
tients undergoing transformation, whereby FL 
and tFL arise from a common mutated ancestor 
through the independent acquisition of distinct 
lesions (Pasqualucci et al. 2014). Most FL and 
tFL derive from a common mutated precursor 
cell through divergent clonal evolution. There 
are some shared molecular determinants such 
as chromatin modification and apoptosis and 
some tFL specific determinants such as cell cy-
cle, proliferation and DNA damage response.  
Interestingly, the most commonly affected 
genes in both FL and tFL where those encod-
ing for histone/chromatin modification en-
zymes, including methyltransferases and 
acetyltransferases (Pasqualucci et al. 2014). The-
se early lesions in FL generally affect epigenetic 
regulators (genes controlling chromatin struc-
ture), including  the H3H4 trimethyl-transferase 
MLL2 mutation, never lost at transformation, 
EZH2 and the acetyltransferases CREBBP and 
EP300 (Okosun et al. 2014; Pasqualucci et al. 
2014; Morin et al. 2010; Morin et al. 2011). 
Other frequent dysregulation in both FL and 
tFL was represented by programmed cell death 
genes, in particular BCL2 translocations, and 
thus presumably in the common ancestor clone 
(Pasqualucci et al. 2014). 
Among tFL specific determinants there were 
alterations of cell cycle control, through muta-
tion or deletion of cyclin-dependent kinase 
2A/B (CDKN2A/B). These latter are two tu-
mor suppressor genes, whose protein products 
p14-ARF, p16-INK4A and p15-INK4B, are  
important for negative regulation of cell cycle 
G1 progression and stabilization of the tumor 
suppressor p53 (Pasqualucci et al. 2014; Sherr 
2004).  
Alterations in Myc (Okosun et al. 2014; 
Pasqualucci et al. 2014), as well as DNA dam-
age response, through losses of genes associat-
ed with regulation of the immune response, 
were also consistent in tFL only. Among the 
mutations that affect the immune response, re-
cent studies found the entire HLA class I locus, 
specifically in β-2-microglobulin (B2M) and 
CD58 (Pasqualucci et al. 2014; Bouska et al. 
2014; Morin et al. 2010).   
 
Although a large number of prognostic markers 
have been implicated as contributing to survival 
in FL, only a handful have specifically examined 
the role of biological factors impacting risk of 
transformation. 
It is becoming evident that phenotype varia-
tions related to genetics events (MYC, BCL2, 
p16, p53) should be routinely identified. FISH 
analysis could also be required to identify genet-
ic alterations in MYC, BCL2 and BCL6. 
The incidence of CD30 expression in tFL has 
also been reported to be 20% in a recent retro-
spective series of cases and CD30 expression 
should be also routinely identified by IHQ.  
In summary, there is not a single mechanism 
driving transformation from FL to DLBCL (O-
kosun et al. 2014; Pasqualucci et al. 2014; Bou-
ska et al. 2014; Andrew J. Davies et al. 2007). 
Rather, there are several mechanisms involved 
in transformation. 
 
Treatment of tFL 
Optimal treatment strategies for tFL still repre-
sents an unmet need. Unfortunately, most clini-
cal trials exclude patients with tFL and there are 
no randomized studies in the modern era, with 
the result that level of evidence is very limited. 
In historic series, as described before, the out-
come of tFL patients was very poor, with a me-
dian OS of approximately 1 or 2 years 
(Montoto and Fitzgibbon 2011). However, the 
majority of published studies were conducted in 
the pre-Rituximab era, making difficult to draw 
any conclusion on the current scenario.  
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In the study conducted by Lynk and colleagues  
in 60 out of 631 patients with biopsy-proven 
tFL, the median OS was 50 months with an OS 
rate of 73% at 5 years after treatment with R-
CHOP chemotherapy (Link et al. 2013). Sur-
vival was similarly in the National Comprehen-
sive Cancer Network (NCCN) database study, 
with a median OS around 5 years in 118 biopsy 
confirmed tFL patients, was (Ban-Hoefen et al. 
2013). Similar results were seen in early-stage 
FL experiencing tFL, with a 3-year OS of 44% 
(Bains et al. 2013). The estimated median OS 
for the patients with a histological diagnosis of 
HT from the PRIMA trial was 3.8 years after a 
median 6 yea follow up (Sarkozy et al. 2016). 
As response after conventional chemotherapy, 
high-dose therapy (HDT) and autologous stem 
cell transplantation (ASCT) has been studied by 
several research groups (Witzig et al. 2002; 
Schouten et al. 1989; Freedman et al. 1991; 
Foran et al. 1998; Berglund et al. 2000; Chen et 
al. 2001; Williams et al. 2001; J W Friedberg et 
al. 1999; Andreadis et al. 2005; Sabloff et al. 
2007; Ramadan KM, Connors JM 2008).  
 Of historical relevance, the efficacy of ASCT 
was shown in tFL patients in old phase 2 and 
transplant registry series prior to the incorpora-
tion of immunotherapy (Wang and Hou 2010; 
Montoto and Fitzgibbon 2011). In particular, 
40% of patients experienced long-term benefit, 
with survival rates similar to patients with re-
lapsed aggressive lymphoma receiving the same 
treatment (Williams et al. 2001). However, most 
of the transplant studies are based on only small 
retrospective series of 20 to 50 patients 
(Hamadani et al. 2008; Williams et al. 2001; 
Chen et al. 2001; J W Friedberg et al. 1999; 
Sabloff et al. 2007). The role of ASCT has been 
further investigated in the Rituximab era, and 
so more relevant  to current practice with the 
result that the addition of the antibody  has im-
proved the outcomes of tFL patients practice.  
The Canadian Bone Marrow Transplant group 
(CBMTG) analyzed 172 patients with tFL ,  53 
treated with rituximab containing chemothera-
py  alone  and  97 underwent instead ASCT.  
This latter approach improved OS and Progres-
sion Free Survival (PFS) of patients over Ritux-
imab-containing chemotherapy regimens, alt-
hough the difference was modest (Villa et al. 
2013). Other groups observed that patients who 
were Rituximab naïve prior to ASCT, seemed 
to achieve better results than those with prior 
Rituximab exposure (Wirk et al. 2014; Kuruvilla 
et al. 2015; Ban-Hoefen et al. 2012; 
Gisselbrecht et al. 2010; Villa et al. 2013; Mad-
sen et al. 2015) paralleling the observation in de 
novo DLBCL patients undergoing ASCT 
(Gisselbrecht et al. 2010). In addition, patients 
with early tFL performed significantly better in 
terms of OS, compared to those with late 
tFL(Link et al. 2013). ASCT had similarly out-
comes in the large NCCN database, with an OS 
of 83% being superior compared to chemo-
therapy alone or ASCT without the incorpora-
tion of monoclonal antibodies (S. D. Smith et 
al. 2009; Villa et al. 2013).  
 
Allogeneic transplantation in tFL has been less 
well studied, with small numbers of patients in 
mostly retrospective series. Some of these stud-
ies showed significantly inferior results than 
ASCT (Ramadan KM, Connors JM 2008), most 
probably due to the higher treatment related 
mortality (TRM) associated with the allogenic 
approach (35% versus 10% at 5 years). In con-
trast, the risk of disease relapse at 5 years was 
tendentially lower. 
For relapses after ASCT, further salvage thera-
py with allogeneic transplantation seemed to 
improve the outcome of tFL regardless of the 
significant transplant related mortality  
(Ratanatharathorn et al. 1994; Doocey et al. 
2005). 
 
Radioimmunotherapy (RIT) has been proposed 
as primary treatment for tFL. In particular, ra-
dioactive nucleotide antibodies yttrium Y90 
ibritumomab (Zevalin) and iodine I131 
tositumomab (Bexxar), have shown some anti-
lymphoma activity in tFL  patients (A. J. Davies 
et al. 2004; Kaminski et al. 2001; Vose et al. 
2000; Witzig et al. 2002). The overall response 
rates of RIT  was 51%, ranging from 39% and 
79%, with half of the responsers achieving 
complete remissions (CR) (Wang and Hou 
2010). (Izidore S. Lossos and Gascoyne 2011).  
In the largest of these studies, Zelenetz et al., 
(Zelenetz AD, Saleh M, Vose J 2002) evaluated 
71 patients from several I131 tositumomab stud-
ies, and showed a median duration of response 
of 36 months in responding patients. Although 
this approach seemed less effective in patients 
with bulky tumor burden and patients who 
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have previously received radiotherapy, it might 
be considered especially in patients not qualify-
ing for more aggressive approaches giving that 
CR patients have shown prolonged response, 
often longer than 1 year (Izidore S. Lossos and 
Gascoyne 2011).  
Moreover, an additional area of interest  in-
volves the integration of RIT with HDT and 
transplant in tFL patients, that has the potential 
to improve disease control, with similar toxici-
ties compare to HDT alone (Krishnan et al. 
2008; Wondergem et al. 2012; Reddy and 
Savani 2011; Mei et al. 2014).  
 
Recently, novel agents have been investigated in 
tFL. In a phase 2 study, Lenalidomide showed 
an overall response rate of 57%, with median 
response duration of over 1 year in tFL patients 
(Czuczman et al. 2011). Specific inhibitors, tar-
geting Aurora A kinase (alisertib) (Jonathan W. 
Friedberg et al. 2014), Bruton tyrosine kinase 
(ibrutinib) (Aalipour and Advani 2013), the ϑ 
isoform of phosphatidylinositol 3-kinase 
(idelalisib) (Gopal et al. 2014; Burger and 
Okkenhaug 2014) and the BCL2 protein 
(GDC-0199/ABT199) (Seymour JF et al. 2013), 
are currently being investigated in both indolent 
and aggressive lymphomas. These novel agents 
seem to have a significant impact on the out-
come of tFL patients.  
Recent efforts are focusing on the immune tol-
erance towards lymphoma cells as an alternative 
therapeutic approach. Pidilizumab is currently 
used as a monoclonal antibody to Programmed 
death-1 (PD-1), a member of the B7 receptor 
family that represents an important immune 
checkpoint regulator. Its efficacy has been re-
cently shown in ASCT patients with DLBCL, 
including a subset with tFL (Armand et al. 
2013). 
 
 
Conclusions 
 
HT is expected as a relatively frequent event in 
the clinical course of patients with indolent 
lymphoma. However, The incidence of HT var-
ies enormously amongst different series, pend-
ing on the definition of HT, which is different 
in different studies., and different treatment ap-
proaches of the FL. Based on the available pub-
lished studies, mostly derived from small retro-
spective studies, there is still not any standard 
therapeutic strategy for tFL patients: treatments 
used are different in different reports and rela-
tionship between treatment and outcome does 
not emerge very well from the literature. The 
fact that the risk of transformation is rarely an 
end-point in prospective studies underlined a 
great obstacle in this field, so there is no clear 
evidence that the initial management has an 
impact on the subsequent risk of transfor-
mation.  
In conclusion, There is need for further studies  
aiming to provide an answer to pending ques-
tion, including i. Definition of tFL; ii. 
Assessement of risk of transformation in non-
treated patients; iii. Potential role of a FL stem 
cell or repopulating cell as a potential cell of 
origin contributing to histologic transformation; 
iv. History of clonal evolution; v. Molecular de-
terminants; vi. Response to salvage therapy of 
tFL; vii. Outcome of tFL in the Rituximab era. 
In addition, other several questions should be 
addressed, such as whether De novo tFL is the 
same or a different disease; whether FL3b is 
different from tFL and if there are differences 
between tFL at first or subsequent relapse. 
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between tFL at first or subsequent relapse. 
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Abstract 
The Obstructive Sleep Apnea (OSA) is becoming a significant problem nowadays because it is associated with an 
increasing cardio-metabolic mortality. This disorder is increasing dramatically in the western world because it re-
lated to obesity. The cost-effectiveness ratio of OSA's diagnostic and therapeutic management is a strategic issue 
for health policy, which faces with recent international discussion involving the Western Health Systems. It has 
been shown that costs for simplified models used for diagnosis and outpatient care for OSA are minimal due to 
a more and more reduction of expenditure for both equipment and medical staff. This lack of investments and 
the utilization of portable and simplified monitoring devices could lead to incorrect diagnosis. This short review 
aims to offer discussion topics on the proper diagnosis and treatment of OSA in view of epidemiological / eco-
nomic factors and results in terms of costs and social benefit of the disease. 
 
Keywords: Obstructive Sleep Apnea (OSA); Epworth Sleepiness Scale (ESS),cost-effectiveness (CE); Health 
Technology Assessment (HTA), Affordable Care Act ( ACA); Teleservice (TelaDoc); Home sleep testing 
(HST); Continuous Positive Airway Pressure (CPAP);  telemedicine interventions (IT) 
 
 
 
Laboratory vs portable monitoring for the management 
of OSA 
 
The growing concern that have been manifest-
ing toward Obstructive Sleep Apnea (OSA), es-
pecially in the Western world, has led the focus 
on the more and more clear correlation be-
tween OSA and the reduced quality of life as 
well as the increment of cardiovascular and 
metabolic mortality (Edinger et al. 2016, 237-
247) . The major OSA risk factor is obesity that 
is growing as the incidence of OSA (Romero-
Corral et al. 2010, 711-719). This condition of-
ten is underrecognized in hospitalized obese pa-
tients. A recent study, (Sharma et al. 2015, 717-
723) has showed  to a total of 636 obese  pa-
tients admitted to medical center were classified 
as high risk  Within 4 of discharge,  87% were 
shown to have OSA. The study shows signifi-
cant under-recognition of OSA in obese hospi-
talized patients.  
OSA (Epstein et al. 2009, 263-276) is character-
ized by daytime sleepiness, huabitual snoring 
and at least 5 respiratory-obstructive events per 
hour of sleep, or >15 apneic events per hour in 
absence of symptoms. Other physical character-
istics are highlighted in the pre-clinical test for 
assessing the probability of OSA, that include: 
BMI> 30, neck circumference >43 cm in men 
and 41 in women, daytime hypersomnolence 
measured with a self-assessment questionnaire, 
called the Epworth Sleepiness Scale (ESS) in 
which the cut-off is greater than 10.American 
Academy of Sleep Medicine guidelines suggests 
that portable monitors (nocturnal cardiorespira-
tory monitoring MCRN) may underestimate the 
seriousness of the ipopneic events compared to 
a complete polysomnography - Level 1 - that 
has been performed in a sleep laboratory The 
exponential increment of the OSA incidence, in 
particular in the general population from 40 to 
70 years old, led to an unmet need to simplify 
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the OSA diagnosis using simplified diagnostic 
tests and to improve the treatment. In the past, 
the OSA diagnosis was performed into the 
sleep laboratory situated in the hospital, using 
polysomnography test, which required complex 
equipment and updated medical staff. Pietzsch 
et al. have performed a cost-utility study for the 
diagnosis of OSA. (Pietzsch et al. 2011, 695-
709). This research group have assessed the 
cost-benefit ratio by comparing the three most 
used diagnostic / therapeutic strategies: a) 
overnight PSG along with a manual titration of 
the CPAP working pressure, in the sleep la-
boratory, b) split-night PSG along with manual 
titration of the CPAP working pressure; c) un-
attended portable monitoring (HST) with sub-
sequent treatment with APAP (auto-titrating 
CPAP). 
Another, recent study (Ayas, Pack et Marra 
2011, 691‑692) has considered 191 suspected 
OSA patients tested in advance using a pre-
clinical test. Among them, more than half 
(56.5%) have manifested obstructive sleep ap-
nea. Diagnosis of OSA was missed in 5.8% pa-
tients only, due to the lack of an accurate diag-
nosis from a specialist doctor of a sleep apnea.  
The probability to obtain an accurate diagnosis 
using pre-clinical tests seems not to be influ-
enced by the presence / absence of a specialist 
doctor in accordance with the severity of the 
disease. The authors concluded that OSA could 
be reliably identified using HST test regardless 
of pre-clinical test. 
The increment of the need in diagnostic tools, 
(Aurora et al. 2016, 725-730; Huang et 
Rosenthal 2014, 1376-1379) have led the US to 
organize a home care model, a simplified Home 
Sleep Testing (HST) service company, refunda-
ble by the US insurance agencies, that deals 
with both diagnosis and therapeutic care of 
OSA patients. The services company called (Af-
fordable Care Act) ACA, aims to provide high 
quality healthcare to OSA patients. 
The ACA is gearing up towards a diagnostic 
model that focuses on the doctor-patient rela-
tionship (PCMH). In this home care model, the 
company puts at the center of this relationship 
a network of healthcare services where the pri-
mary cares are subsequently and rapidly inte-
grated after being diagnosed. Basically, once the 
diagnosis and the treatment are determined, the 
Agency rapidly provides a home care technical 
support. This HST model is not inferior to oth-
er diagnostic / therapeutic models. This home 
care diagnosis and treatment is performed by 
health care professionals along with a consulta-
tion with a sleep specialist once. This approach 
reduces the economic costs of the medical staff 
and simplifies the delivery steps in providing 
the therapeutic equipment at home. This model 
results in a diagnostic improvement and in the 
increment of undiagnosed cases of OSA (Antic 
et al. 2009, 501-508; Davis, Abrams et Stremikis 
2011, 1201-1203). 
 
 
CPAP treatment: clinical and compliance  
 
The treatment with the Continuous Positive 
Airway Pressure (CPAP) devices is the pre-
ferred treatment for severe OSA (Kushida et al. 
2008, 157-171). The CPAP device consists of a 
nasal mask and / or oro-nasal through which 
an airflow is generated at continuous positive 
pressure by a compressed air blower system at 
low pressure. This established controlled pres-
sure is designed to overcome the forces exerted 
by the soft tissues surrounding the upper air-
ways. Because of this, treatment with CPAP is 
referred to as a 'pneumatic splint' (Donovan et 
al. 2015, 1323-1342). 
Same studies have shown the benefits of treat-
ment with CPAP in OSA as a mainstay of the 
treatment of symptoms such as snoring, day-
time sleepiness, improvement of quality of life 
and of sleep as well as secondary depressive 
disorders (Cruz, Drummond et Winck 2012, 
361‑ 66; Donovan et al. 2015, 1323‑ 42). Fur-
thermore, it was shown that the treatment with 
CPAP reduces the risk of cardiovascular com-
plications such as, stroke, heart failure, chronic 
ischemic heart disease and arterial hypertension  
(Barbé et al. 2012, 2161-2168; Gottlieb et al. 
2010, 352-360). 
Unfortunately, this therapy is burdened by a re-
duced compliance by patients that leading them 
to alternative therapies such as the positional 
therapy, surgical, orthodontic, that are able to 
give results superimposable to CPAP and stable 
in time in a well selected patient groups. The 
discovery of clinical phenotypes including 
genotypes with different pathogenic mecha-
nisms has launched a new genetic and biomedi-
cal research field that will lead in the future to 
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new diagnostic and therapeutic strategies in-
creasingly individualized (Malhotra, Orr et 
Owens 2015, 397-403) 
An unmet need in literature is the lack of ad-
herence / compliance to CPAP treatment. It 
should be evaluated, therefore, the possibility to 
develop technical / cultural tools in the form of 
educational / informational interventions able 
to improve adherence to treatment through an 
understanding of OSA and its complications. 
Several studies (Meurice et al. 2007, 37-42) have 
been conducted to assess the effect of educa-
tional / cultural intensive training in OSA and 
CPAP fields. These studies aim to obtain better 
results on the adherence of the patient. Inter-
ventions that have been conducted include the 
verbal-visual instruction by health profession-
als, the applications of the nasal and oral-nasal 
masks as well as the importance of the disease 
and its health effects (Jean Wiese et al. 2005, 
171-174; Golay et al. 2006, 220-227) with 
standardized audiovisual presentations and 
practical demonstrations on performing stand-
ards treatments at home. Up to now, there is 
any "gold standard" training programs in litera-
ture that have steadily improved the adherence 
to CPAP treatment. Many of these clinical trials  
(Wickwire et al. 2013, 680-693) with double 
arm (control and study) have given controver-
sial results. These latter studies were also criti-
cized due to the higher level of education of the 
control arm respect to the study arm, compared 
to a normally routine care. Consequently, re-
sults on the adherence in the study arm has ap-
peared worse. However, the majority of the ex-
perts still recommend to all patients that start 
CPAP, a high level of intensive instruction. 
 
 
Health-care providers and CPAP: cost-effectiveness of 
models of care 
 
The Health Technology Assessment is a multi-
dimensional and multidisciplinary approach for 
the analysis of clinical, social, organizational, 
economic and legal implications in Italy. This 
approach undergoes a multi-dimensional evalu-
ation such as the efficacy, safety, cost, and the 
social and organizational impact (Velardi et al. 
2011). 
Telemedicine interventions (IT) is a remote 
communication system of IT / medical data 
that is used to save time and reduce all the costs 
spent for managing a home care service for 
chronic diseases (Toma et al. 2014, 200-211; 
Park et al. 2014, 65-72). Not surprisingly, a 
number of clinical studies have been conducted 
to evaluate the effectiveness of telemedicine in-
terventions (IT) on adherence to CPAP treat-
ment. An expert IT technician has, in fact, pro-
duced some interesting data on health proce-
dures on CPAP (Fox et al. 2012, 477-481). 
The IT reports were transmitted and received 
from the individual CPAP home units onto the 
reference Provider center wirelessly therefore 
data from the study were collected and pro-
cessed. Recorded data were represented by: a) 
loss of pressure in the mask, b) residual AHI c) 
number of hours of use (5 hours per night). Er-
rors in performing the treatment were easily de-
tected from the technician, who was able to call 
the patients the next morning through the cen-
tral Provider and solve any problems about the 
low efficiency of the treatment. Result were 
seen after three months: the group assigned to 
the intervention in telemedicine had 1.88 hours 
/ night of CPAP more compared to the control 
group with a lower residual AHI. 
Another Spanish clinical multicenter random-
ized controlled trial (Isetta et al. 2015, 1054-
1061) used telemedicine for studying economic 
and clinical impacts as well the improvement of 
the quality of life (QoL) with CPAP treatment 
compared to traditional follow-up with face-to-
face doctor-patient controls. 139 patients were 
enrolled with sufficient knowledge of IT world. 
The follow-up included 3 controls at 1, 3 and 6 
months to assess the quality of sleep, the side 
effects of treatment with CPAP and QoL. In 
this study were also detected the costs of the 
treatment and management from the beginning 
to the end of the study. 
Results of the study were that a strategy based 
on telemedicine for follow-up of CPAP treat-
ment in patients with severe OSAS, was as ef-
fective as a therapy performed in hospital in ac-
cordance with the gold standard, in terms of 
the compliance with CPAP and the improve-
ment of the symptoms, with comparable side 
effects and satisfaction rates. The strategy based 
on telemedicine had a reduction of total costs 
in the transport service and productivity. 
These new IT telemonitoring systems permit to 
save operating costs and manage several pa-
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tients simultaneously (at least a hundred) using 
a single provider. However, they hint at possi-
ble medico-legal disputes. We try to address 
them. The first aspect to be defined is the fact 
that there is no standard of care for telemedi-
cine at international level. Standards of care ex-
ist just for services for the individual but there 
are still not any e-Health practices. Medico-legal 
issues are: a) respect for personal privacy, b) in-
accuracies of self-reporting of patients in data 
recording, c) the resolution limits of data to be 
recorded and the consequent delays due to fail-
ure / delayed treatment after the recording of 
data, d) failure of the systems that do not work 
correctly. In the US, there is a national society 
in telemedicine named TelaDoc (Gallegos 
2015) which features a American National 
Committee to guarantee certification of elec-
tronic systems used in telemedicine, along with 
the production of evidence-based clinical prac-
tice guideline of registered data quality. 
Another English multicenter randomized con-
trolled study (McMillan et al. 2015, 1-188) as-
sessed the clinical and economic aspects of the 
CPAP treatment in OSA elderly patients 
(PREDICT study). The study have showed that 
CPAP treatment in these patients (> 65 years) 
reduced the subjective and objective sleepiness 
similarly compared to younger patients. Sec-
ondary goals were determine the CPAP clinical 
efficacy, the cost-effectiveness ratio and the real 
usefulness of the treatment (model-based cost-
effectiveness analysis) compared to alternative 
treatments with APAP / Bilevel / C FLEX 
(BSC).The QoL at 12 months of treatment was 
measured by the European Quality of Life-5 
Dimensions (EQ-5D); 
In elderly patients with OSA, CPAP treatment 
reduced the somnolence more significantly 
compared to treatment with APAP / Bi-Level / 
C FLEX (BSC) over a period of 12 months, 
improving the EQ-5D.In this recent clinical 
study (Tan et al. 2015, 525-535) approximately 
50% of patients with OSA were intolerant to 
CPAP, this resulted in the selection of other 
therapeutic modalities such as surgical treat-
ment. In order to evaluate the cost-
effectiveness ratio in intolerant patients, this re-
search group have compared three treatment 
strategies: (a) no treatment, (b) only CPAP and 
(c) CPAP followed by surgery (reconstructive 
palate-pharyngeal surgery (PPRS) or multilevel 
surgery (MLS]). Obtained results showed that 
CPAP therapy followed by PPRS (CPAP-
PPRS) was the most profitable treatment com-
pared to treatment with single CPAP and com-
pared to the other strategies. 
Another interesting prospective randomized 
controlled trial, published in 2010 by an Italian 
research group (Vicini et al. 2010, 14-20), have 
compared the efficacy of the ORL surgery, the 
maxilla-mandibular advancement (MMA) ver-
sus positive ventilation (auto-titrating) APAP. 
In conclusion, the study has shown that MMA 
can be a valid alternative therapeutic tool, not 
lower than the treatment with APAP. 
 
 
Conclusions 
 
In conclusion, there are many clinical studies 
that compared the efficacy between the diag-
nostic / ambulatory treatment versus diagnostic 
/ hospital treatment. All these reports have elu-
cidated that the management strategies for OSA 
are not clinically inferior to the hospital treat-
ment and can produce similar results compared 
to the diagnostic / laboratory sleep treatment in 
hospital (Chai-Coetzer, Antic et McEvoy 2013, 
605-615). However, we must point out some 
important limitations about HST when used in 
a long-term management strategy, because it 
can produce: a) limited capacity to diagnose 
sleep disorders other than OSA or non OSA 
syndrome related to metabolic disorders, neuro-
logical; b) the need to review / reevaluate the 
raw data that come automatically without per-
forming a manual analysis of the nocturnal 
polygraphic tracings; c) uncertainties about the 
long-term use of this outpatient strategy on re-
gards to the overall cost-effectiveness results 
compared to the hospital diagnostic plan that is 
based on the supervised polysomnography at 
1st level. 
There are also new emerging results in the liter-
ature that support the role of non-medical 
health professionals expert in sleep study such 
as nurses, care giver, IT / health care, who are 
able to manage the home care OSA in a  cost-
effective way. We still need of more long-term 
prospective studies that can evaluate the cost-
effectiveness ratio, including direct and indirect 
costs of hospital management models versus 
models that take into account new qualified 
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non-medical personnel care. Finally, future 
knowledge in this area will come from the 
application of new technologies. Olivia J.et al 
(Walch, Cochran et Forger 2016, e1501705) to 
have shown that the sleep wake rhythm is 
changed from a social plan. They used 
smartphone app that  have developed, EN-
TRAIN, accurately collects data on sleep habits 
around the world. This work better defines and 
personalizes “normal” sleep, produces hypothe-
ses for future testing in the laboratory, and sug-
gests important ways to counteract the global 
sleep crisis Moreover, we use mobile technolo-
gy to collect a massive data set at essentially no 
cost. In analyzing these large data sets, mathe-
matical modeling will be key to generating use-
ful predictions from the unstructured bulk col-
lection 
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Abstract 
The uterine rupture is a dramatic obstetrical event, fortunately unusual. Unfortunately, onset is often sudden, 
very often during pregnancy, in the third trimester, and during labor. The uterine rupture depends on a number 
of biological and mechanical factors, in which the muscular scarring process is the main responsible factor. The 
biology of uterine muscle scarring depends on a set of biomolecular processes involving growth factors, neuro-
transmitters, neoangiogenesis, deposition and reabsorption of collagen fibers, ect. Any interference in this 
precess creates the conditions for the uterine rupture, which occurs under contract, during the maximum muscu-
lar tension. Separation of the fibers almost always involves a traumatic vascular interruption with copious haem-
orrhage. Here is why uterine rupture is a very rare event, but very dangerous for the life of the woman and the 
fetus inside it. 
 
Keywords: Uterine rupture, pregnancy, myomectomy, fibroids, neonagiogenesis, growth factors 
 
 
 
Introduction 
 
Uterine rupture is an uncommon but life-
threatening obstetric complication. It leads to 
high maternal and perinatal morbidity and mor-
tality, and it is complete or incomplete. It may 
be incomplete, when uterine serosa remains in-
tact, or complete, in cases of disruption of the 
full-thickness of uterine wall including uterine 
serosa, thus resulting in a direct connection be-
tween the peritoneal space and the uterine cavi-
ty with or without protrusion or expulsion of 
the fetus and/or placenta into the peritoneal 
cavity. The uterine rupture may be spontane-
ous, traumatic or the result of the scar dehis-
cence (Guseh et al. 2016, 255‑67).  
It can either occur in women with (Gardeil, 
Daly et Turner 1994, 107‑10) a native, un-
scarred uterus or  a uterus with a surgical scar 
from previous surgery. 
It can occur during pregnancy, early in labor or 
following the prolonged labor, most frequently 
near or at term. Rarely, uterus can rupture dur-
ing early to mid-pregnancy (Guseh et al. 2016, 
255‑67). 
Any surgical insult to the uterus can lead to 
uterine dehiscence and rupture. Nevertheless, 
different surgical procedures and techniques 
may cause a different healing process, thus 
causing differences in the uterine rupture rate. 
Anyway, the initial symptoms and signs of uter-
ine rupture are typically nonspecific, which 
makes the diagnosis difficult and sometimes de-
lays definitive therapy. From the time of diag-
nosis to delivery, generally only 10-37 minutes 
are available before clinically significant fetal 
morbidity becomes inevitable. Fetal morbidity 
occurs as a result of catastrophic hemorrhage, 
fetal anoxia, or both (Nahrum et Pham). 
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Abstract 
The uterine rupture is  dramatic obstetrical ev nt, fortunately unusual. Unfortunately, onset is often s dden,
very ften during pregnan y, in he third tr mest r, and du ing labor. The uterine rupture depe ds on a number
of biological and mechanical factors, in which the muscular scarring r ss i the main responsible factor. The 
biology of uterine muscle scarring depends on a set of biomolecular processes involving growth factors, neuro-
transmitters, neoangiogenesi , deposition and reabsorption of collag n fibe s, ect. Any interference in this 
prec s  creat s the conditions for the uterine rupture, which occ rs under ont act, during the maximum muscu
lar tension. S paration of th  fibers almost always in olves a traumatic vasc lar in erruption with c pious haem-
orrhage. Here is why uterine rupture is a very rare event, but very dangerous for the life of the woman and the 
fetus inside it. 
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Introduction 
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high maternal and perinatal morbidity and mor-
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full-thickness of uteri e wall in luding uterine 
serosa, thus resulting in a direct conn ction be-
tween the peritoneal space and the uterine cavi-
ty with or without protrusion or expulsion of 
the fetus and/or placenta into th  peritoneal 
cavity. The uterine rupture may be spontane-
ous, traumatic or the result of the scar dehis-
cence (Guseh et al. 2016, 255‑67).  
It can either occur in women with (Gardeil, 
Daly et Turner 1994, 107‑10) a native, un-
scarred uter s or  a uterus with a surgical scar 
from previous surgery. 
It can occur during pr gn ncy, early in labor or 
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255‑67). 
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are available before clinically significant fetal 
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fetal anoxia, or both (Nahrum et Pham). 
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From 1976-2012, 25 peer-reviewed publications 
described the incidence of uterine rupture, and 
these reported 2,084 cases among 2,951,297 
pregnant women, yielding an overall uterine 
rupture rate of 1 in 1,146 pregnancies (0.07%) 
(Nahrum et Pham). 
The overall incidence of uterine rupture pub-
lished from less developed countries is 9.3% of 
deliveries; in fact in developing countries this 
rate is much higher than in the developed coun-
tries for obstructed labor (Rajaram, Agrawal et 
Swain 2017, 7‑10).  
In the Second Report on Confidential Enquir-
ies into Maternal Deaths in South Africa 1999–
2001, ruptured uterus caused 6.2% of deaths 
due to direct causes and 3.7% of all deaths 
(1.9% due to rupture of an unscarred uterus 
and 1.8% due to rupture of a scarred uterus) 
(Gülmezoglu et al. 2004, 16). 
No estimates exist to assess the magnitude of 
this potentially life-threatening condition. 
Ofir et al found that the risk for uterine rupture 
among women who had not undergone previ-
ous Cesarean section (CS) is 0.02%, and overall 
risk of uterine rupture is 0.035% of all singleton 
deliveries (Ofir et al. 2004, 425‑29).  
The reported incidence of the uterine rupture 
of an unscarred uterus in developed world is 
near 1:10000-20000 deliveries (Parant 2012, 
803‑16). In developing countries, the published 
incidence of uterine rupture varies from 1,45 to 
25%, with 25% in Ethiopian woman with ob-
structed labor (Berhe et Wall 2014, 695‑707). 
A 10-year Irish study by Gardeil et al showed 
that the overall rate of unscarred uterine rup-
ture during pregnancy was 1 per 30,764 deliver-
ies (0.0033%). No cases of uterine rupture oc-
curred among 21,998 primigravidas, and only 2 
(0.0051%) occurred among 39,529 multigravi-
das with no uterine scar (Guseh et al. 2016, 
255‑67). 
A meta-analysis of 8 large, modern (1975-2009) 
studies from industrialized countries revealed 
174 uterine ruptures among 1,467,534 deliver-
ies. This finding suggests that the modern rate 
of unscarred uterine rupture during pregnancy 
is 0.012% (1 in 8,434). This rate of spontaneous 
uterine rupture has not changed appreciably 
over the last 50 years, and most of these events 
occur at term and during labor. An 8-fold in-
creased incidence of uterine rupture of 0.11% 
(1 in 920) has been noted in developing coun-
tries, with this increased incidence of uterine 
rupture having been attributed to a higher-than-
average incidence of neglected and obstructed 
labor due to inadequate access to medical care 
(Nahrum et Pham). 
Schrinsky and Benson reported 22 cases of 
uterine rupture in gravidas with unscarred uteri. 
Nineteen occurred during labor (86%), and 3 
occurred before labor (14%). This percentage 
was markedly different from that of gravidas 
with a previous uterine scar, for whom the tim-
ing of uterine rupture between labor and the 
antepartum period was nearly evenly distributed 
(Schrinsky et Benson 1978, 217‑32). 
Author conduced a review to evaluate the over-
all incidence of rupture of a uterus with a pre-
vious CS scar for World Health Organization 
(WHO). For unselected pregnant women, the 
prevalence of uterine rupture reported was con-
siderably lower for community-based (median 
0.053, range 0.016–0.30%) than for facility-
based studies (0.31, 0.012–2.9%). The preva-
lence tended to be lower for countries defined 
by the United Nations as developed than the 
less or least developed countries. For women 
with previous caesarean section, the prevalence 
of uterine rupture reported was in the region of 
1%. Only one report gave a prevalence for 
women without previous caesarean section, 
from a developed country, and this was ex-
tremely low (0.006%) (Gülmezoglu et al. 2004, 
16).  
Currently, the problem of uterine rupture is re-
lated, for developing countries, to the increas-
ing rate of cesarean delivery. The increasing 
number of woman presenting with scared uter-
us either from Cesarean Section (CS) or uterine 
surgery leads to an increase in the number of 
women exposed to the uterine rupture risk.  
A Norwegian study published in the Journal has found 
that for women with previous CS, the risk of uterine 
rupture was 8 times higher after trial of labour (TOL) 
than at repeated elective CS. Induction of labor (using 
prostaglandins) was associated with the highest risk of 
uterine rupture (Al-Zirqi et al. 2010, 809‑20). 
The American college of Obstetricians and Gy-
necologists (ACOG) estimated the risk of uter-
ine rupture in women with a previous CS and 
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concluded that the lower segment caesarean 
scar has a minimum risk (0.2-1.5%) of rupture 
during vaginal delivery (AA. VV. 1999, 201‑8). 
Canadian study, trial of labor following previ-
ous CS was associated with increased risk of 
uterine rupture (by 0.56%), but fewer maternal 
deaths than elective CS (1.6 vs 5.6 per 100,000) 
(Wen et al. 2004, 1263‑69). 
A trial of labor following a previous CS increas-
es the risk of uterine rupture compared to the 
elective repeat cesarean section. The risk is also 
influenced by the number of previous cesarean 
deliveries and on whether the labor is induced, 
augmented or spontaneous. The inter-delivery 
interval may also influence this risk.  
In a study by Lydon-Rochelle et al of 10 789 
patients with a single previous CS, who later la-
bored spontaneously in singleton pregnancy, 
the uterine rupture rate was 0.52% (Lydon-
Rochelle et Cahill 2010, 249‑57).  
In cases of trial of labor in women with previ-
ous low vertical scar uterine rupture rate is 
1.1% and the trial of labor following previous 
CS with unknown type of cesarean scar is asso-
ciated with the rate of 0.56% of uterine rupture 
(Nahrum et Pham).  
 
 
Risk factors for uterine rupture 
 
The major characteristics for determining the 
risk of uterine rupture in pregnant are listed be-
low. 
Uterine status is either unscarred or scarred. 
Scarred status may include previous cesarean 
delivery, including the following: single low 
transverse (further subcategorized by 1-layer or 
2-layer hysterectomy closure); single low verti-
cal; classic vertical; multiple previous cesarean 
deliveries (Nahrum et Pham). 
Scarred status may also include previous laparoscopic or 
laparotomic myomectomy (Hagneré et al. 2011, 
162‑65). 
In case of uterine rupture, uterine morphology may be 
regular or may involve a congenital uterine anomaly 
(Shahid et al. 2010, 121‑25). Pregnancy considera-
tions include the following traditional risk factors: grand 
multiparity, maternal age, placentation (accreta, 
percreta, increta, previa, abruption), cornual (or angu-
lar) pregnancy, uterine overdistension (multiple gestation, 
polyhydramnios), dystocia, fetal macrosmia, contracted 
pelvis, gestation longer than 40 weeks, trophoblastic in-
vasion of the myometrium (Ofir et al. 2003, 
1042‑46). 
The risk factors for labor are as follows: patient not in 
labor, patient with spontaneous labor, induced labor - 
with oxytocin, with prostaglandins, augmentation of la-
bor with oxytocin, duration of labor and obstructed la-
bor (Goyal 2009, 1117‑23). 
Obstetric management risk factors for uterine rupture 
include the following: operative delivery (forceps or vacu-
um); intrauterine manipulation (external cephalic ver-
sion, internal podalic version, breech extraction, shoulder 
dystocia, manual extraction of placenta); fundal pressure 
(i.e. Kristeller maneuver) (LANG et LANDON 
2010, 237‑51). 
Uterine trauma linked to uterine ruptures are the fol-
lowing: direct uterine trauma (eg, motor vehicle accident, 
fall), violence (eg, gunshot wound, blunt blow to abdo-
men), rupture of the unscarred uterus (Uccella et al. 
2011). 
The normal, unscarred uterus is least suscepti-
ble to rupture. Grand multiparity, neglected la-
bor, malpresentation, breech extraction, and 
uterine instrumentation are all predisposing fac-
tors for uterine rupture (Guseh et al. 2016, 
255‑67). 
 
 
The problem of uterine scar  
 
Women with prior myomectomy or prior tradi-
tional CS often have an early cesarean delivery 
because of concern for uterine rupture. The 
problem is related to the quality of the uterine 
scar. Unfortunately, until now, nobody has 
been able to perform the "in vivo studies" on 
the uterine muscle, the myometrium, as it is not 
easy to make a monitoring of a scar tissue 
which the myometrium, appropriately, all stud-
ies performed are indirectly, by growth factors 
and proteins, by imaging, or by other non-
invasive methods. All studies conducted so far 
have the limitation of poor biological reliability. 
The problem is not of simple solution in that 
the uterine scar is the weak of the myometrium, 
which, subjected to the contraction stress, can 
suddenly breaking down. Unfortunately, we 
must be content of reports and investigations 
on overall and selected rates of uterine rup-
tures. In fact, the rate of uterine rupture recent-
ly published in developed countries following 
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classical cesarean delivery is 0.88 %, which is 
much lower than the quoted rate of up to 9% in 
women with prior classical cesarean who labor 
(Gülmezoglu et al. 2004, 16).  
This is probably due to elective late preterm de-
livery in such cases. The frequency of uterine 
rupture following prior classical cesarean deliv-
ery in labor is 1.8% (Gyamfi-Bannerman et al. 
2012, 1332‑37).  
The uterine rupture rate in women with previ-
ous classic, inverted T or J incision who either 
refused repeat cesarean delivery or presented in 
labor in Landon et al study was 1.9% (Landon 
et Lynch 2011, 257‑61). 
 
 
Uterine rupture after myomectomy 
 
The same trend is followed for delivery for 
women with prior myomectomy because it is 
thought that the scar from myomectomy is 
functionally equivalent to the scar from classical 
cesarean delivery (Qahtani 2013, 214‑19).  
One of the first author who investigated uterine 
ruptures after myomectomy was, in 1964, Gar-
net who identified 3 (4%) uterine ruptures 
among 83 women who had scars from a previ-
ous abdominal myomectomy (Garnet 1964, 
898‑905).  
The prevalence of uterine rupture following 
myomectomy - all types of surgery – is 0.79 % 
and it is comparable with that after cesarean 
section. Based on the available evidence, there 
is no significant difference between the inci-
dences of a rupture during pregnancy following 
a laparoscopic (1.2 %) versus an open myomec-
tomy (0.4 %)  (Claeys et al. 2014, 197‑206). 
It is not clear whether the laparoscopic proce-
dure is associated with higher risk of subse-
quent rupture or, whether, these cases are being 
more systematically reported. It is also clear 
that the location and size of the fibroids might 
affect the likelihood of uterine rupture follow-
ing previous myomectomy, and the difference 
may be partially explained by confounding fac-
tors. Between 1970 and 2013, there has been an 
overall increase in the CS rates leading to a 
higher primary C-section rate in the last two 
decades (the “era of laparoscopy”) compared to 
the era of open surgery. Indeed, in the last two 
decades, the laparoscopic approach has become 
the preferred technique, with laparoscopic su-
turing requiring more than average technical 
expertise. Furthermore, it is striking to observe 
that a uterine rupture in a woman following a 
myomectomy almost exclusively occurs during 
pregnancy and very exceptionally during active 
labor, as opposed to following a prior cesarean 
section. This can be explained to differences in 
the site of the incision with the majority of my-
omectomies being done in the corporeal part of 
the womb as opposed to the lower uterine 
segment in the case of cesarean delivery. Thus, 
Claeys et al concluded that the risk of a uterine 
rupture following a myomectomy regardless of 
the technique used seems very rare (less than 1 
% of the ongoing pregnancies) (Claeys et al. 
2014, 197‑206). 
Literature data suggest that the overall uterine 
rupture rate following myomectomy is 0.2% 
(Claeys et al. 2014, 197‑206).  
A true evaluation of the uterine rupture rate af-
ter endoscopic myomectomy is difficult, as in-
formation about this comes, primarily, from 
case reports (Pistofidis et al. 2012).  
Anyway, uterine rupture following myomecto-
my is one of the major complications of myo-
mectomy. In the light of advanced age of ob-
stetric population, there is a potential risk of 
uterine rupture on the site of previous myo-
mectomy scar. Both myomectomy and CS can 
be, either directly or indirectly, predisposing 
factors of abnormally invasive placenta, influ-
encing the risk of uterine rupture. The influence 
of myomectomy technique on the incidence of 
the rupture is still a matter of debate, even if 
Tinelli et all published studies showing the re-
duced incidence of uterine rupture by 
intracapsular myomectomy myometrial sparing 
(Tinelli et al. 2016, 129‑39).  
The myometrial healing following myomecto-
my is affected by the method and/or instru-
mentation used during surgery. Uterine inci-
sion, achievement of hemostasis and closing the 
myometrial defect, the extent of tissue damage 
(influenced by myoma characteristics such as 
type, size and number), the potential formation 
of hematoma within the myometrium, gas 
pneumoperitoneum in laparoscopic procedures, 
and patients individual characteristics influence 
the healing process (Mynbaev et al. 2016, 
1013‑15; Tinelli et al. 2012, 119‑29).  
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It is more difficult to make an adequate suture 
by laparoscopy than by laparotomy. At laparot-
omy, closure of the myometrial defect is usually 
accomplished by a multilayered suture. During 
laparoscopy, failure to suture adequately 
myometrial defects, lack of hemostasis with 
subsequent hematoma formation may interfere 
with wound healing and increase the risk of 
rupture (Mettler et al. 2012, 1‑8).  
Inappropriate use of electrocautery may induce 
in-depth necrosis of the myometrium with an 
adverse effect on healing. Excessive use of 
diathermocoagulation (with inflammation, ne-
crosis, fibrosis, neuropeptides damaging) can 
lead to delay in the correct uterine healing and 
generate a weaker uterine scar (Tinelli et 
Malvasi 2015, 73‑93).  
In a review, one rupture occurred on the site of 
later myomectomy in another institute, due to 
placenta percreta over the second scar. Alt-
hough the authors did not calculate this case in 
their count, second myomectomy was the most 
probable causative mechanism of forming an 
abnormally invasive placenta. The other rupture 
case had a rupture on the site of myomectomy 
scar which was re-sutured during second-look 
laparoscopy 7 weeks after the surgery (Parker et 
al. 2010, 551‑54).  
Pistofidis and coworkers investigated all 7 cases 
of uterine rupture after laparoscopic myomec-
tomy reported to the Greek Board of 
Endoscopisc Gynecologic Surgery from 1998 
to 2011. Only one of those patients had intra-
mural myoma, and the endometrial cavity was 
not opened in any of the patients. Bipolar dia-
thermy was the sole method of hemostasis in 
28.6% of cases, and could be characterized as 
excessive in 87.5% of patients. Most of the rup-
tures occurred at 34 weeks of gestation or later, 
with 1 case at 24 weeks of gestation in twin 
pregnancy. Those authors concluded that it 
seems reasonable that women who have under-
gone laparoscopic myomectomy would best 
avoid multiple pregnancies because of poten-
tially increased risk of rupture (Pistofidis et al. 
2012). 
Parker et al. investigated 19 cases of uterine 
rupture following laparoscopic myomecyomy 
and concluded that its reasonable to use in lapa-
roscopy to techniques similar to those adoptes 
for open myomectomy as bipolar diathermy 
during laparoscopic procedures has potentially 
detrimental effect on the healing process 
(Parker et al. 2010, 551‑54). 
Sizzi et al. in a multicentric study of laparoscop-
ic myomectomy complications reported 1 rup-
ture among 386 pregnancies (0.26%) out of 
2050 operations (Sizzi et al. 2007, 453‑62). 
Robotic-assisted laparoscopic surgery is rela-
tively new innovation in the field of gynecolog-
ic surgery. An advantage of robotic-assisted 
laparoscopic myomectomy is the ability to per-
form an identical multilayer closure to the ab-
dominal approach that controls hemostasis 
without the need for significant use of electro-
surgical instruments (Rossi et Prefumo 2015, 
273‑80; Tinelli et al. 2011, 12‑24). 
The incidence of uterine rupture in pregnancy 
after robotic-assisted myomectomy reported by 
Pitter et al is 1.1%, which is incomparable with 
the previously reported incidence after conven-
tional laparoscopic myomectomy (Claeys et al. 
2014, 197‑206). The uterine rupture occurred, 
in this study, in a patient at 33 weeks of gesta-
tion; such patient conceived 18 weeks after the 
robotic multiple myomectomy without entering 
the endometrial cavity. 
The real recurrent uterine rupture rate, in pa-
tients with prior repair is unknown. In the 
Pistofidis study, out of 7 cases of uterine rup-
ture after laparoscopic myomectomy there were 
two cases of recurrent rupture (28.6%) 
(Pistofidis et al. 2012). 
The incidence of peripartum hysterectomy fol-
lowing uterine rupture recently reported by 
Charach and Sheiner is the 20.7% (Charach et 
Sheiner 2013, 1196‑1200). The independent 
risk factors for peripartum hysterectomy fol-
lowing uterine rupture are: relaparotomy, ex-
tended tear involving uterine cervix, severe 
bleeding requiring packed cells transfusion and 
grand multiparity (Charach et Sheiner 2013, 
1196‑1200).  
Although CS and repeated CS were found to be 
separate risk factors for uterine rupture and 
emergency peripartum hysterectomy in previ-
ous publications, cited authors documented a 
significantly reduced number of hysterectomies 
following uterine rupture in the women who 
underwent CS or had a previous CS, thus ex-
pressing the importance of fertility preserving 
surgery in modern obstetrics and use of hyster-
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ectomy as last option procedure (Qahtani 2013, 
214‑19).   
It is more commonly necessary in cases of 
traumatic or spontaneous rupture, and its inci-
dence in such cases in some reports has been 
85% (Charach et Sheiner 2013, 1196‑1200).  
 
 
Spontaneous uterine rupture 
 
Traditionally, primigravidae and women with 
unscarred uterus are considered immune to 
rupture. Spontaneuos uterine rupture usually 
occurs in labor. Rupture of an unscarred uterus 
is a rare event, as the majority of uterine rup-
ture during pregnancy involves scarred uterus. 
Rupture of an unscarred uterus is a rare event 
involving 1 : 5,700–20,000 deliveries (Ofir et al. 
2004, 425‑29). 
This frequency is often higher in developing 
countries, where it can reach 75% of cases in 
some areas (Guèye et al. 2012, 598356).  
In a study of uterine ruptures in The Nether-
lands, the incidence of rupture in unscarred and 
scarred uteri was 0.7 and 5.1 per 10,000 deliver-
ies, respectively; ruptures of unscarred uteri ac-
counted for 13 percent of all ruptures (Al-Zirqi 
et al. 2016, 780‑87). 
Although uncommon in nuliparous woman, 
spontaneous uterine rupture is described in ju-
veniles black African women due to contracted 
pelvis [5,7].  
A major factor in spontaneous uterine rupture 
is obstructed labor, especially in the developing 
world (Berhe et Wall 2014, 695‑707).  
Schrinsky and Benson reported 22 cases of 
uterine rupture in gravidas with unscarred uteri. 
Nineteen occurred during labor (86%), and 3 
occurred before labor (14%). This percentage 
was markedly different from that of gravidas 
with a previous uterine scar, for whom the tim-
ing of uterine rupture between labor and the 
antepartum period was nearly evenly distributed 
(Schrinsky et Benson 1978, 217‑32). 
Rupture of an unscarred uterus may be caused 
by trauma or congenital or acquired weakness 
of the myometrium, such as collagen disease 
(McCarthy et Germain 2013, 71‑80). Sources of 
trauma include motor vehicle accidents and ob-
stetric maneuvers (eg, internal or external ver-
sion). 
Clinical signs of uterine rupture during preg-
nancy are nonspecific and can be confusing. 
Indeed, it is not always easy to distinguish it 
with other abdominal emergencies (appendici-
tis, gallstones, pancreatitis, etc.) (Suner et al. 
1996, 181‑85). 
Early surgical intervention is usually the key to 
successful treatment of uterine rupture. The 
therapeutic management is a total or subtotal 
hysterectomy. The suture can be performed and 
helps to preserve the reproductive function of 
patients who have never given birth with a re-
currence risk of uterine rupture assessed be-
tween 4 and 19% at a subsequent pregnancy. 
For this reason, it has been recommended that 
women with a previous uterine rupture undergo 
an elective Caesarean delivery as soon as fetal 
lung maturity can be demonstrated (Guèye et al. 
2012, 598356). 
 
 
Uterine rupture after cesarean section 
 
The effect of previous cesarean delivery on the 
risk of uterine rupture has been studied exten-
sively. In a meta-analysis, Mozurkewich and 
Hutton used pooled data from 11 studies and 
showed that the uterine rupture rate for women 
undergoing a trial of labor after cesarean sec-
tion (TOLAC) was 0.39% compared with 
0.16% for patients undergoing elective repeat 
cesarean delivery (odds ratio [OR], 2.10; 95% 
CI, 1.45-3.05). After restricting the meta-
analysis to 5 prospective cohort trials, similar 
results were found (OR, 2.06; 95% CI, 1.40-
3.04) (Mozurkewich et Hutton 2000, 1187‑97). 
Hibbard et al examined the risk of uterine rup-
ture in 1,324 women who underwent a 
TOLAC. They reported a significant difference 
in the risk of uterine rupture between women 
who achieved successful vaginal birth com-
pared with women in whom attempted vaginal 
delivery failed (0.22% vs 1.9%; OR, 8.9; 95% 
CI, 1.9-42) (Hibbard et al. 2001, 1365‑73). 
The effect of previous CS on the rate of subse-
quent pregnancy-related uterine rupture have 
been evaluated by investigations on vaginal 
birth after cesarean section (VBAC).  
The overall rate of VBAC in the United States 
increased from 3.4% in 1980 to a peak of 28% 
in 1996. Commensurate with this 8-fold in-
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lands, the incidence of rupture in unscarred and 
scarred uteri was 0.7 and 5.1 per 10,000 deliver-
ies, respectively; ruptures of unscarred uteri ac-
counted for 13 percent of all ruptures (Al-Zirqi 
et al. 2016, 780‑87). 
Although uncommon in nuliparous woman, 
spontaneous uterine rupture is described in ju-
veniles black African women due to contracted 
pelvis [5,7].  
A major factor in spontaneous uterine rupture 
is obstructed labor, especially in the developing 
world (Berhe et Wall 2014, 695‑707).  
Schrinsky and Benson reported 22 cases of 
uterine rupture in gravidas with unscarred uteri. 
Nineteen occurred during labor (86%), and 3 
occurred before labor (14%). This percentage 
was markedly different from that of gravidas 
with a previous uterine scar, for whom the tim-
ing of uterine rupture between labor and the 
antepartum period was nearly evenly distributed 
(Schrinsky et Benson 1978, 217‑32). 
Rupture of an unscarred uterus may be caused 
by trauma or congenital or acquired weakness 
of the myometrium, such as collagen disease 
(McCarthy et Germain 2013, 71‑80). Sources of 
trauma include motor vehicle accidents and ob-
stetric maneuvers (eg, internal or external ver-
sion). 
Clinical signs of uterine rupture during preg-
nancy are nonspecific and can be confusing. 
Indeed, it is not always easy to distinguish it 
with other abdominal emergencies (appendici-
tis, gallstones, pancreatitis, etc.) (Suner et al. 
1996, 181‑85). 
Early surgical intervention is usually the key to 
successful treatment of uterine rupture. The 
therapeutic management is a total or subtotal 
hysterectomy. The suture can be performed and 
helps to preserve the reproductive function of 
patients who have never given birth with a re-
currence risk of uterine rupture assessed be-
tween 4 and 19% at a subsequent pregnancy. 
For this reason, it has been recommended that 
women with a previous uterine rupture undergo 
an elective Caesarean delivery as soon as fetal 
lung maturity can be demonstrated (Guèye et al. 
2012, 598356). 
 
 
Uterine rupture after cesarean section 
 
The effect of previous cesarean delivery on the 
risk of uterine rupture has been studied exten-
sively. In a meta-analysis, Mozurkewich and 
Hutton used pooled data from 11 studies and 
showed that the uterine rupture rate for women 
undergoing a trial of labor after cesarean sec-
tion (TOLAC) was 0.39% compared with 
0.16% for patients undergoing elective repeat 
cesarean delivery (odds ratio [OR], 2.10; 95% 
CI, 1.45-3.05). After restricting the meta-
analysis to 5 prospective cohort trials, similar 
results were found (OR, 2.06; 95% CI, 1.40-
3.04) (Mozurkewich et Hutton 2000, 1187‑97). 
Hibbard et al examined the risk of uterine rup-
ture in 1,324 women who underwent a 
TOLAC. They reported a significant difference 
in the risk of uterine rupture between women 
who achieved successful vaginal birth com-
pared with women in whom attempted vaginal 
delivery failed (0.22% vs 1.9%; OR, 8.9; 95% 
CI, 1.9-42) (Hibbard et al. 2001, 1365‑73). 
The effect of previous CS on the rate of subse-
quent pregnancy-related uterine rupture have 
been evaluated by investigations on vaginal 
birth after cesarean section (VBAC).  
The overall rate of VBAC in the United States 
increased from 3.4% in 1980 to a peak of 28% 
in 1996. Commensurate with this 8-fold in-
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crease in the VBAC rate, reports of maternal 
and perinatal morbidity also increased, in par-
ticular with reference to uterine rupture. By 
2007, the VBAC rate in the United States had 
fallen nationally to 8.5%. Not surprisingly, the 
cesarean delivery rate also reached an all-time 
high of 32% in 2007. In its most recent guide-
lines pertaining to VBAC in August 2010, the 
American Congress of Obstetricians and Gyne-
cologists (ACOG) adopted the recommenda-
tion not to restrict women's access to VBAC 
(AA. VV. 2010, 450‑63). 
About traditional CS by vertical incision, in a 
meta-analysis, Rosen et al reported an 11.5% 
absolute risk of uterine rupture (3 of 26 cases) 
in women with classic vertical cesarean scars 
who underwent an unplanned TOLAC (Rosen, 
Dickinson et Westhoff 1991, 465‑70). 
For women who underwent repeat cesarean 
section, Chauhan et al reported that the uterine 
rupture rate for 157 women with prior classical 
uterine cesarean scars was 0.64% (95% CI, 0.1-
3.5%). All patients in that study underwent re-
peat cesarean delivery, but a high rate of pre-
term labor resulted in 49% of the patients being 
in labor at the time of their cesarean delivery 
(Chauhan et al. 2002, 946‑50). Chauhan et al 
observed also a 9% rate of asymptomatic uter-
ine scar dehiscence (95% CI, 5-15%). 
Landon et al (Landon et al. 2004, 2581‑89) re-
ported a 1.9% absolute uterine rupture rate (2 
of 105 cases) in women with a previous classic, 
inverted T, or J incision who either presented in 
advanced labor or refused repeat cesarean de-
livery. This meta-analysis of pooled data from 5 
studies demonstrated a 1.1% absolute risk (12 
of 1,112 cases) of symptomatic uterine rupture 
in women undergoing a TOLAC with a low 
vertical cesarean scar (Landon et al. 2004, 
2581‑89). Compared to women with low trans-
verse cesarean scars, these data suggest no sig-
nificantly increased risk of uterine rupture or 
adverse maternal and perinatal outcomes. 
For 322 pregnancies that occurred after a low 
vertical cesarean delivery, the overall rate of 
uterine rupture was 0.62%. This rate could be 
further divided as 1.15% for 174 women who 
underwent a TOLAC compared with no rup-
tures among 148 women who underwent elec-
tive repeat cesarean delivery (Naef et al. 1995, 
1666‑74). 
The Maternal-Fetal Medicine Units (MFMU) 
Network cesarean delivery registry reports a 
0.5% risk (15 of 3,206) of uterine rupture for 
patients who underwent a TOLAC with an un-
known uterine scar (Landon et al. 2004, 
2581‑89). 
For cases in which there are 1 or 2 unknown 
prior uterine incisions, there is a single small, 
randomized, controlled trial by Grubb et al that 
compared labor augmentation with oxytocin 
(n=95) with no intervention (n=93) in women 
with prior cesarean deliveries involving either 1 
or 2 unknown uterine incisions. Four uterine 
dehiscences and 1 uterine rupture occurred, all 
in the group that underwent labor augmenta-
tion. In the 1 case of uterine rupture, the un-
known uterine scar was in a patient with 2 prior 
cesarean deliveries, one of which involved a 
vertical incision. Had the uterine scar status for 
this patient been known in advance, it would 
have represented a contraindication to TOLAC 
(Naef et al. 1995, 1666‑74). 
In a study of 20,095 women by Lydon-Rochelle 
et al (Lydon-Rochelle et Cahill 2010, 249‑57), 
the spontaneous uterine rupture rate among 
6,980 women with a single cesarean delivery 
scar who underwent scheduled repeat cesarean 
delivery without a TOL was 0.16%. This inves-
tigation showed that the uterine rupture rate 
among 10,789 women with a single previous 
cesarean delivery who labored spontaneously 
during a subsequent singleton pregnancy was 
0.52% (Lydon-Rochelle et Cahill 2010, 249‑57). 
This rate of uterine rupture implies an increased 
relative risk (RR) of 3.3 (95% CI, 1.8-6.0) for 
women who labor spontaneously compared 
with women who undergo elective repeat cesar-
ean delivery. 
This finding indicates that uteri with cesarean 
scars have an intrinsic propensity for rupture 
that exceeds that of the unscarred organ during 
pregnancy, which is 0.012% (OR increase of 
approximately 12-fold). Therefore, all other 
uterine rupture rates in women with a previous 
cesarean delivery should be referenced to this 
expected baseline rate. 
In a study by Ravasia et al of 1,544 patients 
with a previous cesarean delivery who later la-
bored spontaneously, the uterine rupture rate 
was 0.45% (Ravasia, Wood et Pollard 2000, 
1176‑79). 
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ectomy as last option procedure (Qahtani 2013, 
214‑19).   
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dehiscences and 1 uterine rupture occurred, all 
in the group that underwent labor augmenta-
tion. In the 1 case of uterine rupture, the un-
known uterine scar was in a patient with 2 prior 
cesarean deliveries, one of which involved a 
vertical incision. Had the uterine scar status for 
this patient been known in advance, it would 
have represented a contraindication to TOLAC 
(Naef et al. 1995, 1666‑74). 
In a study of 20,095 women by Lydon-Rochelle 
et al (Lydon-Rochelle et Cahill 2010, 249‑57), 
the spontaneous uterine rupture rate among 
6,980 women with a single cesarean delivery 
scar who underwent scheduled repeat cesarean 
delivery without a TOL was 0.16%. This inves-
tigation showed that the uterine rupture rate 
among 10,789 women with a single previous 
cesarean delivery who labored spontaneously 
during a subsequent singleton pregnancy was 
0.52% (Lydon-Rochelle et Cahill 2010, 249‑57). 
This rate of uterine rupture implies an increased 
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pregnancy, which is 0.012% (OR increase of 
approximately 12-fold). Therefore, all other 
uterine rupture rates in women with a previous 
cesarean delivery should be referenced to this 
expected baseline rate. 
In a study by Ravasia et al of 1,544 patients 
with a previous cesarean delivery who later la-
bored spontaneously, the uterine rupture rate 
was 0.45% (Ravasia, Wood et Pollard 2000, 
1176‑79). 
JDREAM.indd   67 18/01/18   11:0325 2 57
Uterine rupture: up to date 
68 
Zelop et al found that, among 2,214 women 
with 1 previous cesarean delivery who labored 
spontaneously, the uterine rupture rate was 
0.72%. The authors of this article performed a 
meta-analysis of 29,263 pregnancies from 9 
studies from 1987-2004 and showed that the 
overall risk of uterine rupture was 0.44% for 
women who labor spontaneously after a previ-
ous cesarean delivery (Ravasia, Wood et Pollard 
2000, 1176‑79). 
 
 
Uterine rupture in previous CS, with oxytocin and in-
duction of labor 
 
The use of oxytocin during labor in patients 
with previous CS is a very little used practice 
for related fear of uterine rupture. Thus, very 
few studies have stratified their data by labor 
augmentation versus labor induction and the 
data that do exist are conflicting. There is wide 
variance in the frequency of clinical use of oxy-
tocin as well as in the dose and dosing sched-
ules of oxytocin that are used. It is therefore 
not possible to draw complete conclusions 
about the related risk of uterine rupture in such 
patients. 
On the contrary, current ACOG guidelines dis-
courage the use of prostaglandins to induce la-
bor in most women with a previous cesarean 
delivery. This recommendation is based on 
considerable evidence for an increased risk of 
uterine rupture associated with prostaglandins. 
Blanchette et al (Blanchette et al. 2001, 
1478‑87) reported the rate of uterine rupture 
for 288 women who underwent oxytocin aug-
mentation of labor after a previous cesarean de-
livery; it was 1.4%, compared with 0.34% for 
292 women who underwent a trial of sponta-
neous labor. This finding suggests a 4-fold in-
creased risk of uterine rupture in women who 
undergo labor augmentation with oxytocin 
compared with spontaneous labor after a previ-
ous cesarean delivery. 
In the MFMU Network study, the rate of uter-
ine rupture with oxytocin augmentation was 
0.9% (52 of 6,009 cases) versus 0.4% (24 of 
6,685 cases) without oxytocin use. In contrast, a 
meta-analysis of studies published prior to 1989 
found that the use of oxytocin was unassociated 
with uterine rupture (National Institutes of 
Health 2010, 351‑65). 
Zelop et al also found that labor augmentation 
with oxytocin did not significantly increase the 
risk for uterine rupture (Ravasia, Wood et 
Pollard 2000, 1176‑79). 
However, conclusions of such studies are both 
limited and suspect because, in general, no 
proper adjustment has been made for the po-
tential (and very likely) confounding-by-
indication that occurs in the observational stud-
ies that attempt to compare the rate of uterine 
rupture for women receiving treatment with 
oxytocin versus those who do not. 
On the contrary, emerging data indicate that induction 
of labor after a prior cesarean delivery appears to be as-
sociated with an increased risk of uterine rupture. 
Zelop et al found that the rate of uterine rup-
ture in 560 women who underwent labor induc-
tion after a single previous cesarean delivery 
was 2.3% compared with 0.72% for 2,214 
women who had labored spontaneously 
(P =.001) (Ravasia, Wood et Pollard 2000, 
1176‑79). 
In a study by Ravasia et al of 575 patients who 
underwent labor induction, the uterine rupture 
rate was 1.4% compared with 0.45% for wom-
en who labored spontaneously (P =.004) 
(Ravasia, Wood et Pollard 2000, 1176‑79). 
Blanchette et al (Blanchette et al. 2001, 1478‑87) 
found that the uterine rupture rate after previous cesare-
an delivery when labor was induced was 4% compared 
with 0.34% for women who labored spontaneously. This 
last finding suggests a 12-fold increased risk of uterine 
rupture for women who undergo labor induction after 
previous cesarean delivery. 
Bujold et al found no statistically significant dif-
ference among the uterine rupture rates of 
1.1% for spontaneous labor, 1.2% for induction 
by amniotomy with or without oxytocin, and 
1.6% for induction by transcervical Foley cathe-
ter (P =0.81) (Bujold, Blackwell et Gauthier 
2004, 18‑23). 
Hoffman et al reported a 3.67-fold increased 
risk of uterine rupture (95% CI, 1.46-9.23) with 
Foley catheter use for preinduction cervical rip-
ening. Importantly, however, many of these pa-
tients received concomitant oxytocin together 
with application of the transcervical Foley cath-
eter (Hoffman et al. 2004, 217‑22). 
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Pettker et al (Pettker et al. 2008, 1320‑26) 
found that the addition of oxytocin to the use 
of a transcervical Foley catheter for labor in-
duction does not shorten the time to delivery 
and has no effect on either the likelihood of 
delivery within 24 hours or the vaginal delivery 
rate. 
In a systematic review that evaluated maternal 
and neonatal outcomes following induction of 
labor (4,038 women) and spontaneous labor 
(13,374 women) in women who previously un-
derwent cesarean section, Rossi & Prefumo re-
ported a lower incidence of vaginal delivery 
with induced labor but higher rates of uterine 
rupture/dehiscence, repeat cesarean section, 
and postpartum hemorrhage (Rossi et Prefumo 
2015, 273‑80). 
Facchinetti et al (Facchinetti et al. 2015, 55‑58) 
indicated that women with a previous cesarean 
delivery being induced for premature rupture of 
membranes and who have a favorable Bishop 
have a higher likelihood of success. 
 
 
Signs, symptoms and diagnosis of uterine rupture  
 
Classical signs and symptoms of the uterine 
rupture have been reported in 19th century and 
the signs and symptoms of uterine rupture 
largely depend on the timing, site, and extent of 
the uterine defect (Guseh et al. 2016, 255‑67). 
Prolonged, late, or recurrent variable decelera-
tions or fetal bradycardias are often the first 
and only signs of uterine rupture (Gardeil, Daly 
et Turner 1994, 107‑10). 
The most common clinical presentation is sud-
den appearance of fetal distress during labor 
and maternal shock. The classic signs and 
symptoms of uterine rupture are (1) fetal dis-
tress (as evidenced most often by abnormalities 
in fetal heart rate), (2) diminished baseline uter-
ine pressure, (3) loss of uterine contractility, (4) 
abdominal pain, (5) recession of the presenting 
fetal part, (6) hemorrhage, and (7) shock. This 
typical clinical presentation is rarely present, 
and in some cases, uterine rupture is incidental 
finding on laparotomy (Guseh et al. 2016, 
255‑67).  
Uterine rupture at the site of a previous uterine scar is 
typically less violent and less dramatic than a spontane-
ous or traumatic rupture because of their relatively re-
duced vascularity (Golan, Sandbank et Rubin 1980, 
549‑54; Guseh et al. 2016, 255‑67; Gardeil, Daly 
et Turner 1994, 107‑10). 
Sudden or atypical maternal abdominal pain oc-
curs more rarely than fetal heart rate decelera-
tions or bradycardia. In 9 studies from 1980-
2002, abdominal pain occurred in 13-60% of 
cases of uterine rupture. In a review of 10,967 
patients undergoing a TOLAC, only 22% of 
complete uterine ruptures presented with ab-
dominal pain and 76% presented with signs of 
fetal distress diagnosed by continuous electron-
ic fetal monitoring (Revicky et al. 2012, 
665‑73). 
In a study of Bujold and Gauthier (Bujold et al. 
2002, 1199‑1202), abdominal pain was the first 
sign of rupture in only 5% of patients and oc-
curred in women who developed uterine rup-
ture without epidural analgesia but not in wom-
en who received an epidural block. 
So, abdominal pain is an unreliable and un-
common sign of uterine rupture. Initial con-
cerns that epidural anesthesia might mask the 
pain caused by uterine rupture have not been 
verified and there have been no reports of epi-
dural anesthesia delaying the diagnosis of uter-
ine rupture. The ACOG guideline from 2010 
suggests there is no absolute contraindication to 
epidural anesthesia for a TOLAC because epi-
durals rarely mask the signs and symptoms of 
uterine rupture. 
The diagnosis of uterine rupture is complex and 
often relied on the experience and intuition of 
clinicians. Several reports have suggested that 
transabdominal, transvaginal, or 
sonohysterographic ultrasonography may be 
useful for detecting uterine-scar defects after 
cesarean delivery. Rozenberg et al prospectively 
examined 642 women and found that the risk 
of uterine rupture after previous cesarean deliv-
ery was directly related to the thickness of the 
lower uterine segment, as measured during 
transabdominal ultrasonography at 36-38 weeks 
of gestation. The risk of uterine rupture in-
creased significantly when the uterine wall was 
thinner than 3.5 mm. Using a 3.5 mm cutoff, 
the authors had a sensitivity of 88%, specificity 
of 73.2%, positive predictive value of 11.8%, 
and a negative predictive value of 99.3% in 
predicting subsequent uterine rupture 
(Rozenberg et al. 1999, 39‑45). 
 Andrea Tinelli  
69 
Pettker et al (Pettker et al. 2008, 1320‑26) 
found that the addition of oxytocin to the use 
of a transcervical Foley catheter for labor in-
duction does not shorten the time to delivery 
and has no effect on either the likelihood of 
delivery within 24 hours or the vaginal delivery 
rate. 
In a systematic review that evaluated maternal 
and neonatal outcomes following induction of 
labor (4,038 women) and spontaneous labor 
(13,374 women) in women who previously un-
derwent cesarean section, Rossi & Prefumo re-
ported a lower incidence of vaginal delivery 
with induced labor but higher rates of uterine 
rupture/dehiscence, repeat cesarean section, 
and postpartum hemorrhage (Rossi et Prefumo 
2015, 273‑80). 
Facchinetti et al (Facchinetti et al. 2015, 55‑58) 
indicated that women with a previous cesarean 
delivery being induced for premature rupture of 
membranes and who have a favorable Bishop 
have a higher likelihood of success. 
 
 
Signs, symptoms and diagnosis of uterine rupture  
 
Classical signs and symptoms of the uterine 
rupture have been reported in 19th century and 
the signs and symptoms of uterine rupture 
largely depend on the timing, site, and extent of 
the uterine defect (Guseh et al. 2016, 255‑67). 
Prolonged, late, or recurrent variable decelera-
tions or fetal bradycardias are often the first 
and only signs of uterine rupture (Gardeil, Daly 
et Turner 1994, 107‑10). 
The most common clinical presentation is sud-
den appearance of fetal distress during labor 
and maternal shock. The classic signs and 
symptoms of uterine rupture are (1) fetal dis-
tress (as evidenced most often by abnormalities 
in fetal heart rate), (2) diminished baseline uter-
ine pressure, (3) loss of uterine contractility, (4) 
abdominal pain, (5) recession of the presenting 
fetal part, (6) hemorrhage, and (7) shock. This 
typical clinical presentation is rarely present, 
and in some cases, uterine rupture is incidental 
finding on laparotomy (Guseh et al. 2016, 
255‑67).  
Uterine rupture at the site of a previous uterine scar is 
typically less violent and less dramatic than a spontane-
ous or traumatic rupture because of their relatively re-
duced vascularity (Golan, Sandbank et Rubin 1980, 
549‑54; Guseh et al. 2016, 255‑67; Gardeil, Daly 
et Turner 1994, 107‑10). 
Sudden or atypical maternal abdominal pain oc-
curs more rarely than fetal heart rate decelera-
tions or bradycardia. In 9 studies from 1980-
2002, abdominal pain occurred in 13-60% of 
cases of uterine rupture. In a review of 10,967 
patients undergoing a TOLAC, only 22% of 
complete uterine ruptures presented with ab-
dominal pain and 76% presented with signs of 
fetal distress diagnosed by continuous electron-
ic fetal monitoring (Revicky et al. 2012, 
665‑73). 
In a study of Bujold and Gauthier (Bujold et al. 
2002, 1199‑1202), abdominal pain was the first 
sign of rupture in only 5% of patients and oc-
curred in women who developed uterine rup-
ture without epidural analgesia but not in wom-
en who received an epidural block. 
So, abdominal pain is an unreliable and un-
common sign of uterine rupture. Initial con-
cerns that epidural anesthesia might mask the 
pain caused by uterine rupture have not been 
verified and there have been no reports of epi-
dural anesthesia delaying the diagnosis of uter-
ine rupture. The ACOG guideline from 2010 
suggests there is no absolute contraindication to 
epidural anesthesia for a TOLAC because epi-
durals rarely mask the signs and symptoms of 
uterine rupture. 
The diagnosis of uterine rupture is complex and 
often relied on the experience and intuition of 
clinicians. Several reports have suggested that 
transabdominal, transvaginal, or 
sonohysterographic ultrasonography may be 
useful for detecting uterine-scar defects after 
cesarean delivery. Rozenberg et al prospectively 
examined 642 women and found that the risk 
of uterine rupture after previous cesarean deliv-
ery was directly related to the thickness of the 
lower uterine segment, as measured during 
transabdominal ultrasonography at 36-38 weeks 
of gestation. The risk of uterine rupture in-
creased significantly when the uterine wall was 
thinner than 3.5 mm. Using a 3.5 mm cutoff, 
the authors had a sensitivity of 88%, specificity 
of 73.2%, positive predictive value of 11.8%, 
and a negative predictive value of 99.3% in 
predicting subsequent uterine rupture 
(Rozenberg et al. 1999, 39‑45). 
JDREAM.indd   69 18/01/18   11:0325 2 57
 Andrea Tinelli  
69 
Pettker et al (Pettker et al. 2008, 1320‑26) 
found that the addition of oxytocin to the use 
of a transcervical Foley catheter for labor in-
duction does not shorten the time to delivery 
and has no effect on either the likelihood of 
delivery within 24 hours or the vaginal delivery 
rate. 
In a systematic review that evaluated maternal 
and neonatal outcomes following induction of 
labor (4,038 women) and spontaneous labor 
(13,374 women) in women who previously un-
derwent cesarean section, Rossi & Prefumo re-
ported a lower incidence of vaginal delivery 
with induced labor but higher rates of uterine 
rupture/dehiscence, repeat cesarean section, 
and postpartum hemorrhage (Rossi et Prefumo 
2015, 273‑80). 
Facchinetti et al (Facchinetti et al. 2015, 55‑58) 
indicated that women with a previous cesarean 
delivery being induced for premature rupture of 
membranes and who have a favorable Bishop 
have a higher likelihood of success. 
 
 
Signs, symptoms and diagnosis of uterine rupture  
 
Classical signs and symptoms of the uterine 
rupture have been reported in 19th century and 
the signs and symptoms of uterine rupture 
largely depend on the timing, site, and extent of 
the uterine defect (Guseh et al. 2016, 255‑67). 
Prolonged, late, or recurrent variable decelera-
tions or fetal bradycardias are often the first 
and only signs of uterine rupture (Gardeil, Daly 
et Turner 1994, 107‑10). 
The most common clinical presentation is sud-
den appearance of fetal distress during labor 
and maternal shock. The classic signs and 
symptoms of uterine rupture are (1) fetal dis-
tress (as evidenced most often by abnormalities 
in fetal heart rate), (2) diminished baseline uter-
ine pressure, (3) loss of uterine contractility, (4) 
abdominal pain, (5) recession of the presenting 
fetal part, (6) hemorrhage, and (7) shock. This 
typical clinical presentation is rarely present, 
and in some cases, uterine rupture is incidental 
finding on laparotomy (Guseh et al. 2016, 
255‑67).  
Uterine rupture at the site of a previous uterine scar is 
typically less violent and less dramatic than a spontane-
ous or traumatic rupture because of their relatively re-
duced vascularity (Golan, Sandbank et Rubin 1980, 
549‑54; Guseh et al. 2016, 255‑67; Gardeil, Daly 
et Turner 1994, 107‑10). 
Sudden or atypical maternal abdominal pain oc-
curs more rarely than fetal heart rate decelera-
tions or bradycardia. In 9 studies from 1980-
2002, abdominal pain occurred in 13-60% of 
cases of uterine rupture. In a review of 10,967 
patients undergoing a TOLAC, only 22% of 
complete uterine ruptures presented with ab-
dominal pain and 76% presented with signs of 
fetal distress diagnosed by continuous electron-
ic fetal monitoring (Revicky et al. 2012, 
665‑73). 
In a study of Bujold and Gauthier (Bujold et al. 
2002, 1199‑1202), abdominal pain was the first 
sign of rupture in only 5% of patients and oc-
curred in women who developed uterine rup-
ture without epidural analgesia but not in wom-
en who received an epidural block. 
So, abdominal pain is an unreliable and un-
common sign of uterine rupture. Initial con-
cerns that epidural anesthesia might mask the 
pain caused by uterine rupture have not been 
verified and there have been no reports of epi-
dural anesthesia delaying the diagnosis of uter-
ine rupture. The ACOG guideline from 2010 
suggests there is no absolute contraindication to 
epidural anesthesia for a TOLAC because epi-
durals rarely mask the signs and symptoms of 
uterine rupture. 
The diagnosis of uterine rupture is complex and 
often relied on the experience and intuition of 
clinicians. Several reports have suggested that 
transabdominal, transvaginal, or 
sonohysterographic ultrasonography may be 
useful for detecting uterine-scar defects after 
cesarean delivery. Rozenberg et al prospectively 
examined 642 women and found that the risk 
of uterine rupture after previous cesarean deliv-
ery was directly related to the thickness of the 
lower uterine segment, as measured during 
transabdominal ultrasonography at 36-38 weeks 
of gestation. The risk of uterine rupture in-
creased significantly when the uterine wall was 
thinner than 3.5 mm. Using a 3.5 mm cutoff, 
the authors had a sensitivity of 88%, specificity 
of 73.2%, positive predictive value of 11.8%, 
and a negative predictive value of 99.3% in 
predicting subsequent uterine rupture 
(Rozenberg et al. 1999, 39‑45). 
 Andrea Tinelli  
69 
Pettker et al (Pettker et al. 2008, 1320‑26) 
found that the addition of oxytocin to the use 
of a transcervical Foley catheter for labor in-
duction does not shorten the time to delivery 
and has no effect on either the likelihood of 
delivery within 24 hours or the vaginal delivery 
rate. 
In a systematic review that evaluated maternal 
and neonatal outcomes following induction of 
labor (4,038 women) and spontaneous labor 
(13,374 women) in women who previously un-
derwent cesarean section, Rossi & Prefumo re-
ported a lower incidence of vaginal delivery 
with induced labor but higher rates of uterine 
rupture/dehiscence, repeat cesarean section, 
and postpartum hemorrhage (Rossi et Prefumo 
2015, 273‑80). 
Facchinetti et al (Facchinetti et al. 2015, 55‑58) 
indicated that women with a previous cesarean 
delivery being induced for premature rupture of 
membranes and who have a favorable Bishop 
have a higher likelihood of success. 
 
 
Signs, symptoms and diagnosis of uterine rupture  
 
Classical signs and symptoms of the uterine 
rupture have been reported in 19th century and 
the signs and symptoms of uterine rupture 
largely depend on the timing, site, and extent of 
the uterine defect (Guseh et al. 2016, 255‑67). 
Prolonged, late, or recurrent variable decelera-
tions or fetal bradycardias are often the first 
and only signs of uterine rupture (Gardeil, Daly 
et Turner 1994, 107‑10). 
The most common clinical presentation is sud-
den appearance of fetal distress during labor 
and maternal shock. The classic signs and 
symptoms of uterine rupture are (1) fetal dis-
tress (as evidenced most often by abnormalities 
in fetal heart rate), (2) diminished baseline uter-
ine pressure, (3) loss of uterine contractility, (4) 
abdominal pain, (5) recession of the presenting 
fetal part, (6) hemorrhage, and (7) shock. This 
typical clinical presentation is rarely present, 
and in some cases, uterine rupture is incidental 
finding on laparotomy (Guseh et al. 2016, 
255‑67).  
Uterine rupture at the site of a previous uterine scar is 
typically less violent and less dramatic than a spontane-
ous or traumatic rupture because of their relatively re-
duced vascularity (Golan, Sandbank et Rubin 1980, 
549‑54; Guseh et al. 2016, 255‑67; Gardeil, Daly 
et Turner 1994, 107‑10). 
Sudden or atypical maternal abdominal pain oc-
curs more rarely than fetal heart rate decelera-
tions or bradycardia. In 9 studies from 1980-
2002, abdominal pain occurred in 13-60% of 
cases of uterine rupture. In a review of 10,967 
patients undergoing a TOLAC, only 22% of 
complete uterine ruptures presented with ab-
dominal pain and 76% presented with signs of 
fetal distress diagnosed by continuous electron-
ic fetal monitoring (Revicky et al. 2012, 
665‑73). 
In a study of Bujold and Gauthier (Bujold et al. 
2002, 1199‑1202), abdominal pain was the first 
sign of rupture in only 5% of patients and oc-
curred in women who developed uterine rup-
ture without epidural analgesia but not in wom-
en who received an epidural block. 
So, abdominal pain is an unreliable and un-
common sign of uterine rupture. Initial con-
cerns that epidural anesthesia might mask the 
pain caused by uterine rupture have not been 
verified and there have been no reports of epi-
dural anesthesia delaying the diagnosis of uter-
ine rupture. The ACOG guideline from 2010 
suggests there is no absolute contraindication to 
epidural anesthesia for a TOLAC because epi-
durals rarely mask the signs and symptoms of 
uterine rupture. 
The diagnosis of uterine rupture is complex and 
often relied on the experience and intuition of 
clinicians. Several reports have suggested that 
transabdominal, transvaginal, or 
sonohysterographic ultrasonography may be 
useful for detecting uterine-scar defects after 
cesarean delivery. Rozenberg et al prospectively 
examined 642 women and found that the risk 
of uterine rupture after previous cesarean deliv-
ery was directly related to the thickness of the 
lower uterine segment, as measured during 
transabdominal ultrasonography at 36-38 weeks 
of gestation. The risk of uterine rupture in-
creased significantly when the uterine wall was 
thinner than 3.5 mm. Using a 3.5 mm cutoff, 
the authors had a sensitivity of 88%, specificity 
of 73.2%, positive predictive value of 11.8%, 
and a negative predictive value of 99.3% in 
predicting subsequent uterine rupture 
(Rozenberg et al. 1999, 39‑45). 
JDREAM.indd   69 18/01/18   11:0325 2 57
Uterine rupture: up to date 
70 
In a study of 722 women, Gotoh et al (Gotoh 
et al. 2000, 596‑600) reported that a uterine 
wall thinner than 2 mm, as determined with ul-
trasonography performed within 1 week of de-
livery, significantly increased the risk of uterine 
rupture. Positive and negative predictive values 
were 73.9% and 100%, respectively. 
 
 
Conclusion 
 
Uterine rupture is a rare but often catastrophic 
obstetric complication with an overall incidence 
of approximately 1 in 1,536 pregnancies 
(0.07%). In developed countries, the uterine 
rupture rate during pregnancy for a woman 
with an unscarred and normal uterus is 1 in 
8,434 pregnancies (0.012%). Uterine ruptures 
occur, generally, in scarred uteri, most of which 
are the result of previous myomectomy or/and 
CSs. A single cesarean scar increases the overall 
rupture rate to 0.5%, with the rate for women 
with two or more cesarean scars increasing to 
2%. Other subgroups of women who are at in-
creased risk for uterine rupture are those who 
have a previous single-layer hysterotomy clo-
sure, a short interpregnancy interval after a pre-
vious CS, a congenital uterine anomaly, a 
macrosomic fetus, prostaglandin exposure, and 
a failed previous trial of a vaginal delivery. 
Surgeon has less than 10-37 minutes after uter-
ine rupture to minimize the risk of permanent 
perinatal injury to the fetus, even if often the 
damage is not preventable (Nahrum et Pham).  
The general clinical early indicator of uterine 
rupture is the onset of a prolonged, persistent, 
and profound fetal bradycardia. Other signs 
and symptoms, such as abdominal pain, ab-
normal progress in labor, and vaginal bleeding, 
are less consistent and less valuable than 
bradycardia in establishing the appropriate di-
agnosis. 
Generally, the obstetricians should be able to 
start cesarean delivery within 20-30 minutes of 
a diagnosis of fetal distress is of minimal utility 
with respect to uterine rupture. In the case of 
fetal or placental extrusion through the uterine 
wall, irreversible fetal damage can be expected 
before that time.  
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Abstract 
The aim is to highlight the progress of earliness and quality of diagnosis and breast cancer cure in the Province 
of Lecce by surveying a number of indicators obtainable from surgical pathologist’s evaluation. The study, con-
ducted with the software SQTM (www.qtweb.it), is based on breast cancer of women  50-69 years old residing in 
the Province of Lecce  who undergone breast surgery in the years 2003, 2004, 2010, 2011 and 2012 at the "V. 
Fazzi " Hospital, which is reference center for diagnosis and treatment of breast cancer  within the Breast Cancer 
Screening Program of the ASL of Lecce , active since 2008. Compared to the prescreening period, results of all 
the indicators showed an almost progressive and significant improvement along the years, highlighting the first 
beneficial effects, primarily the improvement of early diagnosis, resulting from the impact of screening on the 
female  target population. However, the study has emphasized some important problems arising from persistent 
and systematic deficiencies in the organizational and multidisciplinary approach, on which we must concentrate 
efforts to further improve the screening program results. 
 
Keywords: Breast  Cancer, Diagnosis Quality, Mammographic Screening 
 
 
 
Introduction 
 
The Planned Mammographic Screening (PMS) 
for breast cancer, with the uterine cervix cancer  
screening and  the colon-rectum one’s, is part 
of LEA (Essential Assistance Levels) in Italy 
from several years, implying  the national and 
regional sanitary service assure all the women 
from the target population (50-69 year old) of 
active measures for early diagnosis, based on 
mammography as the first level test carried out 
after a call once every two years. The planned 
screening’s first aim is to reduce mortality for 
all the neoplasias  is addressed to,  with an ac-
ceptable cost/benefit ratio. The second aim is 
to improve the diagnostic and therapeutic  
course quality.  So a planned screening program 
is not limited to appropriate organizational 
measures for a good coverage and compliance 
of the target population in first level testing , it 
provides also a good management of  a right 
diagnostic and therapeutic course, a control sys-
tem and checking the results and a continuous 
action to straighten the shot of screening or-
ganizational machine.  From 2006 is available 
the SQTM (computerized Schedule for Quality  
in Treatment of Mammary carcinoma) dedicat-
ed software developed by Piedmont’s  CPO 
(regional Oncological Prevention Center) with 
European funds from the “Europe against can-
cer” Program and under the auspices of 
EUSOMA.  SQTM is used from several years 
by GISMa (Mammographic Screening Italian 
Group) to do year’s surveys on mammographic 
screening results in Italy, based on monitoring 
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many quality’s indicators of diagnosis and 
treatment. 
 
 
Objective 
  
The aim of this study is to evaluate, by some 
GISMa’s indicators, the quality trend of diagno-
sis and treatment of the mammary carcinoma in 
Salento over a period of ten years during which 
the PMS was introduced in Lecce’s district 
(800.000 residents).  The study is based on cas-
es of breast pathology observed in resident 
women operated at “Vito Fazzi” General Hos-
pital of Lecce, the biggest one in the district, 
that is home to breast unit and also reference 
center for diagnosis and for treatment of 
screen-detected cases of breast carcinoma in the 
PMS of  the ASL of Lecce  (local health author-
ity). PMS in Lecce’s district is  active from 
2008. The cases falling in the study were ob-
served during the years 2003, 2004, 2010, 2011 
and 2012 and were registered with SQTM. 
Their files have been analyzed in partnership 
with Piedmont’s CPO. This work is part of a 
collaboration in monitoring program for 
mammographic screening in Italy, in which 
Lecce’s team is so far the only one from South-
ern Italy. Preliminary data for the years 2003, 
2004 and 2010 only were presented at the 
GISMa’s National Meeting of Palermo in 2011 
(Delos, Tarantino, Olla Atzeni et al. 2011) .   
The years 2003 and 2004 were evaluated for 
prescreening results. On the other side the years 
from 2010 were examined for any positive im-
pact of the local PMS on the target population. 
With this work we hope provide useful 
informations to solve any critical issues of local 
PMS. From Cancer Registry of Lecce’s district 
we can notice an incidence of about 500 breast 
malignant neoplasias a year in women 
(Melcarne, Rashid, Quarta 2010) .  
 
 
In the Graphic 1 we can observe breast malig-
nant tumors, distributed by age groups, in the 
2007, most recent year published available.  
 
 
 
In the Graphic 2, reporting  the same cases dis-
tributed by hospitals of surgical treatment, we 
can observe that 37% of malignant breast tu-
mors was operated at “Vito Fazzi” General 
Hospital of Lecce. 
 
 
Materials and methods  
 
This study concerns malignant and benign  
desease  cases of the breast regarding women 
operated in the years 2003, 2004, 2010, 2011 
and 2012 at Vito Fazzi General Hospital, where 
are treated surgically about 200 breast carcino-
ma cases for year, that is 37% of all breast ma-
lignant tumors cases incident in women of Lec-
ce’s district. All the cases were registered in 
SQTM by Surgical Pathology Unit of “Vito 
Fazzi” Hospital.  For this first evaluation we 
haven’t taken in to account all the indicators of 
the GISMa’s surveys, but only those that usual-
ly can be deduced by the Surgical Pathology’s 
diagnostic report. In particular for this study we 
have calculated with SQTM the values of the 
following indicators: 
1) Pre-operative diagnosis in cancer 
(C5/B5) 
2) Completeness of diagnostic and prog-
nostic data in surgical pathology’s re-
port of invasive cancer  cases (histotype, 
grading,  pTNM)  
3) Only one operation after pre-operative 
diagnosis of invasive cancer 
4) Only one operation after pre-operative 
diagnosis of non-invasive cancer (in situ 
carcinoma) 
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ma cases for year, that is 37% of all breast ma-
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ce’s district. All the cases were registered in 
SQTM by Surgical Pathology Unit of “Vito 
Fazzi” Hospital.  For this first evaluation we 
haven’t taken in to account all the indicators of 
the GISMa’s surveys, but only those that usual-
ly can be deduced by the Surgical Pathology’s 
diagnostic report. In particular for this study we 
have calculated with SQTM the values of the 
following indicators: 
1) Pre-operative diagnosis in cancer 
(C5/B5) 
2) Completeness of diagnostic and prog-
nostic data in surgical pathology’s re-
port of invasive cancer  cases (histotype, 
grading,  pTNM)  
3) Only one operation after pre-operative 
diagnosis of invasive cancer 
4) Only one operation after pre-operative 
diagnosis of non-invasive cancer (in situ 
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5) Axillary staging by Sentinel Lymph 
Node (SLN) only in pN0   
6) No axillary dissection in Ductal Carci-
noma in Situ (DCIS) 
7) Conservative surgery (quadrantectomy) 
in invasive  cancers </=  30 mm  
8) Immediate plastic reconstruction in in-
vasive carcinoma cases  treated  with to-
tal mastectomy 
9) pN0 in invasive cancer cases 
10) Early diagnosis (pTis + pTmc + pT1a 
+ pT1b) in all cancer cases   
11) Benign/Malignant ratio (B/M) in surgi-
cally treated cases 
 
Indicators from 1 to 8 are GISMa’s ones 
(Mano, Ponti, Angiolini et al 2013) . Indicators 
from 9 to 11 usually are not reported in 
GISMa’s Surveys, but they are anyway calculat-
ed for this study and comparated with the cor-
responding values achieved from data of 
GISMa’Survey 2012 (Ponti, Mano, Tomatis et 
al. 2015). 
 
 
Results 
 
We can find in Table 1 the obtained values, re-
ported as cases number and percentages dis-
tributed by years of treatment, for all the differ-
ent indicators considered. The years 2003 and 
2004 are reported together. In the same table  
are reported the corresponding values of the 
national GISMa’s Survey 2012.   
 
 
 
In Graphic 3 we reported changes over time in 
the pT distribution in breast cancer detected 
among women aged between 45 and 70 years, 
who are the ones that benefit most from the 
PMS.  
Indicator n. 1 increases from 17,2% of the pre-
screening period to the 29% for 2011 and to 
23% for 2012. Indicator n. 2 increases from 
31% to 74,7% in 2012. Indicator n. 3 remained 
nearly the same only with little variations over 
time. Indicator n. 4 gets better, from 61,5% of 
2003-2004 to 87,5% of 2012. Indicator n. 5 in-
creases from 29,5% to 63,6%.  Indicator n. 6  
doesn’t improve so much, but it has little varia-
tions (from 76,9% to 80%). Indicator n. 7 has 
improved only slightly over time (from 63,8% 
to 66,7%). Indicator n. 8 increased by 10% over 
time, but started from 0 in the prescreening pe-
riod. Both indicators n. 9 and n. 10 improved a 
little, from 54,9% to 58,2% the first,  from 
31,3% to 37,2% the second.  But in Graphic 3 
you can see that pT distribution highlighted 
changes indicative of an earlier diagnosis in the 
years of PMS. In particular they are increased 
cases of carcinoma in situ, microinvasive carci-
nomas and carcinoma within 1 cm and de-
creased cases of carcinoma above 2 cm. Indica-
tor n. 11, expressed as a ratio, has gotten a lot 
better, gradually improving from 1,41 of the 
prescreening period to 0,56 of 2012.  
 
 
Discussion  
 
The results of this investigation highlight an 
almost progressive and significant improvement 
of all the indicators over time from the pre-
screening period, that is years 2003 and 2004,  
when in the Lecce’s district the early diagnosis 
for mammary tumors wasn’t planned or orga-
nized but it only depended on women them-
selves. In details we want to underline, first of 
all, that the improvement of indicators 9 and 10 
is expression of a meaningful, although initial, 
effect of PMS in diagnostic earliness. Over 
time, in effect, in years of PMS we diagnosed 
more mammary neoplasias of little dimensions 
and that doesn’t affect axillary lymph nodes 
than in the prescreening period. Anyway the 
recorded improvement of these two indicators 
is not satisfactory yet, being their values distant 
from GISMa’s values of 2012 (72,6 and 49,7 re-
spectively), although during 2011 they  got 
nearer (70,2 and 38,8). But we have to pay at-
tention to the fact that GISMa’s values are rep-
resentative of geographic areas of Northern Ita-
ly where PMS, in activity from 90’s, are the re-
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sult of decades of experience and organization 
that allows higher levels of coverage and com-
pliance, as well as a quality of diagnostic and 
therapeutic courses  certainly superiors than in 
Lecce’s experience that was just starting in the 
years of this study. We think however that this 
first result of PMS in Salento, talking about 
more precocious diagnosis, as  highlighted by 
moderate improvement of indicators 9 and 10, 
is important and indicative about what potential 
can be developed over time with an implemen-
tation of screening activities. Particularly posi-
tive was the result of indicator n. 2, typical pro-
cess indicator, that recorded progressive grow-
ing values until it goes over the medium 
GISMa’s survey value (74,7% versus 62,6%). 
This result attests the elevated level reached in 
the ASL of Lecce by the breast surgical pathol-
ogy, that is essential base for appropriateness 
and quality of medical care. About the appro-
priateness for the surgery treatment, we have 
used the indicators from number 3 to 7. Their 
monitoring is useful to pursue a double objec-
tive, on the one hand, of avoiding useless and 
more invasive surgery in favor of the patients 
and, on the other, of saving costs and operating 
room resources. The results regarding the sur-
gical appropriateness were contradictory.  If for 
the indicators 3, 4 and 6 we had remarkable 
values, that improved significantly on time, 
aligning in 2011 to GISMa’s values, indicators 
n. 5 and 7 were disappointing (63,6 and 66,7 re-
spectively), remaining far below of the GISMa’s 
values (91,7 and 83,5). Essentially it seems like 
the conservative surgery is still inadequately ap-
plied, in particular, regarding quadrantectomy 
instead of total mastectomy, as  in effect is 
highlighted by indicator 7, which improved a 
little during years of PMS. Regarding the saving 
of axillary dissection in pN0 cases (indicator n. 
5), the sentinel lymph node technique was still 
underused, although this parameter significantly 
improved if compared with the value (29,5%) 
of prescreening period.  But the most critical 
aspects are those remarked by indicators n. 1, 8 
and 11. Very negative is the result of indicator 
n. 1, for the systemic implications on all the di-
agnostic and therapeutic course and, in particu-
lar, for its adverse effect on appropriateness of 
surgical treatment. The value of this indicator  
improved very little, from 17,2% to 23%,  re-
maining far below of the GISMa’s value 
(82,3%).  Despite this negative result we had 
positive values of  indicators  3, 4, 6, as men-
tioned above,  but this implies  a systematic 
trend to  bypass  the pre-operative diagnosis  by 
fine needle aspiration and/or needle biopsy, in 
favor of intra-operative diagnosis based on fro-
zen sections.  This practice is inadequate for 
several reasons and seems to be the heritage of 
the past when the surgeon was the only and al-
most exclusive reference for the breast  pathol-
ogy  treatment. This practice should be aban-
doned  in favor of the current good clinical 
practice recommendations because it causes the 
following negative consequences:  
1) Increased costs due to overuse of intra-
operative diagnosis, more expensive 
than the pre-operative one, as it length-
ens the operating room time,  requires 
the commitment of the medical and 
technical staff of surgical pathology dur-
ing operations, brings to the operating 
table, as the indicator 11 remarks, many 
benign lesions, with a further consump-
tion of resources and exposition to risk 
and discomfort the women unnecessari-
ly operated; 
2) lowering of the quality and appropriate-
ness  of the treatment plan due to by-
passing the multidisciplinary assessment 
in pre-operative phase, leaving every 
decision to surgeon;  
3) Exclusion of woman/patient from a 
decision regarding the treatment be-
cause she is under anesthesia when a 
decision is taken after a intra-operative 
diagnosis: the  consequent implications, 
also talking about legal validity of con-
sent to the treatment, can be easily un-
derstand. 
About the very low value of indicator n. 8, re-
garding the plastic reconstruction of breast after 
total mastectomy, in part it’s due to the multi-
disciplinary planning deficits of the diagnostic-
therapeutic courses and to underuse of the pre-
operative diagnosis.     
 
 
Conclusions 
  
From the results described above, albeit relative 
to a still initial period of introduction of the 
PMS in the district of the ASL of Lecce, with 
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ing operations, brings to the operating 
table, as the indicator 11 remarks, many 
benign lesions, with a further consump-
tion of resources and exposition to risk 
and discomfort the women unnecessari-
ly operated; 
2) lowering of the quality and appropriate-
ness  of the treatment plan due to by-
passing the multidisciplinary assessment 
in pre-operative phase, leaving every 
decision to surgeon;  
3) Exclusion of woman/patient from a 
decision regarding the treatment be-
cause she is under anesthesia when a 
decision is taken after a intra-operative 
diagnosis: the  consequent implications, 
also talking about legal validity of con-
sent to the treatment, can be easily un-
derstand. 
About the very low value of indicator n. 8, re-
garding the plastic reconstruction of breast after 
total mastectomy, in part it’s due to the multi-
disciplinary planning deficits of the diagnostic-
therapeutic courses and to underuse of the pre-
operative diagnosis.     
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the consequent and deducible limits both in 
terms of effective coverage of the target popu-
lation and compliance of the invited women 
who appeared    to be low (around the 40%),  
emerges already the capacity of this important 
early diagnosis planning tool.  But also they 
emerge several critical issues that are 
attributable mainly to a deficit with regard to 
the approach and organization of 
multidisciplinary preoperative diagnostic and 
therapeutic planning process. These problems 
must be resolved through the efforts of medical 
teams involved , the Breast Unit, the body of 
the local PMS coordination and the 
management of the local health institutions. As 
the persistence over time of these critical issues 
, and still others in this study were not 
examined , produces the effect of devaluing the 
screening program, it is important to implement 
a systematic monitoring of the results with 
appropriate tools, to  constantly correct the 
shooting of PMS and improve the quality of 
diagnostic and therapeutic path of breast cancer 
in the ASL of Lecce district. 
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Abstract 
The study and analysis of the organization in health care depends on some aspects that include the observation 
of social phenomena, law categories, and political strategies as well as the administrative behaviors. All these as-
pects have led to the overcoming of the traditional concept of bureaucracy, which finds a solid theoretical foun-
dation in the studies undertaken by Weber. In the Weber's vision, bureaucracy is the organization of people and 
resources for a collective purpose, public, according to any criteria of rationality, impartiality and impersonality. 
The assumption is that it is hard to perceive organizations oriented towards an end in a rational way, unless as 
bureaucracies, even considering that there may be non-bureaucratic organizational forms, not rationally oriented 
to a purpose (Weber 1922). One of the most original contributions of the late twentieth century comes from 
Luhmann's theory of social systems that is applied to the concept of organization. It provides an understanding 
of the object that goes beyond tautological assumptions (e.g. the organization is composed of men) and that 
permits to talk about organization as autopoietic system, not "closed" but "operationally closed" and therefore 
independent on the structural and operational plan (Luhmann 2000, 29-30). In the theory of systems - although 
the organizations may arise freely – what is defined as "complex" organizations, are formed within functions sys-
tems distinguished in economic organizations, political organizations, trade union organizations, health care or-
ganizations, etc. Main features include the possibility that they have to communicate with other systems in their 
environment (Luhmann and De Giorgi 1994, 328) and the reduction of uncertainty and risk. The absorption of 
uncertainty occurs when an organization elaborates some decisions that are a prerequisite for other decisions. In 
the social systems theory, all the organization activities are classified as decisions, take place at a given time, and 
are always documented. However, the evolutionary path that is used to trace the organizational profiles of com-
plex apparatus cannot ignore the importance of Kuhn's theory, according to which scientific revolutions are 
characterized by the transition from one paradigm to another (Kuhn, 1999). The application of this latter model 
to the public organizations, permits to understand that even these organizations are subjected to the dynamics of 
cultural paradigms, according to which the transition from one paradigm - that no longer recognizes the organi-
zations themselves - to another one, that rather includes new models, methods and practices, definitely involves 
a revolution (Limone 2008, 17). In order to properly talk about organization and e-government, especially in the 
health and medical sector, we first need to verify the most suitable organizational context able to manage innova-
tion solutions and, therefore, analyze the organizational conditions as a prerequisite for the technological condi-
tions. In fact, if the organizational environment does not respond to concrete parameters such as transparency, 
efficiency and economy, even the same e-government process is likely to fail. That is the only viable way to ra-
tionalizing and improving the public organizational system, such as health care systems, that tend to have high 
level of complexity and risk due to their nature. 
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The organization of the current complex struc-
tures - in particular the organization of health 
care facilities - depends on some aspects that 
include the observation of social phenomena, 
law categories, and political strategies as well as 
the administrative behaviors. All these aspects 
have led to the overcoming of the traditional 
concept of bureaucracy, which finds a solid 
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theoretical foundation in the studies undertaken 
by Weber. 
In the Weber's vision, bureaucracy is the organ-
ization of people and resources for a collective 
purpose, public, according to any criteria of ra-
tionality, impartiality and impersonality. The as-
sumption is that it is hard to perceive organiza-
tions oriented towards an end in a rational way, 
unless as bureaucracies, even considering that 
there may be non-bureaucratic organizational 
forms, not rationally oriented to a purpose 
(Weber 1922). 
The Weber's studies have been developed later 
on through the contributions of Merton, alt-
hough with different epistemological assump-
tions. Merton envisions his model by perform-
ing an ambivalent step: a) on one hand, he criti-
cizes the rationality concept of bureaucracy in 
the Weberian model by using a functional ap-
proach; b) on the other side, he retrieves some 
elements of Weberian analysis for making criti-
cism on his ideal model. In addition, Merton 
makes a distinction between the overt functions 
and the latent functions. Only with the analysis 
of latent functions, he shows that the Weber's 
model contains some sources of irrationality 
even with respect to the purpose, which do not 
consist in deficiencies in organizational design, 
but in the unforeseen effects that the pressure 
exerted by structures can provoke on the per-
sonality and behavior of men (Merton 1968). 
In the seventies, Gouldner makes a change in 
the rules of Merton's scheme in tayloristic 
terms: he adopted a critical functionalism on 
the distinction between manifest and latent 
functions, able to identify the latent functions 
of measures, norms and institutions (Gouldner 
1973). He identifies three key regulatory models 
of the bureaucratic action: a) the apparent bu-
reaucracy, which occurs when both the direc-
tors and the employees have indifference atti-
tude towards the respect of a rule imposed by 
an outside authority; b) representative bureau-
cracy, which occurs when both the directors 
and employees agree on the usefulness of ob-
serving certain rules; c) the taxation bureaucra-
cy, which occurs when the rules are imposed 
from one side against the will of the others 
(Bonazzi, 2008, 232-235). 
The Selznick's theoretical model, developed 
through a structural-functional analysis (critical 
functionalism between Parsons and Merton), shows a 
theoretical method that is intended to have 
general validity for any formal organization 
which has an internal bureaucracy. In particular, 
he introduces The institute of cooptation (defined as 
the process of absorption of new elements in 
the structure that determine the organization 
policy, as a way for preventing threats to its 
stability or existence) and performing, then, a 
further distinction between formal cooptation 
and informal or substantial cooptation (Selz-
nick, 1969). 
Crozier is primarily interested in some aspects 
such as safety, regularity and the impersonality 
of the functioning that are only found in the 
public administration entities. The issue that 
arises regards the functioning of such organiza-
tions and the social relations that exist within it, 
moving away from the post-Weberian func-
tionalisms when they consider the difficulties of 
the change in bureaucratic organizations and 
when they highlight the relationship between 
technological innovation opportunities and the 
growing autonomy and cultural sophistication 
of individuals. In particular, (Crozier 1994, 22-
27) Crozier carries out a pejorative interpreta-
tion of bureaucracy term: he conducts a strate-
gic analysis of bureaucratic behaviors and de-
fines power as control of uncertainty, highlight-
ing the importance of National cultural models 
(Bonazzi 2008, 266-273). 
In the eighties, the overcoming of the tradition-
al bureaucracy was mainly defined by the mana-
gerial literature attributed to the studies of 
Drucker and Mintzberg, in which the "man-
agement by aims" model proposed by Drucker 
(Ivi, 287), may be viewed as specular antithesis 
of the traditional Weber’s conception of bu-
reaucracy. In this model, they provide an open 
debate beyond the hierarchies; the identification 
and negotiation of aims; the personalization of 
social relations; the acquisition of skills on the 
field; mobility in the career path and the majori-
ty attention given to the purpose rather than to 
the norms, as well as a form of "competitive 
democracy" at the workplace (Ivi, 292). All the-
se factors result in a complete reversal of the 
axioms of the traditional Weberian model. 
One of the most original contributions of the 
late twentieth century comes from Luhmann's 
theory of social systems that is applied to the 
concept of organization. It provides an under-
standing of the object that goes beyond tauto-
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elements of Weberian analysis for making criti-
cism on his ideal model. In addition, Merton 
makes a distinction between the overt functions 
and the latent functions. Only with the analysis 
of latent functions, he shows that the Weber's 
model contains some sources of irrationality 
even with respect to the purpose, which do not 
consist in deficiencies in organizational design, 
but in the unforeseen effects that the pressure 
exerted by structures can provoke on the per-
sonality and behavior of men (Merton 1968). 
In the seventies, Gouldner makes a change in 
the rules of Merton's scheme in tayloristic 
terms: he adopted a critical functionalism on 
the distinction between manifest and latent 
functions, able to identify the latent functions 
of measures, norms and institutions (Gouldner 
1973). He identifies three key regulatory models 
of the bureaucratic action: a) the apparent bu-
reaucracy, which occurs when both the direc-
tors and the employees have indifference atti-
tude towards the respect of a rule imposed by 
an outside authority; b) representative bureau-
cracy, which occurs when both the directors 
and employees agree on the usefulness of ob-
serving certain rules; c) the taxation bureaucra-
cy, which occurs when the rules are imposed 
from one side against the will of the others 
(Bonazzi, 2008, 232-235). 
The Selznick's theoretical model, developed 
through a structural-functional analysis (critical 
functionalism between Parsons and Merton), shows a 
theoretical method that is intended to have 
general validity for any formal organization 
which has an internal bureaucracy. In particular, 
he introduces The institute of cooptation (defined as 
the process of absorption of new elements in 
the structure that determine the organization 
policy, as a way for preventing threats to its 
stability or existence) and performing, then, a 
further distinction between formal cooptation 
and informal or substantial cooptation (Selz-
nick, 1969). 
Crozier is primarily interested in some aspects 
such as safety, regularity and the impersonality 
of the functioning that are only found in the 
public administration entities. The issue that 
arises regards the functioning of such organiza-
tions and the social relations that exist within it, 
moving away from the post-Weberian func-
tionalisms when they consider the difficulties of 
the change in bureaucratic organizations and 
when they highlight the relationship between 
technological innovation opportunities and the 
growing autonomy and cultural sophistication 
of individuals. In particular, (Crozier 1994, 22-
27) Crozier carries out a pejorative interpreta-
tion of bureaucracy term: he conducts a strate-
gic analysis of bureaucratic behaviors and de-
fines power as control of uncertainty, highlight-
ing the importance of National cultural models 
(Bonazzi 2008, 266-273). 
In the eighties, the overcoming of the tradition-
al bureaucracy was mainly defined by the mana-
gerial literature attributed to the studies of 
Drucker and Mintzberg, in which the "man-
agement by aims" model proposed by Drucker 
(Ivi, 287), may be viewed as specular antithesis 
of the traditional Weber’s conception of bu-
reaucracy. In this model, they provide an open 
debate beyond the hierarchies; the identification 
and negotiation of aims; the personalization of 
social relations; the acquisition of skills on the 
field; mobility in the career path and the majori-
ty attention given to the purpose rather than to 
the norms, as well as a form of "competitive 
democracy" at the workplace (Ivi, 292). All the-
se factors result in a complete reversal of the 
axioms of the traditional Weberian model. 
One of the most original contributions of the 
late twentieth century comes from Luhmann's 
theory of social systems that is applied to the 
concept of organization. It provides an under-
standing of the object that goes beyond tauto-
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logical assumptions (e.g. the organization is 
composed of men) and that permits to talk 
about organization as autopoietic system, not 
"closed" but "operationally closed" and there-
fore independent on the structural and opera-
tional plan (Luhmann 2000, 29-30). In the theo-
ry of systems - although the organizations may 
arise freely – what is defined as "complex" or-
ganizations, are formed within functions sys-
tems distinguished in economic organizations, 
political organizations, trade union organiza-
tions, health care organizations, etc. Main fea-
tures include the possibility that they have to 
communicate with other systems in their envi-
ronment (Luhmann and De Giorgi 1994, 328) 
and the reduction of uncertainty and risk. The 
absorption of uncertainty occurs when an or-
ganization elaborates some decisions that are a 
prerequisite for other decisions. In the social 
systems theory, all the organization activities are 
classified as decisions, take place at a given 
time, and are always documented. 
However, the evolutionary path that is used to 
trace the organizational profiles of complex ap-
paratus cannot ignore the importance of 
Kuhn's theory, according to which scientific 
revolutions are characterized by the transition 
from one paradigm to another (Kuhn, 1999). 
The application of this latter model to the pub-
lic organizations, permits to understand that 
even these organizations are subjected to the 
dynamics of cultural paradigms, according to 
which the transition from one paradigm - that 
no longer recognizes the organizations them-
selves - to another one, that rather includes new 
models, methods and practices, definitely in-
volves a revolution (Limone 2008, 17). In order 
to properly talk about organization and e-
government, especially in the health and medi-
cal sector, we first need to verify the most suit-
able organizational context able to manage in-
novation solutions and, therefore, analyze the 
organizational conditions as a prerequisite for 
the technological conditions. In fact, if the or-
ganizational environment does not respond to 
concrete parameters such as transparency, effi-
ciency and economy, even the same e-
government process is likely to fail. 
The building blocks of the new paradigm reveal 
the need to pay attention to the reorganization 
of structures and internal functions (back-
office) even before external activities (front of-
fice). The systematic intervention on the back-
office ensures, in fact, that technological inno-
vation is the same for the front office. That is 
the only viable way to rationalizing and improv-
ing the public organizational system, such as 
health care systems, that tend to have high level 
of complexity and risk due to their nature. 
 
 
2. Organization in health: risk and quality 
 
The concept of clinical governance was born in 
England, in the late nineties of the last century, 
within the politics of organizational strategies 
and regulatory system of the British National 
Health Service (NHS). The adoption of this 
concept comes from the first interventions on 
the quality management of health services that 
is meant as institutional duty shared among 
clinical professionals, experts in organization, 
health professionals and, in particular, policy 
makers. In the philosophy of clinical govern-
ance - according to NHS's guidelines largely ac-
cepted by our National Health System (SSN), 
organizations are responsible for the continu-
ous improvement of the quality of their services 
and the safeguarding of elevated standards of 
care, through the creation of an environment in 
which the excellence in clinical care need to 
flourish (NHS, Department of Health, 1998). 
The clinical governance can be considered as 
a new expression that may change the cultural 
system totally. In these terms, it provides re-
sources to develop organizational skills ori-
ented on sustainable health care, focused on 
patient, along with guaranteed quality that is 
necessary for the different stakeholders. In 
this perspective: 
∙ Patients needs are in the spotlight of clini-
cians and administrators, who take shared re-
sponsibility, 
∙ Information related to the quality of services 
are available to professionals, patients and the 
public, 
∙ Differences in performance access, care pro-
cesses and clinical results are measured with 
the continued commitment to reduce them, 
∙ All organizations work together to continu-
ously improve service quality, 
∙ Professionals work as a team to deliver bet-
ter performance in terms of clinical outcomes 
and safety, 
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theoretical foundation in the studies undertaken 
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In the Weber's vision, bureaucracy is the organ-
ization of people and resources for a collective 
purpose, public, according to any criteria of ra-
tionality, impartiality and impersonality. The as-
sumption is that it is hard to perceive organiza-
tions oriented towards an end in a rational way, 
unless as bureaucracies, even considering that 
there may be non-bureaucratic organizational 
forms, not rationally oriented to a purpose 
(Weber 1922). 
The Weber's studies have been developed later 
on through the contributions of Merton, alt-
hough with different epistemological assump-
tions. Merton envisions his model by perform-
ing an ambivalent step: a) on one hand, he criti-
cizes the rationality concept of bureaucracy in 
the Weberian model by using a functional ap-
proach; b) on the other side, he retrieves some 
elements of Weberian analysis for making criti-
cism on his ideal model. In addition, Merton 
makes a distinction between the overt functions 
and the latent functions. Only with the analysis 
of latent functions, he shows that the Weber's 
model contains some sources of irrationality 
even with respect to the purpose, which do not 
consist in deficiencies in organizational design, 
but in the unforeseen effects that the pressure 
exerted by structures can provoke on the per-
sonality and behavior of men (Merton 1968). 
In the seventies, Gouldner makes a change in 
the rules of Merton's scheme in tayloristic 
terms: he adopted a critical functionalism on 
the distinction between manifest and latent 
functions, able to identify the latent functions 
of measures, norms and institutions (Gouldner 
1973). He identifies three key regulatory models 
of the bureaucratic action: a) the apparent bu-
reaucracy, which occurs when both the direc-
tors and the employees have indifference atti-
tude towards the respect of a rule imposed by 
an outside authority; b) representative bureau-
cracy, which occurs when both the directors 
and employees agree on the usefulness of ob-
serving certain rules; c) the taxation bureaucra-
cy, which occurs when the rules are imposed 
from one side against the will of the others 
(Bonazzi, 2008, 232-235). 
The Selznick's theoretical model, developed 
through a structural-functional analysis (critical 
functionalism between Parsons and Merton), shows a 
theoretical method that is intended to have 
general validity for any formal organization 
which has an internal bureaucracy. In particular, 
he introduces The institute of cooptation (defined as 
the process of absorption of new elements in 
the structure that determine the organization 
policy, as a way for preventing threats to its 
stability or existence) and performing, then, a 
further distinction between formal cooptation 
and informal or substantial cooptation (Selz-
nick, 1969). 
Crozier is primarily interested in some aspects 
such as safety, regularity and the impersonality 
of the functioning that are only found in the 
public administration entities. The issue that 
arises regards the functioning of such organiza-
tions and the social relations that exist within it, 
moving away from the post-Weberian func-
tionalisms when they consider the difficulties of 
the change in bureaucratic organizations and 
when they highlight the relationship between 
technological innovation opportunities and the 
growing autonomy and cultural sophistication 
of individuals. In particular, (Crozier 1994, 22-
27) Crozier carries out a pejorative interpreta-
tion of bureaucracy term: he conducts a strate-
gic analysis of bureaucratic behaviors and de-
fines power as control of uncertainty, highlight-
ing the importance of National cultural models 
(Bonazzi 2008, 266-273). 
In the eighties, the overcoming of the tradition-
al bureaucracy was mainly defined by the mana-
gerial literature attributed to the studies of 
Drucker and Mintzberg, in which the "man-
agement by aims" model proposed by Drucker 
(Ivi, 287), may be viewed as specular antithesis 
of the traditional Weber’s conception of bu-
reaucracy. In this model, they provide an open 
debate beyond the hierarchies; the identification 
and negotiation of aims; the personalization of 
social relations; the acquisition of skills on the 
field; mobility in the career path and the majori-
ty attention given to the purpose rather than to 
the norms, as well as a form of "competitive 
democracy" at the workplace (Ivi, 292). All the-
se factors result in a complete reversal of the 
axioms of the traditional Weberian model. 
One of the most original contributions of the 
late twentieth century comes from Luhmann's 
theory of social systems that is applied to the 
concept of organization. It provides an under-
standing of the object that goes beyond tauto-
Gianpasquale Preite 
83 
logical assumptions (e.g. the organization is 
composed of men) and that permits to talk 
about organization as autopoietic system, not 
"closed" but "operationally closed" and there-
fore independent on the structural and opera-
tional plan (Luhmann 2000, 29-30). In the theo-
ry of systems - although the organizations may 
arise freely – what is defined as "complex" or-
ganizations, are formed within functions sys-
tems distinguished in economic organizations, 
political organizations, trade union organiza-
tions, health care organizations, etc. Main fea-
tures include the possibility that they have to 
communicate with other systems in their envi-
ronment (Luhmann and De Giorgi 1994, 328) 
and the reduction of uncertainty and risk. The 
absorption of uncertainty occurs when an or-
ganization elaborates some decisions that are a 
prerequisite for other decisions. In the social 
systems theory, all the organization activities are 
classified as decisions, take place at a given 
time, and are always documented. 
However, the evolutionary path that is used to 
trace the organizational profiles of complex ap-
paratus cannot ignore the importance of 
Kuhn's theory, according to which scientific 
revolutions are characterized by the transition 
from one paradigm to another (Kuhn, 1999). 
The application of this latter model to the pub-
lic organizations, permits to understand that 
even these organizations are subjected to the 
dynamics of cultural paradigms, according to 
which the transition from one paradigm - that 
no longer recognizes the organizations them-
selves - to another one, that rather includes new 
models, methods and practices, definitely in-
volves a revolution (Limone 2008, 17). In order 
to properly talk about organization and e-
government, especially in the health and medi-
cal sector, we first need to verify the most suit-
able organizational context able to manage in-
novation solutions and, therefore, analyze the 
organizational conditions as a prerequisite for 
the technological conditions. In fact, if the or-
ganizational environment does not respond to 
concrete parameters such as transparency, effi-
ciency and economy, even the same e-
government process is likely to fail. 
The building blocks of the new paradigm reveal 
the need to pay attention to the reorganization 
of structures and internal functions (back-
office) even before external activities (front of-
fice). The systematic intervention on the back-
office ensures, in fact, that technological inno-
vation is the same for the front office. That is 
the only viable way to rationalizing and improv-
ing the public organizational system, such as 
health care systems, that tend to have high level 
of complexity and risk due to their nature. 
 
 
2. Organization in health: risk and quality 
 
The concept of clinical governance was born in 
England, in the late nineties of the last century, 
within the politics of organizational strategies 
and regulatory system of the British National 
Health Service (NHS). The adoption of this 
concept comes from the first interventions on 
the quality management of health services that 
is meant as institutional duty shared among 
clinical professionals, experts in organization, 
health professionals and, in particular, policy 
makers. In the philosophy of clinical govern-
ance - according to NHS's guidelines largely ac-
cepted by our National Health System (SSN), 
organizations are responsible for the continu-
ous improvement of the quality of their services 
and the safeguarding of elevated standards of 
care, through the creation of an environment in 
which the excellence in clinical care need to 
flourish (NHS, Department of Health, 1998). 
The clinical governance can be considered as 
a new expression that may change the cultural 
system totally. In these terms, it provides re-
sources to develop organizational skills ori-
ented on sustainable health care, focused on 
patient, along with guaranteed quality that is 
necessary for the different stakeholders. In 
this perspective: 
∙ Patients needs are in the spotlight of clini-
cians and administrators, who take shared re-
sponsibility, 
∙ Information related to the quality of services 
are available to professionals, patients and the 
public, 
∙ Differences in performance access, care pro-
cesses and clinical results are measured with 
the continued commitment to reduce them, 
∙ All organizations work together to continu-
ously improve service quality, 
∙ Professionals work as a team to deliver bet-
ter performance in terms of clinical outcomes 
and safety, 
JDREAM.indd   83 18/01/18   11:0325 2 57
Biopolitics, Risk and Organization in Health Care 
84 
∙ The risks and dangers to patients are brought 
to the lowest level, 
∙ Health care is based on evidence and on 
good clinical practice. 
According to this approach, the concept of 
clinical governance implies that the manage-
ment of power takes place inside and outside 
the formal decision tree; these decisions arise 
from the interaction between the various stake-
holders. Any person involved in the process 
becomes the bearer of specific needs and ex-
pectations, different scale of priorities and dif-
ferent capacity of perception of the results ob-
tained (Wright, Hill 2005, 22-23). However, it is 
interesting to observe that once it is stabilized 
the process of clinical governance, the problem 
becomes its integration with all the other ele-
ments that constitute the different aspects of 
the management of health care organizations. 
Integrated governance is a further concept in-
troduced for the first time in England in 2003, 
with the document entitled: "Governing the 
NHS: a Guide for NHS Boards (NHS Ap-
pointment Commission, 2003). The aim of this 
document is the integration of the different sec-
toral systems of governance (health, clinic, fi-
nancial, management, research and infor-
mation) and delete the existing overlays, in or-
der to standardize (harmonize) different basal 
processes. The need for an integrated approach 
is based on the recognition that working for 
sectors - in a not shared way - is scattered and 
unproductive, so it is necessary to develop a 
unifying methodology that helps the organiza-
tions to realize their mission and reach the ob-
jectives (Wall, Halligan, Deighan, Cullen, 2002). 
The concept of integrated governance goes be-
yond the corporate governance that is defined 
as the set of rules and organizational structures 
by which companies are managed and con-
trolled. Health facilities (especially public ones) 
are considered as a constellation of several 
complex systems: there is the system of hospital 
care and the one related to primary care, the 
system of professional clinicians, and the one of 
professionals in organization, the system of the 
most important centers and the one in periph-
eries (Wright, Hill, 2005, 25). 
The management philosophy of integrated gov-
ernance also includes risk management, a 
methodology employed in health care settings 
but derived from the financial sector and that, 
in essence, involves the management of all 
those risks that threaten the value of an organi-
zation and that involve different aspects and 
different dimensions of organizational phe-
nomenon: strategies, market processes, financial 
resources, human resources, technologies. 
However, the application of this methodology 
in the field of health care, cannot collapse in the 
transfer sic et nunc of principles and techniques 
designed in the industrial sector, financial or of 
the ICT (Novaco 2004, 24), although it is clear 
that even a health care company must deal with 
many risks that go beyond a particular risk and 
encompassing any general risks that any organi-
zation, regardless of the sector to which they 
belong, must know how to manage in terms of 
total quality. 
Literature on organization, mainly from North 
American, was concerned to provide the defini-
tion of quality in health care systems and to 
draw up specific models (Donabedian 1966; 
Devlin 1990; Charlesworth 1993, 25). In 1984, 
Maxwell developed a model that includes six 
fundamental dimensions aimed to obtain effi-
cient and effective level of quality in health 
care: 1) access to services; 2) the significance of 
collective needs (of the community); 3) the 
practical effectiveness for the "person" (indi-
vidual patients); 4) the fairness and impartiality 
in the treatment; 5) social acceptability of the 
service supply; 6) the efficiency and economy 
of the service rendered (Maxwell, 1984, 1470-
1472). 
The study of Maxwell can be considered suita-
ble for responding to the following questions: 
a. Is the service physically and temporally acces-
sible to the persons to whom it is addressed (in 
terms of physical accessibility and time)? 
b. Do services, processes and procedures reflect 
the community and individual needs? 
c. Does every single service allow obtaining the 
benefits or providing desired outcomes for in-
dividuals or groups of patients? 
d. Is the service provided in an unbiased man-
ner between the various categories or groups of 
patients? 
e. Are the conditions for the provision of the 
service, the level of protection of privacy, the 
communication grade with patients, families 
and assistance team satisfactory? 
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the community and individual needs? 
c. Does every single service allow obtaining the 
benefits or providing desired outcomes for in-
dividuals or groups of patients? 
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ner between the various categories or groups of 
patients? 
e. Are the conditions for the provision of the 
service, the level of protection of privacy, the 
communication grade with patients, families 
and assistance team satisfactory? 
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f. Are the resources employed in the processes 
and in the phase of supplying services, used 
without waste? 
g. Do detailed rules for the provision of the ser-
vice (and those who provide it) meet the securi-
ty measures that have to minimize the adverse 
effects of a treatment? 
In any case it is observed that - regardless of 
the model used - the priorities linked to the re-
spective principles depend on the needs and 
expectations of the parties involved that, in the 
health sphere, correspond to patients (benefi-
ciaries of a service or a specific treatment), to 
professionals (medical staff and social health), 
managers (management and administrative 
staff) and finally to who really pays the service 
apart from services and performance received 
(taxpayers) (Wright, Hill 2005, 5-6). 
A particular aspect related to health services 
quality, concerns the management of total qual-
ity (Total Quality Management), defined as a con-
tinuous improvement of quality (Continuous 
Quality Improvement) when it addresses to an or-
ganizational effort aimed at improving the 
overall performance. The key principles that are 
at the basis of the total quality management, are 
realized when: (a) the success of the organiza-
tion resides in the accession of all its compo-
nents to the needs of those who benefit from 
the service (patients); (b) quality is a consequen-
tial effect of the production processes in which 
the causal interactions are complex but under-
standable; c) the personnel involved in the pro-
cess is intrinsically motivated to work with ded-
ication and keep ethically corrected behaviors; 
d) the use of simple statistical methods associ-
ated with a correct collection and analysis of da-
ta, can constitute an effective procedure for the 
identification and understanding of problems 
related to operational processes and identifica-
tion of risks. 
In conclusion, total quality management implies 
the focus on operations and on expected re-
sults, analysis and the consequent identification 
of the needs of patients, analysis of the varia-
tions in processes or in results, the existence of 
multifunctional working groups for identifying 
and resolving quality issues, the use of data col-
lected in a systematic manner at any point of 
the problem solving process for high-priority is-
sues, causes, possible solutions and changes, 
learning and continuous improvement, process 
management tools to increase the effectiveness 
of working groups such as, for example, 
flowcharts, cause and effect diagrams, brain-
storming, benchmarking (Wright, Hill 2005, 8). 
 
 
3. The clinical risk and the safety of the patient 
 
A correct definition of risk comes from the 
analysis of risk within the chain of genesis of 
the damage, with the purpose to clearly distin-
guish the different phases that often, in com-
mon parlance, are confused by the use of ge-
neric terms. The strategy is to start from some 
definitions laid down by the Occupational Health 
and Safety Management system (OHSAS 18001: 
1999). In particular, it is distinguished between: 
a) hazard, situation or cause that enhances the 
damage; b) incident, occurrence that may give 
rise to damage; (c) accident, unexpected event 
and unfavorable cause of a damage. 
These terms describe the stages of the chain by 
which it is generated a damage: the hazard rep-
resents an existing danger, which becomes a 
potential source of damage when it overlaps 
with an activity (e.g. the routine activities of a 
department or a health care facility). Some-
times, especially in health care, the link between 
activities and danger is so narrow that they may 
not be readily cleaved. This overlap determines 
the possibility that the danger is translated into 
an adverse event and this probability is the risk 
(risk) that may give rise to an incident, followed 
by a damage (accident). What binds event and 
damage are often unpredictable and fortuitous 
factors and very large number of events, which 
occur in the health and in other sectors without 
bringing any significant damage, demonstrates 
the lability of this bond. If the management of 
risk, in the health sector, is related to systematic 
processes of identification, assessment and 
treatment of actual and potential risks, the goal 
is focused on increment in safety of patients, to 
the improvement of the outcome and  the indi-
rectly reduction of costs, with a consequent re-
duction of preventable adverse events. For this 
purpose, the health care organizations - as it 
happens in industries and in other sectors - 
should analyze adverse events by using rigorous 
investigation techniques, in order to remove the 
system errors that are at the basis of such 
events. 
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In U.S., the publication of the report: To err is 
human: building a safer health care system (Washing-
ton, Institute of Medicine, 2000) allowed the 
starting of a series of researches on human er-
rors in medicine. The report outlines a compre-
hensive strategy among government, market, 
patients and health services that try to reduce 
errors in medicine by inviting the Congress to 
realize a National-popular center for safety of 
the patients, who develop new tools and sys-
tems needed to solve this problem. 
This turning point significantly contributes to 
analyze the relationship between ICT and risk 
management as part of the more general situa-
tion regarding the quality and safety of services 
(Esteves, Joseph, 2008). ICT are, in fact, pow-
erful tools to support the organizational struc-
ture, decision-making processes (Clinical Decision 
Support System, Health Technology Assessment) and 
the monitoring of risk governance processes 
(Clinical Data Repository, Electronic Medical Record) 
(Friedman, Halpern, Fackler 2008, 69-76). 
However, this approach must take into account 
the transition from a purely reactive system 
(management of non-compliance, emergency 
management etc.) to a predominantly pro-active 
and preventive system. 
A further aspect is the increasing attention on 
safety at all organizational levels. Adverse 
events are undoubtedly a problem of quality of 
care, and to that extent, they have a purely clin-
ical relevance, but also have economic and so-
cial implications linked to the costs incurred by 
the health care facility that cause a general 
problem, but not less relevant, that is the loss 
of confidence of the population against the 
health service. 
In this perspective, the safety of patients, as-
sumes an importance that involves all phases 
and aspects of the organization. The lack of in-
tegration between the different organizational 
levels or the predominance of some over oth-
ers, determine the loss of essential components 
of clinical risk management that lead to a partial 
vision and therefore not fully reliable. 
If it is true that the primary purpose of a health 
care company is the protection of the health of 
patients and population, it is also evident that 
the strategies of risk management must be mainly 
oriented on prevention and risk management in 
accordance with the principle of Ippocrate 
primum non nocere (Reason 2004, 25). 
In recent years, the safety of the patients was 
placed as a priority of the health services in 
many countries and this centrality could not be 
attributed to the occurrence of particular 
events, but rather to the dissemination of re-
ports and epidemiological studies relating to iat-
rogenic damage. In the face of this importance, 
the management of risk becomes the strategic 
function of a learning organization model, i.e. an 
organization capable of sharing its knowledge, 
learn through participation in the various expe-
riences and improve through the dissemination 
of new knowledge and culture technical-
professional that characterizes it. 
The cultural approach to the safety of the pa-
tients has a relief that cannot be overlooked, 
especially if you consider its bond with what is 
the vision of "Error" on which it is based. The 
determinant is found, in fact, in the passage 
from a vision of the error, as cause of system 
failure, to the vision of error generated by the 
complexity of the system itself. 
The scientific and technological progress, the 
exponential process of specialization of medical 
sciences and the increasing organizational com-
plexity, contribute to the increase in medical er-
rors, although it has increased the awareness of 
the rights over time and thus the demand for 
greater transparency, clarity, accessibility, intel-
ligibility and safety (Gainotti, Poppi 2004, 61). 
The debate on the issue is very intense and rich 
of paradoxes, "on one hand, no century has 
known such overwhelming progress in biomed-
ical treatments and pharmacological properties 
as the twentieth century […], and everything 
suggests that the increasing pace of innovations 
diagnostic, therapeutic and rehabilitative ser-
vices will continue. However, now as never, the 
uncertainties and suspicions are deep and wide-
spread in fields such as science, basic health 
practices and in the chance of healing, as well as 
to ensure equal health care practice for not 
guaranteed patients "(Ardigo, 1997). According 
to this claim, the success of medicine is at the 
basis of its own weakness. Nowadays, failures 
that occur in diseases that were incurable in the 
past, are no longer perceived as tolerable but 
become errors. In addition, the hard and visible 
dispute between patient and clinician in the 
health care environment is becoming physiolog-
ical. Today, patients expect to be guaranteed in 
terms of security and they demand to be in-
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formed about all the risks associated with clini-
cal practice, but, at the same time, clinicians feel 
heavily the risk of having transparent commu-
nication and free of complaints. That causes a 
gradual distancing and an unfair degradation of 
the fiduciary relationship between the parties 
involved, a fragile "wall of silence" (Gibson, 
Sing 2003) that is often subjected to attacks by 
the media and the specialized press. These situ-
ations lead medical staff to assume precaution-
ary behaviors and the recourse of the so-called 
"defensive medicine". 
In conclusion, in the relationship between clini-
cal risk and patient safety, the recall of a socio-
political role of active dialogue in drawing up 
strategies means, for the health system, the 
recognition and the assessment of risk, invest-
ing resources, introducing evaluation systems 
and organizational practices for proper man-
agement and prevention, making public the re-
sults (Cavicchi 2007). 
The consuetude to provide data and infor-
mation regarding clinical practice or other 
achieved performance data, lead to an internal 
comparison able to certainly increase the 
knowledge in a logic of community empowerment. 
This may gradually transform the cultural mod-
el in a model primarily oriented to the recon-
struction of the fiduciary relationship between 
clinician and patient, despite the obvious diffi-
culties concerning the measurement of the out-
come in health. 
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